

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 10

October 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 10
October 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

BD RX INC
(BD RX)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

PROSAM LABS LLC
(PROSAM LABS)

HIKMA MAPLE LTD
(HIKMA MAPLE)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

OXFORD PHARMACEUTICALS LLC
(OXFORD PHARMS)

EUROHEALTH INTERNATIONAL SARL
(EUROHLTH INTL SARL)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHRID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHRID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHRID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS	17151	17251	17528	17765	
LISTED SINGLE	2664	2693	2664	2665	
SOURCE	(15.5%)	(15.6%)	(15.2%)	(15%)	
MULTISOURCE	14487	14558	14864	15100	
	(84.5%)	(84.4%)	(84.8%)	(85%)	
THERAPEUTICALLY	14366	14434	14731	14968	
EQUIVALENT	(83.8%)	(83.7%)	(84%)	(84.3%)	
NOT THERAPEUTICALLY	121	124	133	132	
EQUIVALENT	(0.7%)	(0.7%)	(0.8%)	(0.7%)	
EXCEPTIONS ¹	73	73	73	73	
	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
NEW MOLECULAR	28	9	20	8	
ENTITIES APPROVED					
NUMBER OF	1011	1007	1023	1027	
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action.

The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		HETERO LABS LTD III	EQ 20MG BASE/ML	A201107	001	Sep 26, 2016	Sep NEWA
		ZIAGEN					

AA	+	VIIV HLTHCARE	EQ 20MG BASE/ML	N020978	001	Dec 17, 1998	Sep CFTG
		TABLET;ORAL					

ABACAVIR SULFATE

>A>	AB		STRIDES ARCOLAB LTD	EQ 300MG BASE	A091050	001	Oct 28, 2016	Oct NEWA
-----	----	--	---------------------	---------------	---------	-----	--------------	----------

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246	001	Sep 29, 2016	Sep NEWA
		EPZICOM					

AB	+	VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Sep CFTG
----	---	---------------	---------------------	---------	-----	--------------	----------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	+	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	May CRLD
----	---	-------------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

AP		PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	May NEWA
----	--	-------------	---------------------	---------	-----	--------------	----------

AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar NEWA
		OFIRMEV					

AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Mar CFTG
----	---	-----------------	---------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		CNTY LINE PHARMS	325MG;50MG	A205120	001	Oct 30, 2015	Aug CAHN
----	--	------------------	------------	---------	-----	--------------	----------

>A>	AA		MIKART INC	300MG;50MG	A207386	001	Nov 15, 2016	Oct NEWA
-----	----	--	------------	------------	---------	-----	--------------	----------

>D>		+	NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011	Oct CTEC
-----	--	---	---------------	------------	---------	-----	--------------	----------

>A>	AA	+		300MG;50MG	A090956	001	Aug 23, 2011	Oct CTEC
-----	----	---	--	------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	+	MAYNE PHARMA INC	325MG;50MG;40MG	A089007	001	Mar 17, 1986	Aug CAHN
--	---	------------------	-----------------	---------	-----	--------------	----------

	+	METRIC	325MG;50MG;40MG	A089007	001	Mar 17, 1986	Jun CAHN
--	---	--------	-----------------	---------	-----	--------------	----------

>D>		+	NEXGEN PHARMA	300MG;50MG;40MG	A040885	001	Nov 16, 2009	Oct CFTG
-----	--	---	---------------	-----------------	---------	-----	--------------	----------

>A>	AB	+		300MG;50MG;40MG	A040885	001	Nov 16, 2009	Oct CFTG
-----	----	---	--	-----------------	---------	-----	--------------	----------

>A>	AB		NUVO PHARM INC	300MG;50MG;40MG	A207118	001	Oct 28, 2016	Oct NEWA
-----	----	--	----------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@	INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jan CAHN
---	-------------------	-----------------	---------	-----	--------------	----------

@	SUN PHARM INDS	325MG;50MG;40MG	A040601	001	Jul 29, 2005	Jan CAHN
---	----------------	-----------------	---------	-----	--------------	----------

FIORICET

AA		ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	May CMFD
----	--	---------------------	-----------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jul CAHN
----	---	---------------------	----------------------	---------	-----	--------------	----------

AB	+	ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Apr CAHN
----	---	--------------------	----------------------	---------	-----	--------------	----------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

	LARKEN LABS INC	325MG;30MG;16MG	A204209	001	Sep 30, 2016	Sep NEWA
--	-----------------	-----------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ FRONTIDA BIOPHARM	300MG; 15MG	A089671	001	Feb 10, 1988	Sep CAHN
@	300MG; 30MG	A089672	001	Feb 10, 1988	Sep CAHN
@	300MG; 60MG	A089673	001	Feb 10, 1988	Jul CAHN
@ SUN PHARM INDS	300MG; 60MG	A089673	001	Feb 10, 1988	Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

ZYFREL

AA	CYPRESS PHARM INC	325MG/15ML; 7.5MG/15ML	A090468	001	Apr 14, 2016	Apr NEWA
----	-------------------	------------------------	---------	-----	--------------	----------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ACTAVIS LABS FL INC	300MG; 5MG	A206470	001	Jun 02, 2016	May NEWA
AA		300MG; 7.5MG	A206470	002	Jun 02, 2016	May NEWA
AA		300MG; 10MG	A206470	003	Jun 02, 2016	May NEWA
	@ ALLERGAN SALES LLC	500MG; 10MG	A040148	002	Feb 14, 1997	Jun CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG	A040746	002	May 10, 2016	Apr NEWA
AA	LARKEN LABS INC	325MG; 5MG	A202935	002	Jun 15, 2016	Jun NEWA
AA		325MG; 7.5MG	A202935	003	Jun 15, 2016	Jun NEWA
AA		325MG; 10MG	A202935	004	Jun 15, 2016	Jun NEWA
AA	PAR PHARM	300MG; 5MG	A205001	001	Jul 05, 2016	Jun NEWA
AA		300MG; 7.5MG	A205001	002	Jul 05, 2016	Jun NEWA
AA		300MG; 10MG	A205001	003	Jul 05, 2016	Jun NEWA
AA	RHODES PHARMS	325MG; 5MG	A202991	001	Apr 12, 2016	Mar NEWA
AA		325MG; 7.5MG	A202991	002	Apr 12, 2016	Mar NEWA
AA		325MG; 10MG	A202991	003	Apr 12, 2016	Mar NEWA
AA	TRIS PHARMA INC	300MG; 5MG	A202214	004	Mar 15, 2016	Jun NEWA
AA		300MG; 7.5MG	A202214	005	Mar 15, 2016	Jun NEWA
AA		300MG; 10MG	A202214	006	Mar 15, 2016	Jun NEWA
	NORCO					
AA	ALLERGAN SALES LLC	325MG; 2.5MG	A040148	004	Jul 07, 2014	Jun CAHN
AA	+	325MG; 5MG	A040099	001	Jun 25, 1997	Jun CAHN
AA		325MG; 5MG	A040148	005	Jul 07, 2014	Jun CAHN
AA	+	325MG; 7.5MG	A040148	003	Sep 12, 2000	Jun CAHN
AA	+	325MG; 10MG	A040148	001	Feb 14, 1997	Jun CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	+	MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006	Aug CRLD
AA			325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006	May CMFD
		ROXICET					
	@	ROXANE	325MG/5ML; 5MG/5ML	A089351	001	Dec 03, 1986	Aug DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ALVOGEN MALTA	325MG; 5MG	A202677	003	Mar 08, 2016	Feb NEWA
AA		325MG; 7.5MG	A202677	001	Jul 26, 2012	Jan CAHN
AA		325MG; 10MG	A202677	002	Jul 26, 2012	Jan CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG	A040778	002	Jun 27, 2014	Apr NEWA
AA	MAYNE PHARMA INC	325MG; 2.5MG	A090177	001	Oct 20, 2008	Feb CAHN
AA		325MG; 5MG	A090177	002	Oct 20, 2008	Feb CAHN
AA		325MG; 7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
AA		325MG; 10MG	A090177	004	Oct 20, 2008	Feb CAHN
	@	500MG; 7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
	@	650MG; 10MG	A090177	006	Oct 20, 2008	Feb CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ATLAS PHARMS LLC	325MG; 37.5MG	A202076	001	Mar 30, 2012	May CAHN
----	------------------	---------------	---------	-----	--------------	----------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB	NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar NEWA
AB	NOVAST LABS LTD	500MG	A203434	001	Sep 30, 2016	Sep NEWA

TABLET; ORAL

ACETAZOLAMIDE

>A> AB	HERITAGE PHARMA	125MG	A205530	001	Oct 27, 2016	Oct NEWA
--------	-----------------	-------	---------	-----	--------------	----------

TABLET;ORAL							
ACETAZOLAMIDE							
>A>	AB	250MG		A205530	002	Oct 27, 2016	Oct NEWA
<u>ACETAZOLAMIDE SODIUM</u>							
INJECTABLE;INJECTION							
ACETAZOLAMIDE SODIUM							
AP	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL		A040089	001	Feb 28, 1995	Sep CAHN
<u>ACETYLCYSTEINE</u>							
INJECTABLE;INTRAVENOUS							
ACETYLCYSTEINE							
AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)		A207358	001	Feb 29, 2016	Feb NEWA
AP	FRESENIUS KABI USA	6GM/30ML (200MG/ML)		A200644	001	Nov 07, 2012	Sep CAHN
TABLET, EFFERVESCENT;ORAL							
CETYLEV							
	ARBOR PHARMS LLC	500MG		N207916	001	Jan 29, 2016	Jan NEWA
	+	2.5GM		N207916	002	Jan 29, 2016	Jan NEWA
<u>ACITRETIN</u>							
CAPSULE;ORAL							
ACITRETIN							
AB	IMPAX LABS INC	10MG		A202552	001	Dec 23, 2015	Aug CAHN
AB		17.5MG		A202552	002	Dec 23, 2015	Aug CAHN
AB		22.5MG		A202552	003	Dec 23, 2015	Aug CAHN
AB		25MG		A202552	004	Dec 23, 2015	Aug CAHN
<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
SEMPREX-D							
	+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994	Mar CAHN
<u>ACYCLOVIR</u>							
CAPSULE;ORAL							
ACYCLOVIR							
	@ RANBAXY	200MG		A074975	001	Sep 30, 1998	Feb DISC
AB	ZYDUS PHARMS USA INC	200MG		A204313	001	Mar 25, 2016	Mar NEWA
OINTMENT;TOPICAL							
ACYCLOVIR							
AB	FOUGERA PHARMS INC	5%		A206633	001	May 11, 2016	Apr NEWA
TABLET;BUCCAL							
SITAVIG							
	+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan CAHN
TABLET;ORAL							
ACYCLOVIR							
	@ SUN PHARM INDS LTD	400MG		A074980	001	Sep 30, 1998	Feb DISC
	@	800MG		A074980	002	Sep 30, 1998	Feb DISC
<u>ACYCLOVIR SODIUM</u>							
INJECTABLE;INJECTION							
ACYCLOVIR SODIUM							
	@ AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL		A074596	002	Apr 22, 1997	Jun CAHN
	@	EQ 1GM BASE/VIAL		A074596	001	Apr 22, 1997	Jun CAHN
	@ BEDFORD	EQ 500MG BASE/VIAL		A074596	002	Apr 22, 1997	Feb DISC
	@	EQ 1GM BASE/VIAL		A074596	001	Apr 22, 1997	Feb DISC
AP	+	EQ 1GM BASE/VIAL		A074596	001	Apr 22, 1997	Feb CTEC
	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL		A074596	002	Apr 22, 1997	Apr CAHN
	@	EQ 1GM BASE/VIAL		A074596	001	Apr 22, 1997	Apr CAHN
AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL		A205771	001	Feb 29, 2016	Feb NEWA
	+	EQ 1GM BASE/VIAL		A205771	002	Feb 29, 2016	Feb CRLD
AP		EQ 1GM BASE/VIAL		A205771	002	Feb 29, 2016	Feb NEWA
<u>ADAPALENE</u>							
GEL;TOPICAL							
ADAPALENE							
AB	TARO	0.3%		A208322	001	Jun 23, 2016	Jun NEWA
SOLUTION;TOPICAL							
ADAPALENE							
AB	CALL INC	0.1%		A203981	001	Sep 23, 2016	Sep NEWA
AB	+	0.1%		A204593	001	Jan 05, 2016	Sep CTEC

ADENOSINE

INJECTABLE; INJECTION							
ADENOSINE							
AP	EUROHLTH INTL SARL	3MG/ML	A076404	001	Jun 16, 2004	Apr	CAHN
SOLUTION; IV (INFUSION)							
ADENOSINE							
AP	+ TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr	CRLD
AP	+	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr	CRLD

ALBUTEROL SULFATE

SOLUTION; INHALATION							
ALBUTEROL SULFATE							
AN	@ HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar	DISC
	@ LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar	DISC
	+ NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar	CRLD
	@ TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar	DISC
	@ WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar	DISC
TABLET; ORAL							
ALBUTEROL SULFATE							
>A>	@ DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989	Oct	CMS1
AB	SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar	CAHN
AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION							
DUONEB							
	@ MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jun	DISC

ALENDRONATE SODIUM

SOLUTION; ORAL							
ALENDRONATE SODIUM							
	+ ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Aug	CRLD
	FOSAMAX						
	@ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Aug	DISC
TABLET; ORAL							
ALENDRONATE SODIUM							
AB	IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008	Aug	CAHN
AB		EQ 10MG BASE	A075710	002	Feb 06, 2008	Aug	CAHN
AB		EQ 35MG BASE	A075710	003	Feb 06, 2008	Aug	CAHN
AB		EQ 40MG BASE	A075710	004	Feb 06, 2008	Aug	CAHN
AB		EQ 70MG BASE	A075710	005	Feb 06, 2008	Aug	CAHN
AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	CAHN
AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	CAHN
AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	CAHN
AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	CAHN
>D>	@ SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Oct	CAHN
>D>	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Oct	CAHN
>D>	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Oct	CAHN
>D>	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Oct	CAHN
>D>	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Oct	CAHN
>A>	@ UPSHER-SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009	Oct	CAHN
>A>	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Oct	CAHN
>A>	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Oct	CAHN
>A>	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Oct	CAHN
>A>	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Oct	CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL							
FOSAMAX PLUS D							
	MERCK	EQ 70MG BASE; 2,800 IU	N021762	001	Apr 07, 2005	Aug	CMFD
	+	EQ 70MG BASE; 5,600 IU	N021762	002	Apr 26, 2007	Aug	CMFD

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL							
ALFUZOSIN HYDROCHLORIDE							
AB	UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan	NEWA

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

>A>	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Oct CAHN
>A>	+	EQ 300MG BASE	N021985	002	Mar 05, 2007	Oct CAHN
>D>	NOVARTIS	EQ 150MG BASE	N021985	001	Mar 05, 2007	Oct CAHN
>D>	+	EQ 300MG BASE	N021985	002	Mar 05, 2007	Oct CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

>A>	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	Oct CAHN
>A>		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	Oct CAHN
>A>	+	EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008	Oct CAHN
>A>	+	EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008	Oct CAHN
>D>	NOVARTIS	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	Oct CAHN
>D>		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	Oct CAHN
>D>	+	EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008	Oct CAHN
>D>	+	EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008	Oct CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	INDOCO REMEDIES	100MG	A204467	001	Jul 28, 2016	Jul NEWA
AB		300MG	A204467	002	Jul 28, 2016	Jul NEWA
AB	SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar CAHN
	ZYLOPRIM					
AB	SEBELA IRELAND LTD	100MG	N016084	001		Jan CAHN
AB	+	300MG	N016084	002		Jan CAHN

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

>D>	AP	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A076870	001	Aug 26, 2004	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076870	001	Aug 26, 2004	Oct CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb NEWA
AB		EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTIRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ ACTAVIS LABS FL INC 0.5MG

@ 1MG

@ 2MG

@ 3MG

@ COREPHARMA 0.5MG

@ 1MG

@ 2MG

@ 3MG

@ IMPAX LABS 0.5MG

@ 1MG

@ 2MG

@ 3MG

A077198	001	May 13, 2010	Jan DISC
A077198	002	May 13, 2010	Jan DISC
A077198	003	May 13, 2010	Jan DISC
A077198	004	May 13, 2010	Jan DISC
A077996	001	Jan 31, 2007	Mar DISC
A077996	002	Jan 31, 2007	Mar DISC
A077996	003	Jan 31, 2007	Mar DISC
A077996	004	Jan 31, 2007	Mar DISC
A077968	004	May 24, 2007	Jan DISC
A077968	003	May 24, 2007	Jan DISC
A077968	002	May 24, 2007	Jan DISC
A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	WEST-WARD PHARMS INT	0.5MG/ML	A074815	001	Jan 20, 1998	Sep CAHN
	EDEX					
	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN

INJECTABLE; INJECTION
EDEX

	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN

SUPPOSITORY; URETHRAL
MUSE

	+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
	+		0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
	+		0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
AB		NEWGEN PHARMS LLC	100MG	A207570	001	Sep 30, 2016	Sep NEWA
AB		ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
>D>	@	EUROHLTH INTL SARL	EQ 50MG BASE/ML	A063274	001	May 18, 1992	Oct CAHN
>D>	@		EQ 250MG BASE/ML	A063275	001	May 18, 1992	Oct CAHN
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA
>A>	@	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992	Oct CAHN
AP	+		EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Sep CAHN
>A>	@		EQ 250MG BASE/ML	A063275	001	May 18, 1992	Oct CAHN
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Sep CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	008	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	016	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	017	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML	N020678	018	Mar 26, 1997	Mar CMS1

INJECTABLE; INJECTION

	CLINIMIX E 5/20 SULFITE	FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER				
		340MG/100ML;59MG/100ML				
	CLINIMIX E 5/25 SULFITE	FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100M	N020678	019	Mar 26, 1997	Mar CMS1
		L;261MG/100ML;340MG/100ML;59MG/100				
		ML				
	CLINIMIX E 5/35 SULFITE	FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100M	N020678	021	Mar 26, 1997	Mar CMS1
		L;261MG/100ML;340MG/100ML;59MG/100				
		ML				

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May NEWA
---	-------------	-----	---------	-----	--------------	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@	IDT AUSTRALIA LTD	100MG	A085261	003		May CAHN
@		100MG	A085262	002		May CAHN
@		200MG	A085261	002		May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May NEWA
AB	MURTY PHARMS	100MG	A077069	003	Oct 04, 2016	Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

@	ANI PHARMS INC	10MG	A085031	002		Sep CMS1
@		50MG	A085031	003		Sep CMS1
@		75MG	A085031	004		Sep CMS1
@	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar DISC
@		10MG	A089399	002	Jul 14, 1987	Mar DISC
AB		10MG	A089399	002	Jul 14, 1987	Mar CAHN
@		25MG	A040816	001	Jun 27, 2008	Mar DISC
@		25MG	A089399	001	Jul 14, 1987	Mar DISC
AB		25MG	A089399	001	Jul 14, 1987	Mar CAHN
@		50MG	A040816	003	Jun 27, 2008	Mar DISC
@		50MG	A089399	003	Jul 14, 1987	Mar DISC
AB		50MG	A089399	003	Jul 14, 1987	Mar CAHN
@		75MG	A040816	004	Jun 27, 2008	Mar DISC
@		75MG	A089399	004	Jul 14, 1987	Mar DISC
AB		75MG	A089399	004	Jul 14, 1987	Mar CAHN
@		100MG	A040816	005	Jun 27, 2008	Mar DISC
@		100MG	A089399	005	Jul 14, 1987	Mar DISC
AB		100MG	A089399	005	Jul 14, 1987	Mar CAHN
@		150MG	A040816	006	Jun 27, 2008	Mar DISC
@		150MG	A089399	006	Jul 14, 1987	Mar DISC
AB		150MG	A089399	006	Jul 14, 1987	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	FRONTIDA BIOPHARM	EQ 12.5MG BASE; 5MG	A070765	001	Dec 10, 1986	Jul CAHN
@		EQ 25MG BASE; 10MG	A070766	001	Dec 10, 1986	Jul CAHN
@	SUN PHARM INDS	EQ 12.5MG BASE; 5MG	A070765	001	Dec 10, 1986	Mar CAHN
@		EQ 25MG BASE; 10MG	A070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG; 2MG	A071077	001	Nov 12, 1986	Mar CAHN
@		10MG; 4MG	A071078	001	Nov 12, 1986	Mar CAHN
@		25MG; 2MG	A070297	001	Nov 12, 1986	Mar CAHN
@		25MG; 4MG	A071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016	May	NEWA
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb	CAHN
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb	CAHN
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb	CAHN
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun	NEWA
AB		EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun	NEWA
AB		EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun	NEWA
	@ SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar	CAHN
	@	EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar	CAHN
	@	EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

>A>	OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE						
>A> AB	PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A206137	001	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;12.5MG;40MG	A206137	002	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;25MG;40MG	A206137	003	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;12.5MG;40MG	A206137	004	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;25MG;40MG	A206137	005	Oct 26, 2016	Oct	NEWA
>A> AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Oct	NEWA
>A> AB	TORRENT PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;12.5MG;40MG	A203580	002	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;25MG;40MG	A203580	003	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Oct	NEWA
	TRIBENZOR						
>D>	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010	Oct	CFTG
>A> AB		EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010	Oct	CFTG
>D>		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010	Oct	CFTG
>A> AB		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010	Oct	CFTG
>D>		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010	Oct	CFTG
>A> AB		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010	Oct	CFTG
>D>		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010	Oct	CFTG
>A> AB		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010	Oct	CFTG
>D>	+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010	Oct	CFTG
>A> AB	+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010	Oct	CFTG

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>A> AB	AJANTA PHARMA LTD	EQ 5MG BASE;20MG	A207216	001	Oct 28, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;40MG	A207216	002	Oct 28, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;20MG	A207216	003	Oct 28, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;40MG	A207216	004	Oct 28, 2016	Oct	NEWA
>A> AB	MACLEODS PHARMS LTD	EQ 5MG BASE;20MG	A206884	001	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;40MG	A206884	003	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;20MG	A206884	002	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;40MG	A206884	004	Oct 26, 2016	Oct	NEWA
>A> AB	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Oct	NEWA
>A> AB		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Oct	NEWA
	AZOR						
>D>	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007	Oct	CFTG
>A> AB		EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007	Oct	CFTG
>D>		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007	Oct	CFTG
>A> AB		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007	Oct	CFTG
>D>		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007	Oct	CFTG
>A> AB		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007	Oct	CFTG
>D>	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007	Oct	CFTG
>A> AB	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007	Oct	CFTG

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr	NEWA
AB		EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Sep	NEWA
AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Sep	NEWA
>A> AB	PAR PHARM INC	EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Oct	CMS1

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan	NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr	CRLD
	LAC-HYDRIN						
	@ RANBAXY	EQ 12% BASE	N020508	001	Aug 29, 1996	Apr	DISC
	LOTION; TOPICAL						
	AMMONIUM LACTATE						
AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr	CRLD
	LAC-HYDRIN						
	@ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Apr	DISC

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

	@ SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Feb	DISC
	@	500MG	A065016	002	Apr 08, 1999	Feb	DISC

TABLET; ORAL

AMOXICILLIN

	@ SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Feb	DISC
	@	875MG	A065059	002	Nov 24, 2000	Feb	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

	@ SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Feb	DISC
	@	250MG	A065021	002	Dec 23, 1999	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

	+ VERNALIS R AND D LTD	775MG	N050813	001	Jan 23, 2008	Jan	CAHN
--	------------------------	-------	---------	-----	--------------	-----	------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	CITRON PHARMA LLC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A206006	001	Oct 07, 2016	Sep	NEWA
----	-------------------	--	---------	-----	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb	CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb	CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb	CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb	DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb	DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb	DISC

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	HIKMA PHARMS	875MG;EQ 125MG BASE	A203824	001	Aug 23, 2016	Aug	NEWA
	@ SUN PHARM INDS LTD	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	DISC
	@	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb DISC
@	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb DISC
AUGMENTIN '125'					
@ DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Jul DISC
	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Mar CTEC
AUGMENTIN '250'					
@ DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Jul DISC
+	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Mar CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan NEWA
	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan NEWA
	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan NEWA
	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan NEWA
	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan NEWA
+	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	May CRLD
	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

@ ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@	100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug CAHN
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Aug CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Aug CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

>D>	@ SANDOZ INC	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Oct CAHN
>D>	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Oct CAHN
>A>	@ UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Oct CAHN
>A>	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Oct CAHN

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE
@ SANDOZ

1MG

A079007 001 Jun 28, 2010 Aug DISC

ARGATROBAN

INJECTABLE; INJECTION
ARGATROBAN

AP HOSPIRA INC 250MG/2.5ML (100MG/ML)

A204120 001 Sep 21, 2016 Sep NEWA

ARIPIPIRAZOLE

INJECTABLE; INTRAMUSCULAR
ABILIFY

@ OTSUKA

9.75MG/1.3ML (7.5MG/ML)

N021866 001 Sep 20, 2006 Jun DISC

SOLUTION; ORAL
ARIPIPIRAZOLE

AA + AMNEAL PHARMS 1MG/ML

A203906 001 Aug 14, 2015 Feb CRLD

TABLET; ORAL

ARIPIPIRAZOLE

AB AJANTA PHARMA LTD 2MG

A206174 001 Sep 12, 2016 Aug NEWA

AB 5MG

A206174 002 Sep 12, 2016 Aug NEWA

AB 10MG

A206174 003 Sep 12, 2016 Aug NEWA

AB 15MG

A206174 004 Sep 12, 2016 Aug NEWA

AB 20MG

A206174 005 Sep 12, 2016 Aug NEWA

AB 30MG

A206174 006 Sep 12, 2016 Aug NEWA

AB AMNEAL PHARMS 2MG

A204838 001 Jun 17, 2016 Jun NEWA

AB 5MG

A204838 002 Jun 17, 2016 Jun NEWA

AB 10MG

A204838 003 Jun 17, 2016 Jun NEWA

AB 15MG

A204838 004 Jun 17, 2016 Jun NEWA

AB 20MG

A204838 005 Jun 17, 2016 Jun NEWA

AB 30MG

A204838 006 Jun 17, 2016 Jun NEWA

AB MACLEODS PHARMS LTD 2MG

A204111 001 Oct 07, 2016 Sep NEWA

AB 5MG

A204111 002 Oct 07, 2016 Sep NEWA

AB 10MG

A204111 003 Oct 07, 2016 Sep NEWA

AB 15MG

A204111 004 Oct 07, 2016 Sep NEWA

AB 20MG

A204111 005 Oct 07, 2016 Sep NEWA

AB 30MG

A204111 006 Oct 07, 2016 Sep NEWA

AB SCIEGEN PHARMS INC 2MG

A206383 001 Sep 29, 2016 Sep NEWA

AB 5MG

A206383 002 Sep 29, 2016 Sep NEWA

AB 10MG

A206383 003 Sep 29, 2016 Sep NEWA

AB 15MG

A206383 004 Sep 29, 2016 Sep NEWA

AB 20MG

A206383 005 Sep 29, 2016 Sep NEWA

AB 30MG

A206383 006 Sep 29, 2016 Sep NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

@ OTSUKA

10MG

N021729 002 Jun 07, 2006 May DISC

@

15MG

N021729 003 Jun 07, 2006 May DISC

ARIPIPIRAZOLE

+ ALEMBIC PHARMS LTD 10MG

A202102 001 Apr 28, 2015 May CRLD

15MG

A202102 002 Apr 28, 2015 May CTEC

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB MYLAN PHARMS INC 50MG

A200043 001 Jun 01, 2012 Apr CMFD

AB 150MG

A200043 002 Jun 01, 2012 Apr CMFD

AB 250MG

A200043 003 Jun 01, 2012 Apr CMFD

NUVIGIL

AB CEPHALON 50MG

N021875 001 Jun 15, 2007 Apr CTEC

AB 150MG

N021875 003 Jun 15, 2007 Apr CTEC

AB + 250MG

N021875 004 Jun 15, 2007 Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRIS

FOREST LABS LLC EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC 325MG;50MG;40MG
FIORINAL

A078149 001 Jun 13, 2007 Jan CAHN

AA + ALLERGAN SALES LLC 325MG;50MG;40MG

N017534 005 Apr 16, 1986 Apr CAHN

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA PHARMACEUTICS INTL 325MG;50MG;40MG
FIORINAL

A204195 001 Sep 22, 2016 Sep NEWA

@ ALLERGAN SALES LLC 325MG;50MG;40MG

N017534 003 Apr 16, 1986 Apr CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE

AB MAYNE PHARMA INC 325MG;50MG;40MG;30MG
FIORINAL W/CODEINE

A203335 001 Oct 30, 2015 Aug CAHN

AB + ALLERGAN SALES LLC 325MG;50MG;40MG;30MG

N019429 003 Oct 26, 1990 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

AB + HERITAGE PHARMS INC 325MG;200MG

A089594 001 Mar 31, 1989 Jun CRLD

AB INGENUS PHARMS NJ 325MG;200MG

A040832 001 Jan 07, 2010 Jan CAHN

SOMA COMPOUND

@ MEDA PHARMS 325MG;200MG

N012365 005 Jul 11, 1983 Jun DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB INGENUS PHARMS NJ 325MG;200MG;16MG

A040860 001 Jan 07, 2010 Mar CMFD

@ 325MG;200MG;16MG

A040860 001 Jan 07, 2010 Jan CAHN

AB + SANDOZ 325MG;200MG;16MG

A040118 001 Apr 16, 1996 Mar CTEC

+ 325MG;200MG;16MG

A040118 001 Apr 16, 1996 Jan CRLD

SOMA COMPOUND W/ CODEINE

@ MEDA PHARMS 325MG;200MG;16MG

N012366 002 Jul 11, 1983 Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

>D> @ AMNEAL PHARMS 25MG;200MG

A206392 001 Mar 08, 2016 Oct CMFD

>A> AB 25MG;200MG

A206392 001 Mar 08, 2016 Oct CMFD

@ 25MG;200MG

A206392 001 Mar 08, 2016 Apr DISC

AB 25MG;200MG

A206392 001 Mar 08, 2016 Feb NEWA

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

ARALEZ PHARMS 81MG;40MG

N205103 001 Sep 14, 2016 Sep NEWA

+ 325MG;40MG

N205103 002 Sep 14, 2016 Sep NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA MAYNE PHARMA INC 325MG;4.8355MG

A091670 001 Mar 16, 2011 Aug CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ SUN PHARM INDS 325MG;4.5MG;0.38MG

A040260 001 Jul 17, 1998 Mar CAHN

@ 325MG;4.5MG;0.38MG

A087794 001 May 26, 1982 Mar CAHN

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jan CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jan CAHN
	@ NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009	Aug DISC
	@	50MG	A078254	002	Sep 25, 2009	Aug DISC
	@	100MG	A078254	003	Sep 25, 2009	Aug DISC
	TENORMIN					
AB	ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan CAHN
AB		50MG	N018240	001		Jan CAHN
AB	+	100MG	N018240	002		Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jan CAHN
AB	SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar CAHN
	TENORETIC 100					
AB	+	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN
	TENORETIC 50					
AB	ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
AB		EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
AB		EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
AB		EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

>D>	AP	+	EUROHLTH INTL SARL	10MG/ML	A074901	001	Jul 18, 1997	Oct CAHN
	AP		NANJING KING-FRIEND	10MG/ML	A091489	001	Feb 17, 2012	Sep CAHN
>A>	AP	+	WEST-WARD PHARMS INT	10MG/ML	A074901	001	Jul 18, 1997	Oct CAHN
			ATRACURIUM BESYLATE PRESERVATIVE FREE					
	AP		NANJING KING-FRIEND	10MG/ML	A091488	001	Feb 17, 2012	Sep CAHN
	AP	+	WEST-WARD PHARMS INT	10MG/ML	A074900	001	Jul 18, 1997	Sep CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@ SUN PHARM INDS	0.025MG;2.5MG	A085506	001		Mar CAHN
	LONOX					
	@ SANDOZ	0.025MG;2.5MG	A085311	002		Aug DISC

AURANOFIN

CAPSULE;ORAL

RIDAURA

	+	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan CAHN
--	---	--------------------	-----	---------	-----	--------------	----------

AVANAFIL

TABLET;ORAL

STENDRA

>A>		METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012	Oct CAHN
>A>			100MG	N202276	002	Apr 27, 2012	Oct CAHN
>A>	+		200MG	N202276	003	Apr 27, 2012	Oct CAHN
>D>		VIVUS	50MG	N202276	001	Apr 27, 2012	Oct CAHN
>D>			100MG	N202276	002	Apr 27, 2012	Oct CAHN
>D>	+		200MG	N202276	003	Apr 27, 2012	Oct CAHN

AXITINIB

TABLET;ORAL

INLYTA

		PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr CAHN
	+		5MG	N202324	002	Jan 27, 2012	Apr CAHN

AZACITIDINE

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Apr NEWA
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Sep NEWA
	POWDER;IV (INFUSION), SUBCUTANEOUS					
	AZACITIDINE					
	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Apr NEWA

AZATHIOPRINE

TABLET;ORAL
IMURAN

	@ SEBELA IRELAND LTD	25MG	N016324	002		Jan CAHN
AB	+	50MG	N016324	001		Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION
AZATHIOPRINE SODIUM

+ WEST-WARD PHARMS INT EQ 100MG BASE/VIAL
IMURAN
@ SEBELA IRELAND LTD EQ 100MG BASE/VIAL

A074419	001	Mar 31, 1995	Sep CAHN
N017391	001		Jan CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
AZELASTINE HYDROCHLORIDE

>A> AT	AKORN	0.05%	A203660	001	Nov 08, 2016	Oct NEWA
--------	-------	-------	---------	-----	--------------	----------

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL
EDARBI

ARBOR PHARMS LLC EQ 40MG MEDOXOMIL
+ EQ 80MG MEDOXOMIL

N200796	001	Feb 25, 2011	Jan CAHN
N200796	002	Feb 25, 2011	Jan CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL
EDARBYCLOR

ARBOR PHARMS LLC EQ 40MG MEDOXOMIL;12.5MG
+ EQ 40MG MEDOXOMIL;25MG

N202331	001	Dec 20, 2011	Jan CAHN
N202331	002	Dec 20, 2011	Jan CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL
AZITHROMYCIN

BX	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Apr CTEC
BX		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Apr CTEC

AZTREONAM

INJECTABLE;INJECTION
AZTREONAM

@ EUROHLTH INTL SARL 1GM/VIAL
@ 2GM/VIAL
@ WEST-WARD PHARMS INT 1GM/VIAL
@ 2GM/VIAL

A065286	001	Mar 23, 2011	Mar DISC
A065286	002	Mar 23, 2011	Mar DISC
A065286	001	Mar 23, 2011	Sep CAHN
A065286	002	Mar 23, 2011	Sep CAHN

BACLOFEN

INJECTABLE;INTRATHECAL
BACLOFEN

AP	SINTETICA SA	0.05MG/ML	A091193	001	May 03, 2016	Apr NEWA
AP		0.5MG/ML	A091193	002	May 03, 2016	Apr NEWA
AP		2MG/ML	A091193	003	May 03, 2016	Apr NEWA
	LIORESAL					
AP	+ SAOL THERAPS RES LTD	0.05MG/ML	N020075	003	Nov 07, 1996	May CAHN
AP	+	0.5MG/ML	N020075	001	Jun 17, 1992	May CAHN
AP	+	2MG/ML	N020075	002	Jun 17, 1992	May CAHN

TABLET;ORAL
BACLOFEN

>A> AB	LANNETT	10MG	A077241	002	Jul 06, 2007	Oct CMS1
AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan NEWA

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

	+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan NEWA
>A>		PASTE; ORAL					
>A>		VARIBAR					
>A>	+	BRACCO	40% (92GM/230ML)	N208844	001	Oct 14, 2016	Oct NEWA
		SUSPENSION; ORAL					
		READI-CAT 2					
	+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA
		READI-CAT 2 SMOOTHIES					
		BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan DISC
@		10MG	A076267	002	Feb 11, 2004	Jan DISC
@		20MG	A076267	003	Feb 11, 2004	Jan DISC
@		40MG	A076267	004	Feb 11, 2004	Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	Jan DISC
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	Jan DISC
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	Jan DISC
@		20MG; 25MG	A076342	004	Feb 11, 2004	Jan DISC
@	IVAX SUB TEVA PHARMS	5MG; 6.25MG	A076348	001	Feb 11, 2004	Mar DISC
@		10MG; 12.5MG	A076348	002	Feb 11, 2004	Mar DISC
@		20MG; 12.5MG	A076348	003	Feb 11, 2004	Mar DISC
@		20MG; 25MG	A076348	004	Feb 11, 2004	Mar DISC
@	SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar DISC
@		10MG; 12.5MG	A077483	002	Sep 08, 2005	Mar DISC
@		20MG; 12.5MG	A077483	003	Sep 08, 2005	Mar DISC
@		20MG; 25MG	A077483	004	Sep 08, 2005	Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May NEWA
AP		100MG/VIAL	A205574	002	May 19, 2016	May NEWA
AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar NEWA
AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May NEWA
AP		100MG/VIAL	A204086	002	May 20, 2016	May NEWA
AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar NEWA

TREANDA

AP	+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar CFTG
AP	+		100MG/VIAL	N022249	001	Mar 20, 2008	Mar CFTG

SOLUTION; IV (INFUSION)

BENDEKA

+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Sep CRLD
---	--------------	---------------------	---------	-----	--------------	----------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	TOLMAR	5%; 1.2%	A203688	001	Aug 25, 2016	Aug NEWA
----	--------	----------	---------	-----	--------------	----------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+ CUTANEA 5%;3%
+ 5%;3%N050769 001 Nov 27, 2000 Sep CTNA
N050769 001 Nov 27, 2000 Feb CAHNBENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ IMPAX LABS 50MG

A040845 001 Nov 18, 2008 Mar DISC

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA ASPEN GLOBAL INC 0.5MG

A204713 001 Apr 14, 2015 Jul CAHN

AA 1MG

A204713 002 Apr 14, 2015 Jul CAHN

AA 2MG

A204713 003 Apr 14, 2015 Jul CAHN

@ FRONTIDA BIOPHARM 1MG

A081264 001 Jan 23, 1992 Sep CAHN

@ 2MG

A081265 001 Jan 23, 1992 Jul CAHN

>A> AA VINTAGE 0.5MG

A040715 001 Aug 27, 2007 Oct CMS1

>A> AA 1MG

A040715 002 Aug 27, 2007 Oct CMS1

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

+ PROMIUS PHARMA LLC EQ 0.05% BASE/SPRAY

N208079 001 Feb 05, 2016 Feb NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB GLENMARK PHARMS EQ 0.05% BASE;1%

A202894 001 Oct 30, 2015 Mar CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT TELIGENT PHARMA INC EQ 0.5% BASE

A075630 001 Apr 12, 2001 Jan CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS 5MG

A040739 001 Nov 01, 2006 Mar DISC

@ 10MG

A040741 001 Nov 01, 2006 Mar DISC

@ 25MG

A040740 001 Nov 01, 2006 Mar DISC

@ 50MG

A040721 004 Nov 01, 2006 Mar DISC

>D> AA SUN PHARM INDS INC 5MG

A040897 001 Apr 22, 2009 Oct DISC

>A> @ 5MG

A040897 001 Apr 22, 2009 Oct DISC

>D> AA 10MG

A040897 002 Apr 22, 2009 Oct DISC

>A> @ 10MG

A040897 002 Apr 22, 2009 Oct DISC

>D> AA 25MG

A040897 003 Apr 22, 2009 Oct DISC

>A> @ 25MG

A040897 003 Apr 22, 2009 Oct DISC

>D> AA 50MG

A040897 004 Apr 22, 2009 Oct DISC

>A> @ 50MG

A040897 004 Apr 22, 2009 Oct DISC

DUVOID

AA BI-COASTAL PHARMA 10MG

A086262 001 Jul CAHN

AA 25MG

A086263 001 Jul CAHN

AA 50MG

A085882 003 Jul CAHN

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT SANDOZ INC 0.03%

A202719 001 Apr 19, 2016 Apr NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

@ SEBELA IRELAND LTD 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,
N/A,500MG

N050719 001 Aug 15, 1996 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL							
BISOPROLOL FUMARATE							
AB	+	@ FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul CAHN
		@	10MG	A075474	002	Oct 25, 2002	Jul CAHN
		MYLAN	10MG	A075831	002	Dec 14, 2005	Aug CRLD
		@ SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Mar CAHN
		@	10MG	A075474	002	Oct 25, 2002	Mar CAHN
		ZEBETA					
		@ TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Aug DISC
		@	10MG	N019982	001	Jul 31, 1992	Aug DISC

BIVALIRUDIN

INJECTABLE; INTRAVENOUS							
BIVALIRUDIN							
>A> AP		FRESENIUS KABI USA	250MG/VIAL	A090189	001	Oct 28, 2016	Oct NEWA

BLEOMYCIN SULFATE

INJECTABLE; INJECTION							
BLEOMYCIN SULFATE							
AP		WEST-WARD PHARMS INT	EQ 15 UNITS BASE/VIAL	A065042	002	Oct 17, 2001	Sep CAHN
AP			EQ 30 UNITS BASE/VIAL	A065042	001	Oct 17, 2001	Sep CAHN

BOCEPREVIR

CAPSULE; ORAL							
VICTRELIS							
		@ MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Jun DISC

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION							
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
		@ B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986	Sep DISC
		@	200MG/100ML	N019121	002	Apr 29, 1986	Sep DISC
		@	400MG/100ML	N019121	003	Apr 29, 1986	Sep DISC

BRIVARACETAM

SOLUTION; INTRAVENOUS							
BRIVIACT							
+	UBC INC	50MG/5ML (10MG/ML)		N205837	001	Feb 18, 2016	Feb NEWA
+	UCB INC	50MG/5ML (10MG/ML)		N205837	001	May 12, 2016	May CMS1
SOLUTION; ORAL							
BRIVIACT							
+	UCB INC	10MG/ML		N205838	001	May 12, 2016	May CMS1
+		10MG/ML		N205838	001	Feb 18, 2016	Feb NEWA
TABLET; ORAL							
BRIVIACT							
	UCB INC	10MG		N205836	001	May 12, 2016	May CMS1
		10MG		N205836	001	Feb 18, 2016	Feb NEWA
		25MG		N205836	002	May 12, 2016	May CMS1
		25MG		N205836	002	Feb 18, 2016	Feb NEWA
		50MG		N205836	003	May 12, 2016	May CMS1
		50MG		N205836	003	Feb 18, 2016	Feb NEWA
		75MG		N205836	004	May 12, 2016	May CMS1
		75MG		N205836	004	Feb 18, 2016	Feb NEWA
+		100MG		N205836	005	May 12, 2016	May CMS1
+		100MG		N205836	005	Feb 18, 2016	Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC							
BROMSITE							
+	INSITE VISION INC	EQ 0.075% ACID		N206911	001	Apr 08, 2016	Apr NEWA
+	SUN PHARMA GLOBAL	EQ 0.075% ACID		N206911	001	Apr 08, 2016	Jul CAHN

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL							
BROMOCRIPTINE MESYLATE							
AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD
TABLET; ORAL							
BROMOCRIPTINE MESYLATE							
AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN

TABLET;ORAL

PARLODEL

AB	US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr	CMFD
	@	EQ 2.5MG BASE	N017962	001		Jan	DISC

BROMPHENIRAMINE MALEATE

TABLET;ORAL

BROMPHENIRAMINE MALEATE

>D>	@ SANDOZ	4MG	A083215	001		Oct	CAHN
>A>	@ UPSHER-SMITH LABS	4MG	A083215	001		Oct	CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	ACELLA PHARMS LLC	2MG/5ML;10MG/5ML;30MG/5ML	A203375	001	Sep 20, 2016	Sep	NEWA
----	-------------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB	ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar	NEWA
AB	MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Aug	CAHN
	ENTOCORT EC						
AB	+ ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan	CAHN
AB	+ PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May	CAHN

SUSPENSION;INHALATION

BUDESONIDE

AN	APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun	CMFD
AN		0.5MG/2ML	A078202	002	Mar 30, 2009	Jun	CMFD
AN	IMPAX LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Aug	CAHN
AN		0.5MG/2ML	A078404	002	Jul 31, 2012	Aug	CAHN
AN	TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb	NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	+ AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun	CAHN
AP	+ EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr	CAHN

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

	+ PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Sep	CMFD
--	---------------------	------------------------	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May	NEWA
AP		0.5%	A207183	002	May 13, 2016	May	NEWA

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP	CLARIS	0.75%	A207266	001	Jul 25, 2016	Jul	NEWA
----	--------	-------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION

PROBUPHINE

	+ BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun	CAHN
	+ TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May	NEWA

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Oct	CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Oct	CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan	NEWA
AB		EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	KREMERS URBAN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205022	001	Sep 19, 2016	Sep NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205022	002	Sep 19, 2016	Sep NEWA
AB	SUN PHARM INDS LTD	EQ 8MG BASE;EQ 2MG BASE	A201633	002	Aug 05, 2016	Jul NEWA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
AB	SUN PHARM INDS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A201633	001	Aug 05, 2016	Jul NEWA
ZUBSOLV						
>A>	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016	Oct NEWA
		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	+	APOTEX INC	100MG	A076143	002	Jan 17, 2006	Sep CRLD
AB		HERITAGE PHARMA	75MG	A206975	001	Aug 19, 2016	Aug NEWA
AB			100MG	A206975	002	Aug 19, 2016	Aug NEWA
WELLBUTRIN							
	@	GLAXOSMITHKLINE	75MG	N018644	002	Dec 30, 1985	Sep DISC
	@		100MG	N018644	003	Dec 30, 1985	Sep DISC

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1		INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB3			150MG	A206556	001	Aug 26, 2016	Aug NEWA
AB1			150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1			200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB3			300MG	A206556	002	Aug 26, 2016	Aug NEWA
AB1		SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1			150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB2			150MG	A206122	001	Aug 17, 2016	Aug NEWA
AB1			200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Apr CAHN
---	----------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
AB			10MG	A204582	002	Sep 18, 2015	Jun CAHN
AB			15MG	A204582	003	Sep 18, 2015	Jun CAHN
AB			30MG	A204582	004	Sep 18, 2015	Jun CAHN
AB		IMPAX LABS INC	5MG	A074253	001	Mar 28, 2001	Aug CAHN
AB			10MG	A074253	002	Mar 28, 2001	Aug CAHN
AB			15MG	A074253	003	Mar 13, 2002	Aug CAHN
>A>	AB	MYLAN	7.5MG	A076008	002	Jul 08, 2013	Oct NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP		LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	--	---------------------	--------	---------	-----	--------------	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@	PERRIGO PHARMA INTL	2%	N019881	001	Feb 07, 1997	Jun CAHN
---	---------------------	----	---------	-----	--------------	----------

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

	@	CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan CAHN
AP		EUROHLTH INTL SARL	2MG/ML	A075046	001	Aug 12, 1998	Apr CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE							
	@	CLARIS	1MG/ML	A075695	001	Oct 23, 2001	Mar CAHN

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

	@	2MG/ML	A075695	002	Oct 23, 2001	Mar	CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075045	001	Aug 12, 1998	Apr	CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Apr	CAHN
SPRAY, METERED;NASAL							
BUTORPHANOL TARTRATE							
AB	APOTEX INC	1MG/SPRAY	A075499	001	Dec 04, 2002	Sep	CAHN

CABERGOLINE

TABLET;ORAL

CABERGOLINE

@	IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007	Mar	DISC
---	----------------	-------	---------	-----	--------------	-----	------

CABOZANTINIB S-MALATE

TABLET;ORAL

CABOMETYX

	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016	Apr	NEWA
		EQ 40MG BASE	N208692	002	Apr 25, 2016	Apr	NEWA
+		EQ 60MG BASE	N208692	003	Apr 25, 2016	Apr	NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFCIT

AP	+	WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Sep	CAHN
SOLUTION;ORAL								
CAFCIT								
AA	+	WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Sep	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

+	HORIZON PHARMA	100MG;2MG	A086557	001	Oct 04, 1983	Jan	CAHN
---	----------------	-----------	---------	-----	--------------	-----	------

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

+	OPKO IRELAND GLOBAL	0.03MG	N208010	001	Jun 17, 2016	Jun	NEWA
---	---------------------	--------	---------	-----	--------------	-----	------

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

AB	GLENMARK PHARMS	0.005%	A205772	001	Jun 09, 2015	Mar	CAHN
----	-----------------	--------	---------	-----	--------------	-----	------

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL

FORTICAL

@	UPSHER SMITH	200 IU/SPRAY	N021406	001	Aug 12, 2005	Sep	DISC
---	--------------	--------------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
AB		0.5MCG	A091174	002	May 24, 2013	Jan	CAHN

INJECTABLE;INJECTION

CALCITRIOL

	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb	CTEC
@	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb	DISC

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>A>	AB	ECI PHARMS LLC	EQ 169MG CALCIUM	A203298	001	Jul 26, 2016	Oct	CAHN
>D>	AB	LOTUS PHARM CO LTD	EQ 169MG CALCIUM	A203298	001	Jul 26, 2016	Oct	CAHN
	AB		EQ 169MG CALCIUM	A203298	001	Jul 26, 2016	Jul	NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

>D>	DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER								
>D>	+ B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML ; 9.2GM/100ML; 9.6GM/100ML	N018807	001	Aug 26, 1983			Oct	DISC
>A>	@	510MG/100ML; 30GM/100ML; 200MG/100ML ; 9.2GM/100ML; 9.6GM/100ML	N018807	001	Aug 26, 1983			Oct	DISC
>D>	+	510MG/100ML; 30GM/100ML; 200MG/100ML ; 9.4GM/100ML; 11GM/100ML	N018807	003	Aug 26, 1983			Oct	DISC
>A>	@	510MG/100ML; 30GM/100ML; 200MG/100ML ; 9.4GM/100ML; 11GM/100ML	N018807	003	Aug 26, 1983			Oct	DISC
>D>	DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER								
>D>	+ B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML ; 9.2GM/100ML; 9.6GM/100ML	N018807	002	Aug 26, 1983			Oct	DISC
>A>	@	510MG/100ML; 50GM/100ML; 200MG/100ML ; 9.2GM/100ML; 9.6GM/100ML	N018807	002	Aug 26, 1983			Oct	DISC
>D>	+	510MG/100ML; 50GM/100ML; 200MG/100ML ; 9.4GM/100ML; 11GM/100ML	N018807	004	Aug 26, 1983			Oct	DISC
>A>	@	510MG/100ML; 50GM/100ML; 200MG/100ML ; 9.4GM/100ML; 11GM/100ML	N018807	004	Aug 26, 1983			Oct	DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

	DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/10 0ML; 567MG/100ML; 392MG/100ML	N018379	002				Feb	DISC
	DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/10 0ML; 567MG/100ML; 392MG/100ML	N018379	003				Feb	DISC
	DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/10 0ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988			Feb	DISC
	DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/1 00ML; 567MG/100ML; 392MG/100ML	N018379	001				Feb	DISC
	DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982			Feb	DISC
	DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982			Feb	DISC
	DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988			Feb	DISC
	DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER								
	@ FRESenius MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/1 00ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982			Feb	DISC
>D>	DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER								
>D>	B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 5 30MG/100ML; 450MG/100ML	N018460	007	Jan 29, 1986			Oct	DISC
>A>	@	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 5 30MG/100ML; 450MG/100ML	N018460	007	Jan 29, 1986			Oct	DISC
>D>	DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER								
>D>	B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 5 30MG/100ML; 450MG/100ML	N018460	005	Nov 02, 1983			Oct	DISC
>A>	@	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 5 30MG/100ML; 450MG/100ML	N018460	005	Nov 02, 1983			Oct	DISC
>D>	DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER								
>D>	B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	009	Jan 29, 1986			Oct	DISC
>A>	@	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	009	Jan 29, 1986			Oct	DISC
	DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER								
	BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/10 0ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985			Feb	CTEC
	DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER								
	BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985			Feb	CTEC

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N016682	001			Aug	CRLD
----	---	-----------------	--	---------	-----	--	--	-----	------

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

INVOKAMET XR

JANSSEN PHARMS

50MG; 500MG

N205879 001 Sep 20, 2016 Sep NEWA

50MG; 1GM

N205879 002 Sep 20, 2016 Sep NEWA

150MG; 500MG

N205879 003 Sep 20, 2016 Sep NEWA

>D> 150MG; 1GM

N205879 004 Sep 20, 2016 Oct CRLD

>A> + 150MG; 1GM

N205879 004 Sep 20, 2016 Oct CRLD

150MG; 1GM

N205879 004 Sep 20, 2016 Sep NEWA

CANGRELOR

POWDER; IV (INFUSION)

KENGREAL

+ CHIESI USA INC 50MG/VIAL

N204958 001 Jun 22, 2015 Jul CAHN

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB ROXANE 150MG

A200483 001 Jul 14, 2016 Jul NEWA

AB 500MG

A200483 002 Jul 14, 2016 Jul NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ APOTEX 12.5MG

A074737 001 Oct 28, 1998 Mar DISC

@ 25MG

A074737 002 Oct 28, 1998 Mar DISC

@ 50MG

A074737 003 Oct 28, 1998 Mar DISC

@ 100MG

A074737 004 Oct 28, 1998 Mar DISC

AB HIKMA INTL PHARMS 12.5MG

A074505 001 Feb 13, 1996 Jun CAHN

AB 25MG

A074505 002 Feb 13, 1996 Jun CAHN

AB 50MG

A074505 003 Feb 13, 1996 Jun CAHN

AB 100MG

A074505 004 Feb 13, 1996 Jun CAHN

AB PRINSTON INC 12.5MG

A074477 001 Feb 13, 1996 Jul CMFD

AB 25MG

A074477 002 Feb 13, 1996 Jul CMFD

AB 50MG

A074477 003 Feb 13, 1996 Jul CMFD

AB 100MG

A074477 004 Feb 13, 1996 Jul CMFD

@ SANDOZ 12.5MG

A074363 001 Nov 09, 1995 Jan DISC

@ 25MG

A074363 002 Nov 09, 1995 Jan DISC

@ 50MG

A074363 003 Nov 09, 1995 Jan DISC

@ 100MG

A074363 004 Nov 09, 1995 Jan DISC

@ STASON 12.5MG

A074677 004 May 30, 1997 Mar DISC

@ 25MG

A074677 002 May 30, 1997 Mar DISC

@ 50MG

A074677 001 May 30, 1997 Mar DISC

@ 100MG

A074677 003 May 30, 1997 Mar DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB MYLAN IRELAND LTD 100MG

A076697 001 May 20, 2011 Jan CAHN

AB 200MG

A076697 002 May 20, 2011 Jan CAHN

AB 300MG

A076697 003 May 20, 2011 Jan CAHN

>A> SOLUTION; IV (INFUSION)

>A> CARNEXIV

>A> + LUNDBECK LLC 200MG/20ML (10MG/ML)

N206030 001 Oct 07, 2016 Oct NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB EDENBRIDGE PHARMS 25MG

A205304 001 Feb 17, 2016 Feb NEWA

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	@	IDT AUSTRALIA LTD	10MG;100MG	A 073586	001	Jun 29, 1995	May CAHN
	@		25MG;100MG	A 073587	001	Jun 29, 1995	May CAHN
	@		25MG;250MG	A 073620	001	Jun 29, 1995	May CAHN
AB		MAYNE PHARMA	10MG;100MG	A 073618	001	Aug 28, 1992	Aug CAHN
AB			25MG;100MG	A 073589	001	Aug 28, 1992	Aug CAHN
AB			25MG;250MG	A 073607	001	Aug 28, 1992	Aug CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

		MIKART INC	6MG	A 207484	001	May 31, 2016	May NEWA
--	--	------------	-----	----------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

>D>	@	EUROHLTH INTL SARL	50MG/VIAL	A 076099	001	Oct 14, 2004	Oct CAHN
>D>	@		150MG/VIAL	A 076099	002	Oct 14, 2004	Oct CAHN
>D>	@		450MG/VIAL	A 076099	003	Oct 14, 2004	Oct CAHN
>A>	@	WEST-WARD PHARMS INT	50MG/VIAL	A 076099	001	Oct 14, 2004	Oct CAHN
>A>	@		150MG/VIAL	A 076099	002	Oct 14, 2004	Oct CAHN
>A>	@		450MG/VIAL	A 076099	003	Oct 14, 2004	Oct CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

	@	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A 078732	001	Feb 06, 2012	Apr DISC
	@		150MG/15ML (10MG/ML)	A 078732	002	Feb 06, 2012	Apr DISC
	@		450MG/45ML (10MG/ML)	A 078732	003	Feb 06, 2012	Apr DISC
	@		600MG/60ML (10MG/ML)	A 078732	004	Feb 06, 2012	Apr DISC
>D> AP		EUROHLTH INTL SARL	50MG/5ML (10MG/ML)	A 077244	001	Oct 15, 2004	Oct CAHN
>D> AP			150MG/15ML (10MG/ML)	A 077244	002	Oct 15, 2004	Oct CAHN
>D> AP			450MG/45ML (10MG/ML)	A 077244	003	Oct 15, 2004	Oct CAHN
>D> AP			600MG/60ML (10MG/ML)	A 077244	004	Jan 20, 2006	Oct CAHN
>A> AP		NANJING KING-FRIEND	50MG/5ML (10MG/ML)	A 077096	001	Jun 14, 2005	Oct CAHN
>A> AP			150MG/15ML (10MG/ML)	A 077096	002	Jun 14, 2005	Oct CAHN
>A> AP			450MG/45ML (10MG/ML)	A 077096	003	Jun 14, 2005	Oct CAHN
>A> AP			600MG/60ML (10MG/ML)	A 077096	004	Jun 03, 2013	Oct CAHN
>D> AP		SAGENT PHARMS	50MG/5ML (10MG/ML)	A 077096	001	Jun 14, 2005	Oct CAHN
>D> AP			150MG/15ML (10MG/ML)	A 077096	002	Jun 14, 2005	Oct CAHN
>D> AP			450MG/45ML (10MG/ML)	A 077096	003	Jun 14, 2005	Oct CAHN
>D> AP			600MG/60ML (10MG/ML)	A 077096	004	Jun 03, 2013	Oct CAHN
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A 078280	001	May 08, 2008	Feb CAHN
AP			150MG/15ML (10MG/ML)	A 078280	002	May 08, 2008	Feb CAHN
AP			450MG/45ML (10MG/ML)	A 078280	003	May 08, 2008	Feb CAHN
AP		SANJA PHARMS CO	50MG/5ML (10MG/ML)	A 205487	001	Mar 28, 2016	Mar NEWA
AP			150MG/15ML (10MG/ML)	A 205487	002	Mar 28, 2016	Mar NEWA
AP			450MG/45ML (10MG/ML)	A 205487	003	Mar 28, 2016	Mar NEWA
>A> AP		WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A 077244	001	Oct 15, 2004	Oct CAHN
>A> AP			150MG/15ML (10MG/ML)	A 077244	002	Oct 15, 2004	Oct CAHN
>A> AP			450MG/45ML (10MG/ML)	A 077244	003	Oct 15, 2004	Oct CAHN
>A> AP			600MG/60ML (10MG/ML)	A 077244	004	Jan 20, 2006	Oct CAHN

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

		ONYX THERAP	30MG/VIAL	N 202714	002	Jun 03, 2016	Jun NEWA
+			60MG/VIAL	N 202714	001	Jul 20, 2012	Feb CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>A>	AB	AUROBINDO PHARMA	250MG	A 040792	002	Nov 08, 2016	Oct NEWA
	AA	INGENUS PHARMS NJ	350MG	A 040823	001	Oct 22, 2008	Jan CAHN
	AB	STRIDES PHARMA	250MG	A 205513	001	Nov 12, 2015	May CAHN
	AA		350MG	A 205513	002	Nov 12, 2015	May CAHN

CARVEDILOLTABLET; ORAL
COREG

AB	SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	May CAHN
AB		6.25MG	N020297	003	Sep 14, 1995	May CAHN
AB	+	12.5MG	N020297	002	Sep 14, 1995	May CAHN
AB		25MG	N020297	001	Sep 14, 1995	May CAHN

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE; ORAL
COREG CR

	SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	May CAHN
		20MG	N022012	002	Oct 20, 2006	May CAHN
+		40MG	N022012	003	Oct 20, 2006	May CAHN
		80MG	N022012	004	Oct 20, 2006	May CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION; ORAL
CEFADROXIL

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb DISC
@		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb DISC
@		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb DISC

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

>D>	@	EUROHLTH INTL SARL	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988	Oct CAHN
>D>	@		EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988	Oct CAHN
>D>	@		EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988	Oct CAHN
>D>	@		EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988	Oct CAHN
>D>	@		EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988	Oct CAHN
>D>	@		EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988	Oct CAHN
AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan NEWA
>A>	@	WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988	Oct CAHN
>A>	@		EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988	Oct CAHN
>A>	@		EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988	Oct CAHN
>A>	@		EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988	Oct CAHN
>A>	@		EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988	Oct CAHN
>A>	@		EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988	Oct CAHN

CEFDITOREN PIVOXILTABLET; ORAL
SPECTRACEF

@	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr DISC
@		400MG	N021222	002	Jul 21, 2008	Apr DISC

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP		QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan NEWA
AP			EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan NEWA
AP			EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
AP			EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA
		CLAFORAN					
AP	+	US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
AP	+		EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
AP	+		EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
AP	+		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN
		CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun DISC
	@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun DISC
	+		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN
		CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
	@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION							
CEFOTAN							
AP	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan	CAHN
		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
AP	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan	CAHN
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan	CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan	CAHN
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER							
+	+ B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun	CMS2
	+	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun	CMS2

CEFOXITIN SODIUM

INJECTABLE; INJECTION							
CEFOXITIN							
AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May	CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May	CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May	CAHN
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER							
AP	+ B BRAUN	EQ 1GM BASE/VIAL	N065214	001	Mar 10, 2006	Aug	CRLD
AP	+	EQ 2GM BASE/VIAL	N065214	002	Mar 10, 2006	Aug	CRLD

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL							
CEFPODOXIME PROXETIL							
@	@ SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb	DISC
	@	EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb	DISC
TABLET; ORAL							
CEFPODOXIME PROXETIL							
@	@ SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb	DISC
	@	EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL							
CEDAX							
@	PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun	DISC
FOR SUSPENSION; ORAL							
CEDAX							
@	@ PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun	DISC
	@	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun	DISC

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION							
CEFTRIAXONE							
@	@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr	DISC
	@	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr	DISC
	@	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr	DISC
	@	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr	DISC
ROCEPHIN							
@	@ HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr	DISC
	@	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr	DISC
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS							
CEFTRIAXONE							
@	@ BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun	DISC
	@	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun	DISC
	@	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun	DISC
	@	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun	DISC
AP	QILU PHARM CO LTD	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jun	NEWA
AP		EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jun	NEWA
AP		EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jun	NEWA
AP		EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jun	NEWA

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL							
CEFTIN							
+	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb	CTEC
	+	EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb	CTEC

FOR SUSPENSION;ORAL
CEFUROXIME AXETIL

@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
@	EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC

TABLET;ORAL

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb DISC
@	EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb DISC
@	EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb DISC

CEFUROXIME SODIUMINJECTABLE;INJECTION
ZINACEF

AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan CAHN

ZINACEF IN PLASTIC CONTAINER

@ IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan CAHN
+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
ZINACEF

AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan CAHN
----	---	--------------	--------------------	---------	-----	--------------	----------

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB		AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan NEWA
AB			100MG	A206827	002	Feb 01, 2016	Jan NEWA
AB			200MG	A206827	003	Feb 01, 2016	Jan NEWA
AB			400MG	A206827	004	Feb 01, 2016	Jan NEWA
AB		MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb NEWA
AB			100MG	A204590	002	Mar 16, 2016	Feb NEWA
AB			200MG	A204590	003	Mar 16, 2016	Feb NEWA
AB			400MG	A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

@ SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb DISC
@	EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb DISC

KEFLEX

AB		PRAGMA PHARMS LLC	EQ 250MG BASE	N050405	002		Jul CAHN
	@		EQ 333MG BASE	N050405	004	May 12, 2006	Jul CAHN
AB			EQ 500MG BASE	N050405	003		Jul CAHN
AB	+		EQ 750MG BASE	N050405	005	May 12, 2006	Jul CAHN

FOR SUSPENSION;ORAL
KEFLEX

@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar CAHN
@	EQ 125MG BASE/5ML	N050406	001		Mar CAHN
@	EQ 250MG BASE/5ML	N050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
AA	+	PERRIGO R AND D	5MG/5ML	A078398	001	Jun 17, 2008	Aug CRLD
	@	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC
		ZYRTEC					
	@	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

>D>	@	SANDOZ	5MG	A084678	001		Oct CAHN
>D>	@		10MG	A084041	001		Oct CAHN
>A>	@	UPSHER-SMITH LABS	5MG	A084678	001		Oct CAHN
>A>	@		10MG	A084041	001		Oct CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDECAPSULE;ORAL
LIBRAX

+ VALEANT PHARMS 5MG;2.5MG N012750 001 Jul NEWA

CHLORHEXIDINE GLUCONATESOLUTION;DENTAL
PERIOGARD

AT COLGATE-PALMOLIVE CO 0.12% A203212 001 Jan 28, 2016 Jan NEWA

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT 2% A040273 001 Sep 09, 1998 Sep CAHN

AP 3% A040273 002 Sep 09, 1998 Sep CAHN

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

@ IMPAX LABS EQ 150MG BASE A080880 001 Mar DISC

@ EQ 300MG BASE A040516 001 Aug 29, 2003 Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 4MG A080961 001 Mar CAHN

@ SUN PHARM INDS 4MG A080700 001 Jun CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

@ SPRIASO LLC 8MG;54.3MG N206323 001 Jun 22, 2015 Jun DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA MAYNE PHARMA INC 4MG/5ML;5MG/5ML;60MG/5ML A205657 001 Aug 03, 2015 Feb CAHN

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC 100MG A088725 001 Aug 31, 1984 Mar CAHN

@ 250MG A088726 001 Aug 31, 1984 Mar CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB MYLAN 25MG A086831 002 Jan CTEC

AB SUN PHARM INDS 25MG A089286 002 Jul 21, 1986 Jan NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC 250MG A089852 001 May 04, 1988 Feb CAHN

@ 500MG A089853 001 May 04, 1988 Feb CAHN

+ MIKART 750MG A040861 002 Jun 01, 2010 Apr CRLD

+ MIKART INC 250MG A207483 001 Jun 24, 2016 Jun NEWA

@ SUN PHARM INDS 500MG A089970 001 Sep 27, 1990 Mar CAHN

AA + WATSON LABS 500MG A089859 001 May 04, 1988 Jul CRLD

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB IMPAX LABS INC EQ 45MG FENOFIBRIC ACID A200264 001 Sep 07, 2016 Aug NEWA

AB EQ 135MG FENOFIBRIC ACID A200264 002 Sep 07, 2016 Aug NEWA

CICLESONIDEAEROSOL, METERED; INHALATION
ALVESCO

+ TAKEDA GMBH 0.08MG/INH N021658 002 Jan 10, 2008 Jan CRLD

CILASTATIN SODIUM; IMIPENEMPOWDER; INTRAMUSCULAR
PRIMAXIN

@ MERCK EQ 500MG BASE/VIAL; 500MG/VIAL N050630 001 Dec 14, 1990 May DISC

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

	@ FRONTIDA BIOPHARM	50MG	A077208	002	Mar 29, 2006	Jul	CAHN
	@	100MG	A077208	001	Mar 29, 2006	Jul	CAHN
	@ SUN PHARM INDS	50MG	A077208	002	Mar 29, 2006	Jun	CAHN
	@	100MG	A077208	001	Mar 29, 2006	Jun	CAHN
AB	+ TEVA	50MG	A077027	001	Nov 24, 2004	Jun	CRLD
AB	+ PLETAL	100MG	A077027	002	Nov 24, 2004	Jun	CRLD
	@ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jun	DISC
	@	100MG	N020863	002	Jan 15, 1999	Jun	DISC

CIMETIDINETABLET; ORAL
CIMETIDINE

>D>	@ SANDOZ	200MG	A074506	001	Jan 24, 1996	Oct	CAHN
>D>	@	300MG	A074506	002	Jan 24, 1996	Oct	CAHN
>D>	@	400MG	A074506	003	Jan 24, 1996	Oct	CAHN
>D>	@	800MG	A074506	004	Jan 24, 1996	Oct	CAHN
>A>	@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Oct	CAHN
>A>	@	300MG	A074506	002	Jan 24, 1996	Oct	CAHN
>A>	@	400MG	A074506	003	Jan 24, 1996	Oct	CAHN
>A>	@	800MG	A074506	004	Jan 24, 1996	Oct	CAHN

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

AT TELIGENT PHARMA INC EQ 0.3% BASE A076754 001 Jun 09, 2004 Jul CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	EQ 100MG BASE	A075939	001	Mar 03, 2005	May	CAHN
	@	EQ 250MG BASE	A075939	002	Jun 09, 2004	May	CAHN
	@	EQ 500MG BASE	A075939	003	Jun 09, 2004	May	CAHN
	@	EQ 750MG BASE	A075939	004	Jun 09, 2004	May	CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDESOLUTION/DROPS; OTIC
OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE; 0.025% N208251 001 Apr 29, 2016 Apr NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

	@ ACTAVIS LABS FL INC	212.6MG; EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan	DISC
	@	425.2MG; EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan	DISC

CISPLATININJECTABLE; INJECTION
CISPLATIN

>D>	AP	EUROHLTH INTL SARL	1MG/ML	A075036	001	Nov 07, 2000	Oct	CAHN
>A>	AP	WEST-WARD PHARMS INT	1MG/ML	A075036	001	Nov 07, 2000	Oct	CAHN

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

	@ SUN PHARM INDS	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar	CAHN
	@	EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar	CAHN
	@	EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar	CAHN

CLADRIBINEINJECTABLE; INJECTION
CLADRIBINE

>D>	AP	EUROHLTH INTL SARL	1MG/ML	A075405	001	Feb 28, 2000	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	1MG/ML	A075405	001	Feb 28, 2000	Oct CAHN

CLARITHROMYCINTABLET, EXTENDED RELEASE; ORAL
CLARITHROMYCIN

AB		ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb NEWA
		@ IDT AUSTRALIA LTD	500MG	A065250	001	Aug 25, 2005	May CAHN
AB	+	MAYNE PHARMA	500MG	A065154	001	May 18, 2005	Aug CAHN

CLEVIDIPINEEMULSION; INTRAVENOUS
CLEVIPREX

+	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Aug CAHN
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Aug CAHN
+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Aug CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	May NEWA
----	--	------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATECREAM; VAGINAL
CLINDESSE

+	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004	Jun CAHN
---	---------------------	------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

>D>		@ EUROHLTH INTL SARL	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987	Oct CAHN
>D>	AP		EQ 150MG BASE/ML	A062889	001	Apr 25, 1988	Oct CAHN
>D>		@	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988	Oct CAHN
>D>		@	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989	Oct CAHN
	AP		EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Apr CAHN
>A>		@ WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987	Oct CAHN
>A>	AP		EQ 150MG BASE/ML	A062889	001	Apr 25, 1988	Oct CAHN
>A>		@	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988	Oct CAHN
>A>		@	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989	Oct CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>A>		@ INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Oct CAHN
>D>		@ RENAISSANCE PHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Oct CAHN

CLINDAMYCIN PHOSPHATE; TRETINOINGEL; TOPICAL
VELTIN

BX	+	AQUA PHARMS LLC	1.2%; 0.025%	N050803	001	Jul 16, 2010	Jan CAHN
----	---	-----------------	--------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

>A>		@ INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	Oct CAHN
>D>		@ RENAISSANCE PHARMA	0.05%	A075733	001	Aug 22, 2001	Oct CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar CRLD
		TEMOVATE					
		@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan CRLD

CLONIDINEFILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE

AB	MAYNE PHARMA	0.1MG/24HR	A079090	001	Aug 20, 2010	Aug CAHN
AB		0.2MG/24HR	A079090	002	Aug 20, 2010	Aug CAHN
AB		0.3MG/24HR	A079090	003	Aug 20, 2010	Aug CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb CAHN
	@	0.2MG	A070886	001	Aug 31, 1988	Feb CAHN
	@	0.3MG	A071294	001	Aug 31, 1988	Feb CAHN
AB	FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987	Jul CAHN
AB		0.2MG	A070924	001	Sep 04, 1987	Jul CAHN
AB		0.3MG	A070923	001	Sep 04, 1987	Jul CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

	@ ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun DISC
AB	SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG
@	7.5MG
@	15MG

A072219	001	Aug 26, 1988	Apr CAHN
A072220	001	Aug 26, 1988	Feb CAHN
A072112	001	Aug 26, 1988	Feb CAHN

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG
@	7.5MG
@	15MG

A072512	001	May 11, 1990	Mar CAHN
A072513	001	May 11, 1990	Mar CAHN
A072514	001	May 11, 1990	Feb CAHN

TRANXENE

@ RECORDATI RARE 3.75MG

N017105 006 Jun DISC

CLOZAPINE

TABLET;ORAL

CLOZAPINE

AB	MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015	Aug CAHN
AB		100MG	A203807	002	Sep 17, 2015	Aug CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	NOSTRUM LABS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Feb CAHN
----	------------------	---------------------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL

MITIGARE

+ HIKMA INTL PHARMS 0.6MG

N204820 001 Sep 26, 2014 Mar CRLD

TABLET;ORAL

COLCRYS

>D> AB + TAKEDA PHARMS USA 0.6MG

N022352 001 Jul 29, 2009 Oct CTEC

>A> + 0.6MG

N022352 001 Jul 29, 2009 Oct CTEC

AB + 0.6MG

N022352 001 Jul 29, 2009 Sep CFTG

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

AB	INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Jan CAHN
----	-------------------	-------------	---------	-----	--------------	----------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

+ ENDO PHARMS INC EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG
BASE/ML;0.5MG/ML

N050356 001 Feb CAHN

CORTICOTROPIN

INJECTABLE;INJECTION
PURIFIED CORTROPHIN GEL

@ ANI PHARMS 40 UNITS/ML
@ 80 UNITS/ML

N008975 001
N008975 002

Feb CAHN
Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML

N009854 001

Feb CAHN

CROFELEMER

TABLET, DELAYED RELEASE;ORAL
FULYZAQ

+ NAPO PHARMS INC 125MG

N202292 001 Dec 31, 2012 Jun CAHN

CROTAMITON

LOTION;TOPICAL
CROTAN

AT MARNEL PHARMS 10%

A087204 001

Aug CAHN

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML

A206503 001 Dec 11, 2015 Mar CAHN

SPRAY, METERED;NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY

N021642 001 Jan 31, 2005 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
AMRIX

>D> AB IVAX INTL 15MG

N021777 001 Feb 01, 2007 Oct CAHN

>D> AB + 30MG

N021777 002 Feb 01, 2007 Oct CAHN

>A> AB TEVA PHARMS INTL 15MG

N021777 001 Feb 01, 2007 Oct CAHN

>A> AB + 30MG

N021777 002 Feb 01, 2007 Oct CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

>D> AB TWI PHARMS INC 15MG

A091281 001 Jan 31, 2013 Oct DISC

>A> @ 15MG

A091281 001 Jan 31, 2013 Oct DISC

>D> AB 30MG

A091281 002 Jan 31, 2013 Oct DISC

>A> @ 30MG

A091281 002 Jan 31, 2013 Oct DISC

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB FRONTIDA BIOPHARM 5MG

A073541 002 Apr 06, 2006 Jul CAHN

AB 10MG

A073541 001 May 23, 1995 Jul CAHN

>D> @ SANDOZ 5MG

A072854 002 Feb 03, 2006 Oct CAHN

>D> @ 10MG

A072854 001 Nov 19, 1991 Oct CAHN

>A> @ UPSHER-SMITH LABS 5MG

A072854 002 Feb 03, 2006 Oct CAHN

>A> @ 10MG

A072854 001 Nov 19, 1991 Oct CAHN

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL

N012142 003

Mar DISC

@ 1GM/VIAL

N012142 004 Aug 30, 1982

Mar DISC

@ 2GM/VIAL

N012142 005 Aug 30, 1982

Mar DISC

>D> TABLET;ORAL

>D> CYCLOPHOSPHAMIDE

>D> ROXANE 25MG

A040032 001 Aug 17, 1999 Oct DISC

>A> @ 25MG

A040032 001 Aug 17, 1999 Oct DISC

>D> + 50MG

A040032 002 Aug 17, 1999 Oct DISC

>A> @ 50MG

A040032 002 Aug 17, 1999 Oct DISC

CYCLOSPORINE

CAPSULE;ORAL
CYCLOSPORINE

AB1 MAYNE PHARMA 25MG

A065044 002 Dec 20, 2000 Aug CAHN

AB1 100MG

A065044 001 Dec 20, 2000 Aug CAHN

INJECTABLE; INJECTION							
CYCLOSPORINE							
AP	WEST-WARD PHARMS INT	50MG/ML	A065004	001	Oct 29, 1999	Sep	CAHN
SOLUTION; ORAL							
CYCLOSPORINE							
AB1	MAYNE PHARMA	100MG/ML	A065054	001	Dec 18, 2001	Aug	CAHN
<u>CYPROHEPTADINE HYDROCHLORIDE</u>							
TABLET; ORAL							
CYPROHEPTADINE HYDROCHLORIDE							
AA	INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan	CAHN
<u>CYTARABINE</u>							
INJECTABLE; INJECTION							
CYTARABINE							
AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
AP		20MG/ML	A200916	001	Dec 13, 2011	Mar	CAHN
AP	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Sep	CAHN
AP		500MG/VIAL	A071472	001	Aug 02, 1989	Sep	CAHN
AP		1GM/VIAL	A074245	001	Aug 31, 1994	Sep	CAHN
AP		2GM/VIAL	A074245	002	Aug 31, 1994	Sep	CAHN
<u>DACARBAZINE</u>							
INJECTABLE; INJECTION							
DACARBAZINE							
>D> AP	EUROHLTH INTL SARL	200MG/VIAL	A075812	001	Jun 15, 2001	Oct	CAHN
>D> AP		500MG/VIAL	A075812	002	Oct 31, 2002	Oct	CAHN
>A> AP	WEST-WARD PHARMS INT	200MG/VIAL	A075812	001	Jun 15, 2001	Oct	CAHN
>A> AP		500MG/VIAL	A075812	002	Oct 31, 2002	Oct	CAHN
<u>DACLATASVIR DIHYDROCHLORIDE</u>							
TABLET; ORAL							
DAKLINZA							
	BRISTOL-MYERS SQUIBB	EQ 90MG BASE	N206843	003	Apr 13, 2016	Apr	NEWA
<u>DACTINOMYCIN</u>							
INJECTABLE; INJECTION							
DACTINOMYCIN							
>D>	@ EUROHLTH INTL SARL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Oct	CAHN
	@	0.5MG/VIAL	A090304	001	Mar 16, 2010	Feb	DISC
>A>	@ WEST-WARD PHARMS INT	0.5MG/VIAL	A090304	001	Mar 16, 2010	Oct	CAHN
<u>DALBAVANCIN HYDROCHLORIDE</u>							
POWDER; IV (INFUSION)							
DALVANCE							
+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jan	CDFR
<u>DANAZOL</u>							
CAPSULE; ORAL							
DANAZOL							
AB	LANNETT	50MG	A077246	002	Apr 19, 2007	Sep	NEWA
AB		100MG	A077246	003	Apr 19, 2007	Sep	NEWA
<u>DANTROLENE SODIUM</u>							
FOR SUSPENSION; INTRAVENOUS							
RYANODEX							
+	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jun	CRLD
INJECTABLE; INJECTION							
DANTROLENE SODIUM							
AP	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Feb	NEWA
<u>DAPSONE</u>							
GEL; TOPICAL							
ACZONE							
+	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016	Feb	NEWA
TABLET; ORAL							
DAPSONE							
AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Mar	CAHN
AB		100MG	A205429	002	Jan 07, 2016	Mar	CAHN
AB	NORTH CREEK PHARMS	25MG	A204074	001	May 10, 2016	Apr	NEWA
AB		100MG	A204074	002	May 10, 2016	Apr	NEWA

TABLET;ORAL
DAPSONE

AB	NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016	Apr NEWA
AB		100MG	A203887	002	May 06, 2016	Apr NEWA

DAPTOMYCIN

POWDER;INTRAVENOUS
CUBICIN

AP	+ CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan CDFR
AP	+ CUBIST PHARMS LLC	500MG/VIAL	N021572	002	Sep 12, 2003	Aug CAHN
	CUBICIN RF					
	+ CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016	Aug NEWA
	DAPTOMYCIN					
AP	CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016	Jun NEWA
AP	HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR
AP	TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Mar NEWA
	POWDER;IV (INFUSION)					
	CUBICIN					
	@ CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR
	@ CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003	Aug CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 7.5MG BASE	A206743	001	Sep 19, 2016	Sep NEWA
AB		EQ 15MG BASE	A206743	002	Sep 19, 2016	Sep NEWA
AB	CIPLA LTD	EQ 7.5MG BASE	A207664	001	Sep 01, 2016	Aug NEWA
AB		EQ 15MG BASE	A207664	002	Sep 01, 2016	Aug NEWA
>A> AB	JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Oct NEWA
>A> AB		EQ 15MG BASE	A205550	002	Oct 12, 2016	Oct NEWA
	ENABLEX					
AB	APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR

+	ABBVIE INC	EQ 200MG BASE;8.33MG;50MG;33.33MG	N208624	001	Jul 22, 2016	Jul NEWA
---	------------	-----------------------------------	---------	-----	--------------	----------

DASATINIB

TABLET;ORAL
DASATINIB

AB	APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
AB		50MG	A202103	002	Jun 10, 2016	May NEWA
AB		70MG	A202103	003	Jun 10, 2016	May NEWA
AB		100MG	A202103	004	Jun 10, 2016	May NEWA
	SPRYCEL					
AB	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
AB		50MG	N021986	002	Jun 28, 2006	May CFTG
AB		70MG	N021986	003	Jun 28, 2006	May CFTG
AB	+	100MG	N021986	004	May 30, 2008	May CFTG

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL;INJECTION
DAUNOXOME

@	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	May DISC
---	------------	----------------	---------	-----	--------------	----------

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
CERUBIDINE

AP	+ WEST-WARD PHARMS INT	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Sep CAHN
	DAUNORUBICIN HYDROCHLORIDE					
AP	+ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Sep CAHN

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan NEWA

TABLET, FOR SUSPENSION;ORAL
EXJADE

AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION
DEFEROXAMINE MESYLATE

>D>	AP	EUROHLTH INTL SARL	500MG/VIAL	A078086	001	May 30, 2007	Oct CAHN
>D>	AP		2GM/VIAL	A078086	002	May 30, 2007	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	500MG/VIAL	A078086	001	May 30, 2007	Oct CAHN
>A>	AP		2GM/VIAL	A078086	002	May 30, 2007	Oct CAHN

DEFIBROTIDE SODIUM

SOLUTION;IV (INFUSION)
DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Aug CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL
DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
@		300MG	A065094	002	Mar 22, 2004	Mar DISC

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
>A>	AB	COREPHARMA	A205153	001	Oct 28, 2016	Oct NEWA
>A>	AB		A205153	002	Oct 28, 2016	Oct NEWA
>A>	AB		A205153	003	Oct 28, 2016	Oct NEWA
>A>	AB		A205153	004	Oct 28, 2016	Oct NEWA
>A>	AB		A205153	005	Oct 28, 2016	Oct NEWA
>A>	AB		A205153	006	Oct 28, 2016	Oct NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun CAHN
AB		25MG	A207433	002	May 05, 2016	Jun CAHN
AB		50MG	A207433	003	May 05, 2016	Jun CAHN
AB		75MG	A207433	004	May 05, 2016	Jun CAHN
AB		100MG	A207433	005	May 05, 2016	Jun CAHN
AB		150MG	A207433	006	May 05, 2016	Jun CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA
AB		25MG	A207433	002	May 05, 2016	Apr NEWA
AB		50MG	A207433	003	May 05, 2016	Apr NEWA
AB		75MG	A207433	004	May 05, 2016	Apr NEWA
AB		100MG	A207433	005	May 05, 2016	Apr NEWA
AB		150MG	A207433	006	May 05, 2016	Apr NEWA
	NORPRAMIN					
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
AB		25MG	N014399	001		Jan CAHN
AB		50MG	N014399	003		Jan CAHN
AB		75MG	N014399	004		Jan CAHN
AB	+	100MG	N014399	005		Jan CAHN
AB		150MG	N014399	006		Jan CAHN

DESLORATADINE

SOLUTION;ORAL
DESLORATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May NEWA
----	------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL
STIMATE (NEEDS NO REFRIGERATION)

+	CSL BEHRING	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Aug CPOT
---	-------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

DESMOPRESSIN ACETATE

	@ FERRING	0.1MG	N021795	001	May 08, 2008	Jun	DISC
	@	0.2MG	N021795	002	May 08, 2008	Jun	DISC
AB	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug	CAHN
AB		0.2MG	A077122	002	Jan 25, 2006	Aug	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	+ DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	002	Aug 12, 1999	Sep	CRLD
AB	MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Aug	CAHN
AB		0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Aug	CAHN
	ORTHO-CEPT						
	@ JANSSSEN PHARMS	0.15MG;0.03MG	N020301	002	Dec 14, 1992	Sep	DISC
	VOLNEA						
AB	SANDOZ INC	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug	NEWA

DESONIDE

CREAM;TOPICAL

DESONIDE

AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

GEL;TOPICAL

DESOXIMETASONE

AB	GROUPE PARIMA INC	0.05%	A204675	001	Aug 12, 2016	Aug	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

DESOXIMETASONE

>A> AB	ACTAVIS MID ATLANTIC	0.25%	A204965	001	Nov 07, 2016	Oct	NEWA
AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr	NEWA
AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May	CAHN
AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb	NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul	NEWA
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul	NEWA
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul	NEWA
AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb	NEWA
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb	NEWA
	PRISTIQ						
AB	WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul	CFTG

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

@ IDT AUSTRALIA LTD

@ SUN PHARM INDS

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

	@ IDT AUSTRALIA LTD	0.75MG	A080399	001		May	CAHN
	@ SUN PHARM INDS	0.25MG	A084013	001		Mar	CAHN
	@	0.25MG	A084764	001		Mar	CAHN
	@	0.5MG	A084084	001		Mar	CAHN
	@	0.5MG	A084766	001		Mar	CAHN
	@	0.75MG	A084081	001		Mar	CAHN
	@	0.75MG	A084765	001		Mar	CAHN
	@	1.5MG	A084086	001		Mar	CAHN
	@	1.5MG	A084763	001		Mar	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+ FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar	CTNA
----	----------------------	----------------------	---------	-----	--------------	-----	------

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

+ TAKEDA PHARMS USA

30MG

N208056	001	Jan 26, 2016	Jan	NEWA
---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan NEWA
>A> AP	ACTAVIS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204686	001	Oct 17, 2016	Oct NEWA
AP	AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar NEWA
AP	SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May NEWA
	PRECEDEX					
+	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb CRLD

DESMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

AB	IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015	Aug CAHN
AB		10MG	A079108	002	Aug 05, 2015	Aug CAHN
AB		15MG	A079108	003	May 19, 2014	Aug CAHN
AB		20MG	A079108	004	Dec 21, 2015	Aug CAHN
AB		30MG	A079108	005	Nov 21, 2013	Aug CAHN

TABLET; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
AB		5MG	A201231	002	Sep 24, 2015	Feb CAHN
AB		10MG	A201231	003	Sep 24, 2015	Feb CAHN
AB	TRIS PHARMA INC	2.5MG	A207901	001	Aug 26, 2016	Aug NEWA
AB		5MG	A207901	002	Aug 26, 2016	Aug NEWA
AB		10MG	A207901	003	Aug 26, 2016	Aug NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

>D> AP	EUROHLTH INTL SARL	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Oct CAHN
>D> AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Oct CAHN
>A> AP	WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Oct CAHN
>A> AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Oct CAHN
	TOTECT					
+	CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

AB	MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Aug CAHN
AB		10MG	A076137	002	Jan 18, 2002	Aug CAHN
AB		15MG	A076137	003	Jan 18, 2002	Aug CAHN
AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

	@ COREPHARMA	5MG	A090652	001	Mar 07, 2014	Sep DISC
	@	10MG	A090652	002	Mar 07, 2014	Sep DISC
	@ IDT AUSTRALIA LTD	5MG	A085370	001		Aug CAHN
AA	NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA		10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA		10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@	ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984	Feb CMS1
---	------------	----------------------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

>A> AP	FRESENIUS KABI USA	50MG/ML	A207449	001	Oct 21, 2016	Oct NEWA
--------	--------------------	---------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;1	N019515	001	May 08, 1986	Sep DISC
	00MG/100ML;180MG/100ML;280MG/100ML				
	;16MG/100ML				

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;2	N017484	001		Feb CMS1
	0MG/100ML;12MG/100ML;260MG/100ML				

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;	N018840	001	Jun 29, 1983	Feb CMS1
	120MG/100ML;220MG/100ML				

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D> AP	BAXTER HLTHCARE	2.5GM/100ML;450MG/100ML	N016697	001		Oct CRLD
>A> AP	+	2.5GM/100ML;450MG/100ML	N016697	001		Oct CRLD
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	HOSPIRA	5GM/100ML;225MG/100ML	N017606	001		Oct CRLD
>A>	+	5GM/100ML;225MG/100ML	N017606	001		Oct CRLD
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	HOSPIRA	5GM/100ML;300MG/100ML	N017799	001		Oct CRLD
>A>	+	5GM/100ML;300MG/100ML	N017799	001		Oct CRLD

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

>D>	@ EUROHLTH INTL SARL	5MG/ML	A070311	001	Dec 16, 1985	Oct CAHN
>D>	@	5MG/ML	A070312	001	Dec 16, 1985	Oct CAHN
>D>	@	5MG/ML	A070313	001	Dec 16, 1985	Oct CAHN
	@	5MG/ML	A070313	001	Dec 16, 1985	Jan CAHN
>D>	@	5MG/ML	A071308	001	Jul 17, 1987	Oct CAHN
>D>	@	5MG/ML	A071309	001	Jul 17, 1987	Oct CAHN
>D>	@	5MG/ML	A071310	001	Jul 17, 1987	Oct CAHN
>A>	@ WEST-WARD PHARMS INT	5MG/ML	A070311	001	Dec 16, 1985	Oct CAHN
>A>	@	5MG/ML	A070312	001	Dec 16, 1985	Oct CAHN
>A>	@	5MG/ML	A070313	001	Dec 16, 1985	Oct CAHN
>A>	@	5MG/ML	A071308	001	Jul 17, 1987	Oct CAHN
>A>	@	5MG/ML	A071309	001	Jul 17, 1987	Oct CAHN
>A>	@	5MG/ML	A071310	001	Jul 17, 1987	Oct CAHN

SOLUTION;ORAL

DIAZEPAM

AA	LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun NEWA
AA	+	ROXANE	A070928	001	Apr 03, 1987	Jun CFTG

TABLET;ORAL

DIAZEPAM

	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan NEWA
		5MG	A070228	003	Sep 26, 1985	Jan NEWA
AB	MAYNE PHARMA	2MG	A071134	001	Feb 03, 1987	Aug CAHN
AB		5MG	A071135	001	Feb 03, 1987	Aug CAHN
AB		10MG	A071136	001	Feb 03, 1987	Aug CAHN
>D>	@ SANDOZ	2MG	A070302	001	Dec 20, 1985	Oct CAHN
>D>	@	5MG	A070303	001	Dec 20, 1985	Oct CAHN
>D>	@	10MG	A070304	001	Dec 20, 1985	Oct CAHN
>A>	@ UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Oct CAHN
>A>	@	5MG	A070303	001	Dec 20, 1985	Oct CAHN
>A>	@	10MG	A070304	001	Dec 20, 1985	Oct CAHN

DICLOFENAC POTASSIUM

CAPSULE; ORAL					
DICLOFENAC POTASSIUM					
AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016 Feb NEWA
ZIPSOR					
AB	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009 Feb CFTG
FOR SOLUTION; ORAL					
CAMBIA					
AB	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009 Apr CFTG
DICLOFENAC POTASSIUM					
AB	PAR FORM	50MG	A202964	001	May 02, 2016 Apr NEWA
TABLET; ORAL					
CATAFLAM					
@ NOVARTIS		50MG	N020142	002	Nov 24, 1993 Mar DISC
DICLOFENAC POTASSIUM					
AB	+ MYLAN	50MG	A075463	001	Jul 26, 1999 Mar CRLD
@ SUN PHARM INDS		50MG	A075470	001	Feb 21, 2002 Jun CAHN

DICLOFENAC SODIUM

GEL; TOPICAL					
DICLOFENAC SODIUM					
AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016 Mar NEWA
AB	GLENMARK PHARMS LTD	3%	A208301	001	Sep 13, 2016 Aug NEWA
AB	TARO	3%	A206298	001	Apr 28, 2016 Apr NEWA
VOLTAREN					
AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007 Mar CFTG
SOLUTION; TOPICAL					
DICLOFENAC SODIUM					
AT	AMNEAL PHARMS	1.5%	A206116	001	Sep 02, 2016 Aug NEWA
AT	TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015 May CAHN
SOLUTION/DROPS; OPHTHALMIC					
DICLOFENAC SODIUM					
AT	RIISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007 Jan CAHN
TABLET, EXTENDED RELEASE; ORAL					
DICLOFENAC SODIUM					
AB	+ ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002 Feb CRLD
VOLTAREN-XR					
@ NOVARTIS		100MG	N020254	001	Mar 08, 1996 Feb DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL					
DICLOFENAC SODIUM AND MISOPROSTOL					
AB	EXELA PHARMA SCS LLC	50MG; 0.2MG	A200540	001	Mar 14, 2014 Mar CAHN
AB		75MG; 0.2MG	A200540	002	Mar 14, 2014 Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL					
DICYCLOMINE HYDROCHLORIDE					
@ SUN PHARM INDS		10MG	A084505	001	Oct 21, 1986 Mar CAHN
INJECTABLE; INJECTION					
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)					
AP	EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003 Mar CMS1
AP	WEST-WARD PHARMS INT	10MG/ML	A040465	001	Jun 30, 2003 Sep CAHN
SYRUP; ORAL					
DICYCLOMINE HYDROCHLORIDE					
+ MIKART		10MG/5ML	A040169	001	Mar 24, 2005 Jan CRLD
TABLET; ORAL					
DICYCLOMINE HYDROCHLORIDE					
@ SUN PHARM INDS		20MG	A084600	001	Jul 29, 1985 Mar CAHN

DIENOEST; ESTRADIOL VALERATE

TABLET; ORAL					
ESTRADIOL VALERATE AND DIENOEST					
AB	WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	A202349	001	May 06, 2016 Apr NEWA
NATAZIA					
AB	+ BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	N022252	001	May 06, 2010 Apr CFTG

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL					
DIETHYLPROPION HYDROCHLORIDE					
	@ COREPHARMA	25MG	A040828	001	Nov 05, 2008 Mar DISC
TENUATE					
AA	+ ACTAVIS LABS UT INC	25MG	N011722	002	Apr CAHN
AA	+ ALLERGAN SALES LLC	25MG	N011722	002	Mar CAHN
TABLET, EXTENDED RELEASE; ORAL					
TENUATE DOSPAN					
AB	+ ACTAVIS LABS UT INC	75MG	N012546	001	Apr CAHN
AB	+ ALLERGAN SALES LLC	75MG	N012546	001	Mar CAHN

DIFLUNISAL

TABLET; ORAL					
DIFLUNISAL					
	@ IDT AUSTRALIA LTD	500MG	A074604	001	Jun 10, 1996 May CAHN

DIGOXIN

INJECTABLE; INJECTION					
LANOXIN					
AP	+ COVIS PHARMA SARL	0.25MG/ML	N009330	002	Jun CAHN
	LANOXIN PEDIATRIC				
	+ COVIS PHARMA SARL	0.1MG/ML	N009330	004	Jun CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION					
DIHYDROERGOTAMINE MESYLATE					
AP	EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003 Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
DILACOR XR					
	@ ALLERGAN SALES LLC	120MG	N020092	001	May 29, 1992 Jul CAHN
	@	180MG	N020092	002	May 29, 1992 Jul CAHN
	@	240MG	N020092	003	May 29, 1992 Jul CAHN
DILTIAZEM HYDROCHLORIDE					
	@ ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997 Jan DISC
	@	180MG	A074852	002	Oct 10, 1997 Jan DISC
	@	240MG	A074852	003	Oct 10, 1997 Jan DISC
AB3	VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999 Jan CAHN
AB3		180MG	A075116	002	Dec 23, 1999 Jan CAHN
AB3		240MG	A075116	003	Dec 23, 1999 Jan CAHN
AB3		300MG	A075116	004	Dec 23, 1999 Jan CAHN
INJECTABLE; INJECTION					
DILTIAZEM HYDROCHLORIDE					
AP	+ AMPHASTAR PHARMS INC	5MG/ML	A074617	001	Feb 28, 1996 Jun CAHN
AP	+ EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996 Apr CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL					
CERVIDIL					
	+ FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL					
DIPHENHYDRAMINE HYDROCHLORIDE					
	@ HIKMA INTL PHARMS	50MG	A083567	001	Jul CAHN
	@ HIKMA PHARMS	50MG	A083567	001	Feb CAHN
	@ SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987 Mar CAHN
	@	50MG	A089489	001	Jan 02, 1987 Jun CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION					
DIPYRIDAMOLE					
AP	+ AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998 Jun CAHN
>D> AP	EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996 Oct CAHN
AP	+	5MG/ML	A074939	001	Apr 13, 1998 Apr CAHN
>A> AP	WEST-WARD PHARMS INT	5MG/ML	A074521	001	Oct 18, 1996 Oct CAHN

TABLET;ORAL									
DIPYRIDAMOLE									
	@	IDT AUSTRALIA LTD	25MG		A086944	002	Apr 16, 1991	May	CAHN
	@		50MG		A087562	001	Feb 25, 1992	May	CAHN
	@		75MG		A087561	001	Feb 25, 1992	May	CAHN
	@	LANNETT	25MG		A040898	001	Apr 23, 2008	Aug	DISC
	@		50MG		A040898	002	Apr 23, 2008	Aug	DISC
	@		75MG		A040898	003	Apr 23, 2008	Aug	DISC
	@	PUREPAC PHARM	25MG		A089425	001	Jul 12, 1990	Jul	DISC
<u>DISOPYRAMIDE PHOSPHATE</u>									
CAPSULE;ORAL									
DISOPYRAMIDE PHOSPHATE									
	@	AUROLIFE PHARMA LLC	EQ 100MG BASE		A070470	001	Dec 10, 1985	Feb	CAHN
	@		EQ 150MG BASE		A070471	001	Dec 10, 1985	Feb	CAHN
AB		MAYNE PHARMA	EQ 100MG BASE		A070173	001	May 31, 1985	Aug	CAHN
AB			EQ 150MG BASE		A070174	001	May 31, 1985	Aug	CAHN
	@	SUN PHARM INDS	EQ 100MG BASE		A070351	001	Dec 17, 1985	Mar	CAHN
	@		EQ 150MG BASE		A070352	001	Dec 17, 1985	Mar	CAHN
<u>DISULFIRAM</u>									
TABLET;ORAL									
DISULFIRAM									
AB		ALVOGEN MALTA	250MG		A091681	001	Aug 08, 2013	Jan	CAHN
<u>DIVALPROEX SODIUM</u>									
TABLET, EXTENDED RELEASE;ORAL									
DIVALPROEX SODIUM									
	@	IMPAX LABS	EQ 250MG VALPROIC ACID		A078791	001	May 06, 2009	Feb	DISC
	@		EQ 500MG VALPROIC ACID		A078791	002	Aug 04, 2009	Feb	DISC
<u>DOBUTAMINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
DOBUTAMINE HYDROCHLORIDE									
	@	TELIGENT PHARMA INC	EQ 12.5MG BASE/ML		A074098	001	Feb 21, 1995	Jan	CAHN
AP		WEST-WARD PHARMS INT	EQ 12.5MG BASE/ML		A074277	001	Oct 31, 1994	Sep	CAHN
<u>DOCETAXEL</u>									
INJECTABLE;INJECTION									
DOCETAXEL									
		HOSPIRA INC	20MG/ML (20MG/ML)		N022234	004	Jun 23, 2016	Jun	NEWA
			80MG/4ML (20MG/ML)		N022234	005	Jun 23, 2016	Jun	NEWA
			120MG/6ML (20MG/ML)		N022234	006	Jun 23, 2016	Jun	NEWA
SOLUTION;IV (INFUSION)									
DOCETAXEL									
		EAGLE PHARMS	20MG/ML (20MG/ML)		N205934	001	Dec 22, 2015	Jan	CAHN
			80MG/4ML (20MG/ML)		N205934	002	Dec 22, 2015	Jan	CAHN
			160MG/8ML (20MG/ML)		N205934	003	Dec 22, 2015	Jan	CAHN
<u>DOFETILIDE</u>									
CAPSULE;ORAL									
DOFETILIDE									
AB		TIGER PHARMS LLC	0.125MG		A207058	001	Jun 06, 2016	May	NEWA
AB			0.25MG		A207058	002	Jun 06, 2016	May	NEWA
AB			0.5MG		A207058	003	Jun 06, 2016	May	NEWA
TIKOSYN									
AB		PFIZER	0.125MG		N020931	001	Oct 01, 1999	May	CFTG
AB			0.25MG		N020931	002	Oct 01, 1999	May	CFTG
AB	+		0.5MG		N020931	003	Oct 01, 1999	May	CFTG
<u>DOLASETRON MESYLATE</u>									
INJECTABLE;INJECTION									
ANZEMET									
+		US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)		N020624	002	Sep 11, 1997	Jan	CAHN
+			12.5MG/0.625ML (20MG/ML)		N020624	002	Sep 11, 1997	Jan	CAHN
+			100MG/5ML (20MG/ML)		N020624	001	Sep 11, 1997	Jan	CAHN
	@		500MG/25ML (20MG/ML)		N020624	003	Dec 11, 2001	Jun	DISC
+			500MG/25ML (20MG/ML)		N020624	003	Dec 11, 2001	Jan	CAHN
TABLET;ORAL									
ANZEMET									
		US PHARM HOLDINGS	50MG		N020623	001	Sep 11, 1997	Jan	CAHN
+			100MG		N020623	002	Sep 11, 1997	Jan	CAHN

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

VIIV HLTHCARE

EQ 10MG BASE

N204790 002 Jun 09, 2016 Jun NEWA

EQ 25MG BASE

N204790 003 Jun 09, 2016 Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB DEXCEL PHARMA 23MG

A203713 001 Feb 19, 2016 Feb NEWA

AB INDICUS PHARMA 23MG

A203419 001 Apr 12, 2016 Mar NEWA

AB OSMOTICA PHARM CORP 23MG

A203114 001 Jan 26, 2016 Jan NEWA

AB OSMOTICA PHARM US 23MG

A203114 001 Jan 26, 2016 Jun CAHN

AB UNICHEM LABS LTD 5MG

A203656 001 Jun 23, 2016 Jun NEWA

AB 10MG

A203656 002 Jun 23, 2016 Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS 5MG

A077975 002 Dec 11, 2009 Mar CAHN

@ 10MG

A077975 001 Dec 11, 2009 Mar CAHN

>A> AB UNICHEM LABS LTD 5MG

A204831 001 Nov 10, 2016 Oct NEWA

>A> AB 10MG

A204831 002 Nov 10, 2016 Oct NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

FOREST LABS LLC

10MG; 7MG

N206439 003 Jul 18, 2016 Aug NEWA

10MG; 21MG

N206439 004 Jul 18, 2016 Aug NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ LANNETT HOLDINGS INC EQ 2% BASE; EQ 0.5% BASE

A201998 001 Dec 17, 2014 Aug DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

>D> AP + EUROHLTH INTL SARL 20MG/ML

N014879 001 Oct CAHN

>A> AP + WEST-WARD PHARMS INT 20MG/ML

N014879 001 Oct CAHN

DOXAPRAM HYDROCHLORIDE

AP AMPHASTAR PHARMS INC 20MG/ML

A076266 001 Jan 10, 2003 Jun CAHN

AP EUROHLTH INTL SARL 20MG/ML

A076266 001 Jan 10, 2003 Apr CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ IDT AUSTRALIA LTD EQ 1MG BASE

A075432 001 Oct 18, 2000 Mar CAHN

@ EQ 2MG BASE

A075432 002 Oct 18, 2000 Mar CAHN

@ EQ 4MG BASE

A075432 003 Oct 18, 2000 Mar CAHN

@ EQ 8MG BASE

A075432 004 Oct 18, 2000 Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@ SUN PHARM INDS EQ 25MG BASE

A071502 001 Feb 18, 1988 Mar CAHN

@ EQ 50MG BASE

A071653 001 Feb 18, 1988 Mar CAHN

@ EQ 75MG BASE

A071654 001 Feb 18, 1988 Mar CAHN

@ EQ 100MG BASE

A071521 001 Feb 18, 1988 Mar CAHN

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB MYLAN PHARMS INC EQ 3MG BASE

A202337 001 Jan 20, 2016 Jan NEWA

AB EQ 6MG BASE

A202337 002 Jan 20, 2016 Jan NEWA

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

AB RISING PHARMS INC 0.5MCG

A201518 001 Sep 09, 2016 Aug NEWA

AB 1MCG

A201518 002 Sep 09, 2016 Aug NEWA

AB 2.5MCG

A201518 003 Sep 09, 2016 Aug NEWA

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
	HECTOROL					
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	May CRLD
AP		200MG/100ML	A203622	002	Jun 27, 2014	May CRLD
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	May CRLD
AP	+	200MG/100ML	N050629	002	May 03, 1988	May CRLD
AP	WEST-WARD PHARMS INT	2MG/ML	A062975	001	Mar 17, 1989	Sep CAHN
AP	+	10MG/VIAL	A062921	001	Mar 17, 1989	Sep CAHN
AP	+	20MG/VIAL	A062921	002	Mar 17, 1989	Sep CAHN
AP	+	50MG/VIAL	A062921	003	Mar 17, 1989	Sep CAHN
AP		200MG/100ML	A064097	001	Sep 13, 1994	Sep CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb NEWA

TABLET;ORAL

DOXYCYCLINE

@ SUN PHARM INDS

@

@

EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE

A065471 001 Apr 17, 2009 Jun CAHN
A065471 002 Apr 17, 2009 Jun CAHN
A065471 003 Apr 17, 2009 Jun CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

+ AQUA PHARMS

EQ 75MG BASE

N208253 001 Apr 26, 2016 Apr NEWA

DOXYCYCLINE HYCLATE

AB	AMNEAL PHARMS	EQ 100MG BASE	A207289	001	Jun 27, 2016	Jun NEWA
AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar CAHN

INJECTABLE;INJECTION

DOXYCYCLINE

>D>	@ EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Oct CAHN
>D>	@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Oct CAHN
>A>	@ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Oct CAHN
AP	+	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988	Sep CAHN
>A>	@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Oct CAHN
	@	EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988	Sep CAHN

DOXYCYCLINE HYCLATE

>D>	@ EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	Oct CAHN
>D>	@	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	Oct CAHN
>A>	@ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	Oct CAHN
>A>	@	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	Oct CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ COREPHARMA

AB		EQ 20MG BASE	A065182	001	May 13, 2005	Mar DISC
AB	SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar CAHN
AB		EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar CAHN
	@ VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar DISC

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jul CTNA
AB		EQ 50MG BASE	N050795	006	Dec 19, 2014	May CFTG
AB		EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr CFTG
AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	May CFTG

DORYX MPC

MAYNE PHARMA

EQ 60MG BASE
EQ 60MG BASE
EQ 120MG BASE
EQ 120MG BASE

N050795 007 May 20, 2016 Jul CTNA
N050795 007 May 20, 2016 May NEWA
N050795 008 May 20, 2016 Jul CTNA
N050795 008 May 20, 2016 May NEWA

TABLET, DELAYED RELEASE;ORAL
DOXYCYCLINE HYCLATE

	@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar DISC
	@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar DISC
AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May NEWA
AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr NEWA
AB		EQ 200MG BASE	A090431	005	May 19, 2016	May NEWA
>A> AB	PRINSTON INC	EQ 150MG BASE	A207494	001	Nov 15, 2016	Oct NEWA
>A> AB		EQ 200MG BASE	A207494	002	Nov 15, 2016	Oct NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL
DICLEGIS

AB	+ DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Aug CFTG
AB	DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE					
AB	ACTAVIS LABS FL INC	10MG;10MG	A205811	001	Aug 19, 2016	Aug NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
MELAMISA

AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan NEWA
	TABLET;ORAL-28					
	DROSPIRENONE AND ETHINYL ESTRADIOL					
AB	APOTEX INC	3MG;0.03MG	A205876	001	Sep 21, 2016	Sep NEWA
AB	GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar NEWA
AB	MAYNE PHARMA	3MG;0.03MG	A090081	001	Sep 07, 2010	Aug CAHN

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

	BEYAZ					
AB	BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep CFTG
	DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM					
AB	WATSON LABS INC	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	A203593	001	Oct 11, 2016	Sep NEWA
AB		3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	A203594	001	Oct 11, 2016	Sep NEWA
	SAFYRAL					
AB	+ BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Sep CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul NEWA
AB		EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul NEWA
AB		EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul NEWA

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

>A> AB	ASCENT PHARMS INC	0.5MG	A206574	001	Oct 21, 2016	Oct NEWA
AB	AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr CAHN
AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA
AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May NEWA
AB	STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar CAHN

DYPHYLLINE

TABLET;ORAL
LUFYLLIN

@	MEDA PHARMS	200MG	A084566	001		Jun DISC
@		400MG	A084566	002		Jun DISC

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL
ECOZA

	+ EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013	Jul CAHN
	CREAM;TOPICAL					
	ECONAZOLE NITRATE					
AB	TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May CAHN
	SPECTAZOLE					
	@ ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Jul CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
TENSILON PRESERVATIVE FREE

@ TELIGENT PHARMA INC 10MG/ML

N007959 002

Jan CAHN

EFAVIRENZ

TABLET; ORAL

EFAVIRENZ

AB MYLAN LABS LTD 600MG

A091471 001 Feb 17, 2016

Feb NEWA

AB MYLAN PHARMS INC 600MG

A091471 001 Feb 17, 2016

Jun CAHN

SUSTIVA

AB + BRISTOL MYERS SQUIBB 600MG

N021360 002 Feb 01, 2002

Feb CFTG

ELBASVIR; GRAZOPREVR

TABLET; ORAL

ZEPATIER

+ MERCK SHARP DOHME 50MG; 100MG

N208261 001 Jan 28, 2016

Jan NEWA

ELUXADOLINE

TABLET; ORAL

VIBERZI

+ ALLERGAN HOLDINGS 75MG

N206940 001 May 27, 2015

May CAHN

+ 100MG

N206940 002 May 27, 2015

May CAHN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

ODEFSEY

+ GILEAD SCIENCES INC 200MG; EQ 25MG BASE; EQ 25MG BASE

N208351 001 Mar 01, 2016

Apr CAIN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ODEFSEY

+ GILEAD SCIENCES INC 200MG; EQ 25MG BASE; EQ 25MG BASE

N208351 001 Mar 01, 2016

Mar NEWA

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOVY

+ GILEAD SCIENCES INC 200MG; EQ 25MG BASE

N208215 001 Apr 04, 2016

Apr NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

GILEAD 100MG; 150MG

N021752 002 Mar 10, 2016

Mar NEWA

133MG; 200MG

N021752 003 Mar 10, 2016

Mar NEWA

167MG; 250MG

N021752 004 Mar 10, 2016

Mar NEWA

ENALAPRIL MALEATE

SOLUTION; ORAL

EPANED

SILVERGATE PHARMS 1MG/ML

N208686 001 Sep 20, 2016

Sep NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D> @ SANDOZ INC 5MG; 12.5MG

A076116 001 Sep 19, 2001

Oct CAHN

>D> @ 10MG; 25MG

A076116 002 Sep 19, 2001

Oct CAHN

>A> @ UPSHER-SMITH LABS 5MG; 12.5MG

A076116 001 Sep 19, 2001

Oct CAHN

>A> @ 10MG; 25MG

A076116 002 Sep 19, 2001

Oct CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP + AMPHASTAR PHARMS INC 1.25MG/ML

A075634 001 Aug 22, 2000

Jun CAHN

AP + EUROHLTH INTL SARL 1.25MG/ML

A075634 001 Aug 22, 2000

Apr CAHN

ENFLURANELIQUID; INHALATION
ENFLURANE

@ PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994	Aug DISC
ETHRANE					
@ BAXTER HLTHCARE	99.9%	N017087	001		Aug DISC

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
AKOVAZ

+ FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016	Apr NEWA
----------------------	---------	---------	-----	--------------	----------

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Mar CAHN
----	----------------------	-------	---------	-----	--------------	----------

EPINEPHRINEINJECTABLE; INJECTION
SUS-PHRINE SULFITE FREE

@ FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999	Mar CMS1
@	5MG/ML	N007942	001		Mar CMS1

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q

BX	+ KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Mar CAHN
BX		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Mar CAHN

TWINJECT 0.15

@ AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May DISC
-----------------	--------------------	---------	-----	--------------	----------

TWINJECT 0.3

@ AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May DISC
-----------------	-------------------	---------	-----	--------------	----------

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul CAIN
--------------------	---------------------------------	---------	-----	--------------	----------

EPINEPHRINE HYDROCHLORIDESOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb CDFR
--------------------	---------------------------------	---------	-----	--------------	----------

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

AP	IMPAX LABS INC	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Aug CAHN
AP		200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Aug CAHN
AP	WEST-WARD PHARMS INT	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007	Sep CAHN
AP		200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007	Sep CAHN

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

@ TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015	Aug DISC
-------------------	------------	---------	-----	--------------	----------

ERGOALCIFEROLCAPSULE; ORAL
DRISDOL

AA	+ US PHARM HOLDINGS	50,000 IU	N003444	001		Jan CAHN
	VITAMIN D					
AA	BIONPHARMA INC	50,000 IU	A080704	001		Jan CAHN

ERGOLOID MESYLATESTABLET; ORAL
ERGOLOID MESYLATES

AB	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar CAHN
----	----------------	-----	---------	-----	--------------	----------

TABLET; SUBLINGUAL
ERGOLOID MESYLATES

@ SUN PHARM INDS	0.5MG	A087407	001		Jun CAHN
@	1MG	A087552	001		Jun CAHN

ERGOTAMINE TARTRATETABLET;SUBLINGUAL
ERGOMAR

+ TERSERA THERAP

2MG

A087693 001 Feb 24, 1983 Aug CAHN

ERYTHROMYCINSOLUTION;TOPICAL
C-SOLVE-2

@ FOUGERA PHARMS

2%

A062468 001 Jul 03, 1985 Feb DISC

ERYTHRO-STATIN

@ HI TECH PHARMA

2%

A064101 001 Oct 22, 1996 Feb DISC

ERYTHROMYCIN

AT + FOUGERA PHARMS

2%

A064187 001 Sep 30, 1997 Jan CRLD

AT PERRIGO NEW YORK

2%

A063038 001 Jan 11, 1991 Jan CRLD

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA MACLEODS PHARMS LTD

EQ 5MG BASE/5ML

A202754 001 Mar 31, 2016 Mar NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

>D> AP EUROHLTH INTL SARL

10MG/ML

A076323 001 Aug 10, 2004 Oct CAHN

>A> AP WEST-WARD PHARMS INT

10MG/ML

A076323 001 Aug 10, 2004 Oct CAHN

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+ HQ SPCLT PHARMA

2GM/100ML (20MG/ML)

N205703 002 Apr 07, 2016 Apr NEWA

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

+ HQ SPCLT PHARMA

2.5GM/250ML (10MG/ML)

N205703 001 Apr 07, 2016 Jun CRLD

2.5GM/250ML (10MG/ML)

N205703 001 Apr 07, 2016 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB AUROBINDO PHARMA LTD

EQ 20MG BASE

A205606 001 Apr 21, 2016 Apr NEWA

AB

EQ 40MG BASE

A205606 002 Apr 21, 2016 Apr NEWA

BX HETERO LABS LTD III

EQ 20MG BASE

A202784 001 Sep 21, 2015 Apr CTEC

BX

EQ 40MG BASE

A202784 002 Sep 21, 2015 Apr CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP AUROBINDO PHARMA LTD

EQ 20MG BASE/VIAL

A204657 001 Aug 10, 2016 Jul NEWA

AP

EQ 40MG BASE/VIAL

A204657 002 Aug 10, 2016 Jul NEWA

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

AB MAYNE PHARMA

1MG

A074921 001 Jul 10, 1997 Aug CAHN

AB +

2MG

A074921 002 Jul 10, 1997 Aug CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRACE

+ ALLERGAN SALES LLC

0.01%

A086069 001 Jan 31, 1984 Apr CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX ALLERGAN SALES LLC

0.025MG/24HR

N020655 004 Apr 05, 2002 Mar CAHN

BX

0.05MG/24HR

N020655 001 Dec 20, 1996 Mar CAHN

BX

0.075MG/24HR

N020655 002 Dec 20, 1996 Mar CAHN

BX

0.1MG/24HR

N020655 003 Dec 20, 1996 Mar CAHN

TABLET;ORAL

ESTRADIOL

>D> @ EPIC PHARMA INC

0.5MG

A040275 001 Dec 29, 1998 Oct CMFD

>A> AB

0.5MG

A040275 001 Dec 29, 1998 Oct CMFD

>D> @

1MG

A040275 002 Dec 29, 1998 Oct CMFD

>A> AB

1MG

A040275 002 Dec 29, 1998 Oct CMFD

>D> @

2MG

A040275 003 Dec 29, 1998 Oct CMFD

>A> AB

2MG

A040275 003 Dec 29, 1998 Oct CMFD

AB MAYNE PHARMA

0.5MG

A040114 003 Mar 14, 1996 Aug CAHN

TABLET;ORAL							
ESTRADIOL							
AB		1MG	A040114	001	Mar 14, 1996	Aug	CAHN
AB		2MG	A040114	002	Mar 14, 1996	Aug	CAHN
	@ USL PHARMA	0.5MG	A040297	001	Apr 17, 2002	Sep	DISC
	@	1MG	A040297	002	Apr 17, 2002	Sep	DISC
	@	2MG	A040297	003	Apr 17, 2002	Sep	DISC
TABLET;VAGINAL							
ESTRADIOL							
AB	AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	Aug	CMFD
VAGIFEM							
AB	+ NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009	Aug	CTEC
<u>ESTRADIOL ACETATE</u>							
INSERT, EXTENDED RELEASE;VAGINAL							
FEMRING							
	APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN
TABLET;ORAL							
FEMTRACE							
	APIL	0.45MG	N021633	001	Aug 20, 2004	Jan	CAHN
		0.9MG	N021633	002	Aug 20, 2004	Jan	CAHN
+		1.8MG	N021633	003	Aug 20, 2004	Jan	CAHN
<u>ESTRADIOL HEMIHYDRATE</u>							
EMULSION;TOPICAL							
ESTRASORB							
+	EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun	CAHN
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>							
TABLET;ORAL							
AMABELZ							
AB	LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016	Jun	NEWA
AB		1MG;0.5MG	A203339	002	Jun 20, 2016	Jun	NEWA
<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>							
TABLET;ORAL							
CENESTIN							
	@ TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	DISC
	@	0.45MG	N020992	005	Feb 05, 2004	Jun	DISC
	@	0.625MG	N020992	002	Mar 24, 1999	Jun	DISC
	@	0.9MG	N020992	003	Mar 24, 1999	Jun	DISC
	@	1.25MG	N020992	004	Mar 13, 2000	Jun	DISC
<u>ESTROGENS, CONJUGATED SYNTHETIC B</u>							
TABLET;ORAL							
ENJUVIA							
	@ TEVA WOMENS	0.625MG	N021443	003	May 10, 2004	Jun	DISC
	@	1.25MG	N021443	004	May 10, 2004	Sep	DISC
<u>ESZOPICLONE</u>							
TABLET;ORAL							
ESZOPICLONE							
AB	AUROBINDO PHARMA LTD	1MG	A208451	001	Sep 15, 2016	Sep	NEWA
AB		2MG	A208451	002	Sep 15, 2016	Sep	NEWA
AB		3MG	A208451	003	Sep 15, 2016	Sep	NEWA
<u>ETEPLIRSEN</u>							
SOLUTION;IV (INFUSION)							
EXONDYS 51							
+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016	Sep	NEWA
+		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016	Sep	NEWA
<u>ETHACRYNATE SODIUM</u>							
INJECTABLE;INJECTION							
ETHACRYNATE SODIUM							
AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016	Aug	NEWA

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

AB	+	ATON	25MG	N016092	001		Jun CFTG
AB		ETHACRYNIC ACID					
AB		EDENBRIDGE PHARMS	25MG	A205609	001	Jun 30, 2016	Jun NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		JAI PHARMA LTD	0.05MG; 1MG	A204704	001	Feb 09, 2016	Jan NEWA
		ZOVIA 1/35E-28					
AB		MAYNE PHARMA	0.035MG; 1MG	A072721	001	Dec 30, 1991	Aug CAHN
		ZOVIA 1/50E-28					
AB	+	WATSON LABS	0.05MG; 1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

FAYOSIM

AB		LUPIN LTD	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	A205943	001	Mar 29, 2016	Mar NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB		AMNEAL PHARMS	0.03MG; 0.15MG	A203871	001	Nov 13, 2015	Jul CAHN
AB		HAUPT PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Jul CMS1
AB		MAYNE PHARMA	0.02MG, 0.01MG; 0.1MG, N/A	A200407	001	Oct 25, 2011	Aug CAHN
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
AB		MAYNE PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A078834	001	May 31, 2011	Aug CAHN
		QUARTETTE					
AB	+	TEVA BRANDED PHARM	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	N204061	001	Mar 28, 2013	Mar CFTG

TABLET; ORAL-21

TRIVORA-21

@ MAYNE PHARMA

0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG

A074538 001 Dec 18, 1997 Aug CAHN

TABLET; ORAL-28

AFIRMELLE

>A>	AB1	AUROBINDO PHARMA LTD	0.02MG; 0.1MG	A206886	001	Nov 14, 2016	Oct NEWA
		AYUNA					
	AB	AUROBINDO PHARMA LTD	0.03MG; 0.15MG	A206866	001	Sep 23, 2016	Sep NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL					
	AB1	AMNEAL PHARMS	0.02MG; 0.1MG	A201108	001	Feb 05, 2014	May CAHN
	AB		0.03MG; 0.15MG	A201095	001	Dec 08, 2014	Jul CAHN
	AB1	+	MAYNE PHARMA	A076625	001	Nov 18, 2004	Aug CAHN
	AB2	+	0.02MG; 0.1MG	A077681	001	May 31, 2006	Aug CAHN
		LEVORA 0.15/30-28					
	AB	+	MAYNE PHARMA	A073594	001	Dec 13, 1993	Aug CAHN
		TRIVORA-28					
	AB	+	MAYNE PHARMA	A074538	002	Dec 18, 1997	Aug CAHN
			0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG				

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

@ ALLERGAN SALES LLC

0.035MG; 0.5MG

N017566 001

Apr CAHN

NORINYL 1+35 21-DAY

AB		ALLERGAN SALES LLC	0.035MG; 1MG	N017565	001		Mar CAHN
		TRI-NORINYL 21-DAY					
		@ MAYNE PHARMA	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	001	Apr 13, 1984	Aug CAHN

TABLET; ORAL-28

BREVICON 28-DAY

ALLERGAN SALES LLC

0.035MG; 0.5MG

N017743 001

Mar CAHN

CYONANZ

>A>	AB	AUROBINDO PHARMA LTD	0.035MG; 0.5MG	A207055	001	Oct 21, 2016	Oct NEWA
		NORETHINDRONE AND ETHINYL ESTRADIOL					
	AB	MAYNE PHARMA	0.035MG; 0.5MG	A070686	001	Jan 29, 1987	Aug CAHN
		NORINYL 1+35 28-DAY					
	AB	ALLERGAN SALES LLC	0.035MG; 1MG	N017565	002		Mar CAHN
>A>		NYLIA 1/35					
>A>	AB	AUROBINDO PHARMA LTD	0.035MG; 1MG	A207056	001	Oct 21, 2016	Oct NEWA

>A>		TABLET;ORAL-28 NYLIA 7/7/7							
>A>	AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75 MG,1MG	A207054	001	Oct 21, 2016	Oct	NEWA	
	AB	TRI-NORINYL 28-DAY + MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG, 0.5MG	N018977	002	Apr 13, 1984	Aug	CAHN	
	AB	TABLET, CHEWABLE;ORAL FEMCON FE + APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan	CAHN	
	AB	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE + APIL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CAHN	
	AB	LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar	NEWA	
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>									
		CAPSULE;ORAL TAYTULLA							
		+ APIL	0.02MG;1MG	N204426	001	Apr 19, 2013	Aug	CTNA	
		@	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr	CAHN	
		TABLET;ORAL FEMHRT							
	AB	APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan	CAHN	
		@	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan	CAHN	
		LERIBANE							
	AB	NOVAST LABS LTD	0.0025MG;0.5MG	A203435	002	Jun 03, 2016	May	NEWA	
	AB		0.005MG;1MG	A203435	001	Jun 03, 2016	May	NEWA	
		LO LOESTRIN FE							
	AB	+ APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CFTG	
		+ LOESTRIN 24 FE	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan	CAHN	
	AB	APIL	0.02MG;1MG	N021871	001	Feb 17, 2006	Aug	CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	AB	JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May	NEWA	
		TABLET;ORAL-21 ESTROSTEP 21							
		@ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan	CAHN	
		LOESTRIN 21 1.5/30							
	AB	APIL	0.03MG;1.5MG	N017875	001		Apr	CAHN	
		LOESTRIN 21 1/20							
	AB	APIL	0.02MG;1MG	N017876	001		Apr	CAHN	
		MICROGESTIN 1.5/30							
	AB	MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Aug	CAHN	
		MICROGESTIN 1/20							
	AB	MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Aug	CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
	AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan	NEWA	
		TABLET;ORAL-28 ESTROSTEP FE							
	AB	+ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan	CAHN	
		LOESTRIN FE 1.5/30							
	AB	+ APIL	0.03MG;1.5MG	N017355	001		Apr	CAHN	
		LOESTRIN FE 1/20							
	AB	APIL	0.02MG;1MG	N017354	001		Apr	CAHN	
		MICROGESTIN FE 1.5/30							
	AB	MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Aug	CAHN	
		MICROGESTIN FE 1/20							
	AB	MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Aug	CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
	AB	MAYNE PHARMA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Aug	CAHN	
		TABLET, CHEWABLE;ORAL MIBELAS 24 FE							
	AB	LUPIN ATLANTIS	0.02MG;1MG	A206287	001	May 24, 2016	May	NEWA	
		MINASTRIN 24 FE							
	AB	+ APIL	0.02MG;1MG	N203667	001	May 08, 2013	May	CFTG	
		+ 0.02MG;1MG		N203667	001	May 08, 2013	Jan	CAHN	
		TABLET, CHEWABLE, TABLET;ORAL LO MINASTRIN FE							
		+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	CAHN	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MILI

AB	AUROBINDO PHARMA LTD	0.035MG;0.25MG	A205449	001	Jul 07, 2016	Jun NEWA
	NORGESTIMATE AND ETHINYL ESTRADIOL					
AB	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A203870	001	Nov 12, 2015	Sep CAHN
		15MG,0.25MG				
AB		0.035MG;0.25MG	A203865	001	Oct 27, 2015	May CAHN
AB	GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Jun CAHN
		15MG,0.25MG				
AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Feb NEWA
		15MG,0.25MG				
AB	HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A203873	001	May 12, 2016	May NEWA
		15MG,0.25MG				
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG,	A201897	001	Jan 27, 2016	Jan NEWA
		0.215MG, 0.25MG				
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan NEWA
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205588	001	Apr 26, 2016	Apr NEWA
		15MG,0.25MG				
>A> AB		0.035MG;0.25MG	A205630	001	Oct 27, 2016	Oct NEWA
>A>	TRI-LO-MILI					
>A> AB	AUROBINDO PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A205762	001	Nov 04, 2016	Oct NEWA
		15MG,0.25MG				
	TRI-MILI					
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205441	001	Jul 06, 2016	Jun NEWA
		15MG,0.25MG				

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

	@ PELAGIUS	0.03MG;0.3MG	N017612	001		Jun CAHN
	LOW-OGESTREL-21					
	@ MAYNE PHARMA	0.03MG;0.3MG	A075288	001	Jul 28, 1999	Aug CAHN
	TABLET; ORAL-28					
	LO/OVRAL-28					
	@ WYETH PHARMS	0.03MG;0.3MG	N017802	001		Jun DISC
	LOW-OGESTREL-28					
AB	MAYNE PHARMA	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Aug CAHN
	NORGESTREL AND ETHINYL ESTRADIOL					
AB	JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun NEWA

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001		Aug CPOT
---	---------	---	---------	-----	--	----------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

AB	APIL	200MG	N017831	001		Apr CAHN
AB	+	400MG	N017831	002		Apr CAHN

ETODOLAC

CAPSULE; ORAL

ETODOLAC

	@ IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May CAHN
	@	300MG	A074840	002	Aug 29, 1997	May CAHN
	@ LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	ETODOLAC					
	@ IDT AUSTRALIA LTD	400MG	A075943	001	Jul 26, 2002	Aug CAHN
	@	500MG	A075943	002	Jul 26, 2002	Aug CAHN
	@	600MG	A075943	003	Jul 26, 2002	Aug CAHN

ETOMIDATE

INJECTABLE; INJECTION
ETOMIDATE

AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr CAHN
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb NEWA

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	WEST-WARD PHARMS INT	20MG/ML	A074290	001	Jul 17, 1995	Sep CAHN
----	----------------------	---------	---------	-----	--------------	----------

EXEMESTANE

TABLET; ORAL
EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN
----	---------------	------	---------	-----	--------------	----------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb NEWA
---	----------------	-----	---------	-----	--------------	----------

EZETIMIBE

TABLET; ORAL
EZETIMIBE

>D>	@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Oct CMFD
>A> AB		10MG	A078560	001	Jun 26, 2015	Oct CMFD
	ZETIA					
>D>	+ MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Oct CTEC
>A> AB	+	10MG	N021445	001	Oct 25, 2002	Oct CTEC

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE

AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN
	FAMOTIDINE PRESERVATIVE FREE					
AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET; ORAL
FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar CAHN
@		40MG	A075639	001	Dec 12, 2001	Mar CAHN

FELBAMATE

TABLET; ORAL
FELBAMATE

AB	ALVOGEN MALTA	400MG	A204595	001	Jan 11, 2016	Aug CAHN
AB		600MG	A204595	002	Jan 11, 2016	Aug CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
FELODIPINE

AB	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Aug NEWA
AB		5MG	A203983	002	Aug 19, 2016	Aug NEWA
AB		10MG	A203983	003	Aug 19, 2016	Aug NEWA
AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

TABLET; ORAL
FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA
AB		145MG	A205118	002	May 05, 2016	Apr NEWA
AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun NEWA
AB		145MG	A204598	002	Jul 12, 2016	Jun NEWA
AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun NEWA

TABLET;ORAL
FENOFIBRATE

AB		120MG	A204475	002	Jun 23, 2016	Jun NEWA
	FENOGLIDE					
AB	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun CFTG
AB	+	120MG	N022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

	ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr CAHN
+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION
FENOLDOPAM MESYLATE

>D>	AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Oct CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar CAHN
@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN
@	SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

>A>	AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Oct NEWA
-----	----	------------------	-----------	---------	-----	--------------	----------

FENTANYL-12

>A>	AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Oct NEWA
	AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan NEWA

FENTANYL-25

>A>	AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Oct NEWA
-----	----	------------------	----------	---------	-----	--------------	----------

FENTANYL-50

>A>	AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Oct NEWA
-----	----	------------------	----------	---------	-----	--------------	----------

FENTANYL-75

>A>	AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Oct NEWA
-----	----	------------------	----------	---------	-----	--------------	----------

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

>D>	AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Oct CAHN
>A>	AP	+	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Oct CAHN

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr NEWA
---	----------------------	-------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

@	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan DISC
@		8MG	A204827	002	Dec 10, 2015	Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar DISC
@	IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar DISC

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS
SMOFLIPID 20%

+	FRESENIUS KABI USA	3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (100ML)	N207648	001	Jul 13, 2016	Jul	NEWA
+		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (250ML)	N207648	002	Jul 13, 2016	Jul	NEWA
+		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (500ML)	N207648	003	Jul 13, 2016	Jul	NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

@	IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar	DISC
---	--------------	-------	---------	-----	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

	@	IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May	CAHN
	@		100MG	A076030	002	Oct 28, 2002	May	CAHN
	@		150MG	A076030	003	Oct 28, 2002	May	CAHN
		TAMBOCOR						
>D>	@	CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Oct	CMFD
>A> AB			50MG	N018830	004	Aug 23, 1988	Oct	CMFD
>D>	@		100MG	N018830	001	Oct 31, 1985	Oct	CMFD
>A> AB			100MG	N018830	001	Oct 31, 1985	Oct	CMFD
>D>	@		150MG	N018830	003	Jun 03, 1988	Oct	CMFD
>A> AB			150MG	N018830	003	Jun 03, 1988	Oct	CMFD

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

@	AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012	Sep	DISC
---	----------------------	----------------------	---------	-----	--------------	-----	------

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

>D> AP	+	EUROHLTH INTL SARL	500MG/VIAL	A075387	001	Apr 16, 2000	Oct	CAHN
>A> AP	+	WEST-WARD PHARMS INT	500MG/VIAL	A075387	001	Apr 16, 2000	Oct	CAHN

FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May	NEWA
---	------------	-------------	---------	-----	--------------	-----	------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC
@		200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr	CAHN
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr	CAHN
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr	CAHN
	@	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan	DISC
	@		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan	DISC
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CMS1
AP			400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CMS1
AP		EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun	CAHN
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun	CAHN

TABLET; ORAL

FLUCONAZOLE

@	IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May	CAHN
@		100MG	A076086	002	Jul 29, 2004	May	CAHN
@		150MG	A076086	003	Jul 29, 2004	May	CAHN
@		200MG	A076086	004	Jul 29, 2004	May	CAHN

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

AP	SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003	Aug CAHN
AP		50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Aug CAHN

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDEOIL; TOPICAL
FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May NEWA
AT		0.01%	A209336	001	May 19, 2016	May NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr NEWA
AT	VERSAPHARM INC	0.01%	A202705	001	Sep 09, 2016	Aug NEWA

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

>A>	AT	ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Oct NEWA
	AT	G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Sep NEWA

FLUOCINONIDEOINTMENT; TOPICAL
LIDEX

AB	CNTY LINE PHARMS	0.05%	N016909	002		Sep CMFD
----	------------------	-------	---------	-----	--	----------

FLUOROURACILINJECTABLE; INJECTION
FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

@ SUN PHARM INDS

EQ 10MG BASE

A075787 001 Jan 29, 2002 Mar CAHN

@

EQ 20MG BASE

A075787 002 Jan 29, 2002 Mar CAHN

FLUOXETINE HYDROCHLORIDE

MYLAN

EQ 10MG BASE

A078045 001 Nov 17, 2008 Sep CTEC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

@ LANNETT

EQ 20MG BASE/5ML

A076458 001 May 14, 2004 Aug DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

+ EDMONT PHARMS LLC

EQ 60MG BASE

N202133 001 Oct 06, 2011 Mar CRLD

AB	+	MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001	Aug CTEC
----	---	-------	--------------	---------	-----	--------------	----------

AB		PAR FORM	EQ 10MG BASE	A203836	001	Aug 19, 2016	Aug NEWA
----	--	----------	--------------	---------	-----	--------------	----------

AB			EQ 20MG BASE	A203836	002	Aug 19, 2016	Aug NEWA
----	--	--	--------------	---------	-----	--------------	----------

>A>	AB1	TORRENT PHARMS LTD	EQ 10MG BASE	A206937	001	Oct 21, 2016	Oct NEWA
-----	-----	--------------------	--------------	---------	-----	--------------	----------

>A>	AB1		EQ 20MG BASE	A206937	002	Oct 21, 2016	Oct NEWA
-----	-----	--	--------------	---------	-----	--------------	----------

SARAFEM

AB1		APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
-----	--	------	--------------	---------	-----	--------------	----------

AB1			EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
-----	--	--	--------------	---------	-----	--------------	----------

AB1	+		EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN
-----	---	--	--------------	---------	-----	--------------	----------

FLUPHENAZINE DECANOATEINJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

AO	WEST-WARD PHARMS INT	25MG/ML	A074531	001	Aug 30, 1996	Sep CAHN
----	----------------------	---------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDETABLET; ORAL
FLUPHENAZINE HYDROCHLORIDE

AB	LANNETT	1MG	A089743	002	Aug 25, 1988	Sep NEWA
AB		2.5MG	A089743	003	Aug 25, 1988	Sep NEWA
AB		5MG	A089743	004	Aug 25, 1988	Sep NEWA
>A> AB	SANDOZ	1MG	A089586	002	Oct 16, 1987	Oct CMS1
>A> AB		2.5MG	A089586	003	Oct 16, 1987	Oct CMS1
>A> AB		5MG	A089586	004	Oct 16, 1987	Oct CMS1

FLURANDRENOLIDECREAM; TOPICAL
CORDRAN SP

AT	+ AQUA PHARMS	0.05%	N012806	002		Mar CFTG
----	---------------	-------	---------	-----	--	----------

FLURANDRENOLIDE

AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
----	---------------------	-------	---------	-----	--------------	----------

LOTION; TOPICAL
CORDRAN

AT	+ AQUA PHARMS	0.05%	N013790	001		Aug CTEC
----	---------------	-------	---------	-----	--	----------

FLURANDRENOLIDE

AT	PERRIGO UK FINCO	0.05%	A207133	001	Aug 30, 2016	Aug NEWA
----	------------------	-------	---------	-----	--------------	----------

TAPE; TOPICAL
CORDRAN

	+ ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001		Apr CAHN
--	----------------------	---------------	---------	-----	--	----------

FLURANDRENOLIDE; NEOMYCIN SULFATECREAM; TOPICAL
CORDRAN N

@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001		Mar CMS1
---------	------------------------	---------	-----	--	----------

OINTMENT; TOPICAL
CORDRAN N

@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001		Mar CMS1
---------	------------------------	---------	-----	--	----------

FLURAZEPAM HYDROCHLORIDECAPSULE; ORAL
FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb CAHN
@	30MG	A071717	001	Jul 31, 1991	Feb CAHN
@ HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May CAHN
@ SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986	Mar CAHN
@	30MG	A070455	001	Aug 04, 1986	Mar CAHN

FLURBIPROFENTABLET; ORAL
FLURBIPROFEN

@ AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb CAHN
@	100MG	A074448	002	Jul 28, 1995	Feb CAHN

FLUTAMIDECAPSULE; ORAL
FLUTAMIDE

AB	+ CIPLA LTD	125MG	A075780	001	Sep 19, 2001	Sep CAHN
----	-------------	-------	---------	-----	--------------	----------

FLUTICASONE FUROATEPOWDER; INHALATION
ARNUITY ELLIPTA

	+ GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Mar CRLD
--	-------------------	-----------	---------	-----	--------------	----------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREQ ELLIPTA

	+ GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar CRLD
--	-----------------	-------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATESPRAY, METERED;NASAL
FLONASE

@ GLAXOSMITHKLINE 0.05MG/SPRAY

N020121 001 Oct 19, 1994 Jun DISC

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB MYLAN PHARMS INC EQ 80MG BASE

A202458 001 Sep 11, 2015 May CPOT

AB TEVA PHARMS USA EQ 80MG BASE

A079011 001 Jan 27, 2016 May CPOT

AB 80MG

A079011 001 Jan 27, 2016 Jan NEWA

LESCOL XL

AB + NOVARTIS EQ 80MG BASE

N021192 001 Oct 06, 2000 May CPOT

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

@ NOSTRUM LABS INC 25MG

A075900 001 Feb 23, 2006 Feb CAHN

@ 50MG

A075900 002 Feb 23, 2006 Feb CAHN

@ 100MG

A075900 003 Feb 23, 2006 Feb CAHN

>D> @ SANDOZ 25MG

A075887 001 Jan 05, 2001 Oct CAHN

>D> AB 25MG

A075888 001 Nov 29, 2000 Oct CAHN

>D> @ 50MG

A075887 002 Jan 05, 2001 Oct CAHN

>D> AB 50MG

A075888 002 Nov 29, 2000 Oct CAHN

>D> @ 100MG

A075887 003 Jan 05, 2001 Oct CAHN

>D> AB + 100MG

A075888 003 Nov 29, 2000 Oct CAHN

@ SUN PHARM INDS 25MG

A076125 001 Apr 29, 2002 Mar CAHN

@ 50MG

A076125 002 Apr 29, 2002 Mar CAHN

@ 100MG

A076125 003 Apr 29, 2002 Mar CAHN

>A> @ UPSHER-SMITH LABS 25MG

A075887 001 Jan 05, 2001 Oct CAHN

>A> AB 25MG

A075888 001 Nov 29, 2000 Oct CAHN

>A> @ 50MG

A075887 002 Jan 05, 2001 Oct CAHN

>A> AB 50MG

A075888 002 Nov 29, 2000 Oct CAHN

>A> @ 100MG

A075887 003 Jan 05, 2001 Oct CAHN

>A> AB + 100MG

A075888 003 Nov 29, 2000 Oct CAHN

FOLIC ACID

INJECTABLE;INJECTION

FOLVITE

@ WYETH PHARMS INC 5MG/ML

N005897 008 May CAHN

TABLET;ORAL

FOLIC ACID

@ SUN PHARM INDS 1MG

A040582 001 Jul 18, 2005 Mar CAHN

FOLVITE

@ WYETH PHARMS INC 1MG

N005897 004 May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

FOLLISTIM AQ

@ ORGANON USA INC 75 IU/0.5ML

N021273 001 Aug 26, 2005 Jun DISC

@ 150 IU/0.5ML

N021273 002 Aug 26, 2005 Jun DISC

FOMEPIZOLE

INJECTABLE;INJECTION

ANTIZOL

>D> AP + PALADIN LABS 1.5GM/1.5ML (1GM/ML)

N020696 001 Dec 04, 1997 Oct CAHN

>A> AP + PAR PHARM INC 1.5GM/1.5ML (1GM/ML)

N020696 001 Dec 04, 1997 Oct CAHN

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BEVESPI AEROSPHERE

+ PEARL THERAPS INC 0.0048MG/INH;0.0090MG/INH

N208294 001 Apr 25, 2016 Apr NEWA

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

AB MYLAN PHARMS INC EQ 700MG BASE

A204060 001 Apr 15, 2016 Apr NEWA

LEXIVA

AB + VIIV HLTHCARE EQ 700MG BASE

N021548 001 Oct 20, 2003 Apr CFTG

FOSAPREPITANT DIMEGLUMINEPOWDER; INTRAVENOUS
EMEND

AP	+	MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May CFTG
		FOSAPREPITANT DIMEGLUMINE					
AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May NEWA

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

		@ ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
		@	20MG	A076620	002	Oct 15, 2004	Jan DISC
		@	40MG	A076620	003	Oct 15, 2004	Jan DISC
AB		PRINSTON INC	10MG	A205670	001	Aug 29, 2016	Aug NEWA
AB			20MG	A205670	002	Aug 29, 2016	Aug NEWA
AB			40MG	A205670	003	Aug 29, 2016	Aug NEWA
>D>	AB	SANDOZ	10MG	A076483	001	Apr 23, 2004	Oct CAHN
>D>	AB		20MG	A076483	002	Apr 23, 2004	Oct CAHN
>D>	AB		40MG	A076483	003	Apr 23, 2004	Oct CAHN
>A>	AB	UPSHER-SMITH LABS	10MG	A076483	001	Apr 23, 2004	Oct CAHN
>A>	AB		20MG	A076483	002	Apr 23, 2004	Oct CAHN
>A>	AB		40MG	A076483	003	Apr 23, 2004	Oct CAHN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

		@ ACTAVIS LABS FL INC	10MG; 12.5MG	A076608	001	Dec 03, 2004	Jan DISC
		@	20MG; 12.5MG	A076608	002	Dec 03, 2004	Jan DISC
		@ SUN PHARM INDS LTD	10MG; 12.5MG	A076739	001	Dec 17, 2004	Feb DISC
		@	20MG; 12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP	+	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Aug CRLD
		FOSPHENYTOIN SODIUM					
AP		EUROHLTH INTL SARL	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jun CAHN
		@ FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Aug DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP		AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul NEWA
AP		CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May CAHN
>D>		@ EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Oct CAHN
		@	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
>D>		@	10MG/ML	N018267	001		Oct CAHN
>A>		@ WEST-WARD PHARMS INT	10MG/ML	A071439	001	Sep 14, 1990	Oct CAHN
>A>		@	10MG/ML	N018267	001		Oct CAHN

TABLET; ORAL

FUROSEMIDE

		@ SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar CAHN
		@	80MG	A070100	001	Jan 26, 1988	Mar CAHN
		LASIX					
AB		US PHARM HOLDINGS	20MG	N016273	002		Jan CAHN
AB			40MG	N016273	001		Jan CAHN
AB	+		80MG	N016273	003		Jan CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb NEWA
AB			300MG	A204989	002	Feb 18, 2016	Feb NEWA
AB			400MG	A204989	003	Feb 18, 2016	Feb NEWA
		@ SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar CAHN
		@	300MG	A076537	002	Jun 30, 2005	Mar CAHN

CAPSULE; ORAL									
GABAPENTIN									
	@	400MG	A076537	003	Jun 30, 2005	Mar	CAHN		
	@ SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Sep	DISC		
	@	300MG	A076606	002	Oct 07, 2005	Sep	DISC		
	@	400MG	A076606	003	Oct 07, 2005	Sep	DISC		
SOLUTION; ORAL									
GABAPENTIN									
AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb	NEWA		
TABLET; ORAL									
GABAPENTIN									
AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan	NEWA		
AB		800MG	A205101	002	Feb 04, 2016	Jan	NEWA		
<u>GABAPENTIN ENACARBIL</u>									
TABLET, EXTENDED RELEASE; ORAL									
HORIZANT									
	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Jul	CAHN		
	+	600MG	N022399	001	Apr 06, 2011	Jul	CAHN		
<u>GADOFOSESET TRISODIUM</u>									
SOLUTION; INTRAVENOUS									
ABLAVAR									
	@ LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008	Sep	DISC		
	@	3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008	Sep	DISC		
<u>GALANTAMINE HYDROBROMIDE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
GALANTAMINE HYDROBROMIDE									
AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul	NEWA		
AB		EQ 16MG BASE	A204895	002	Aug 05, 2016	Jul	NEWA		
AB		EQ 24MG BASE	A204895	003	Aug 05, 2016	Jul	NEWA		
	@ IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC		
	@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC		
	@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC		
SOLUTION; ORAL									
GALANTAMINE HYDROBROMIDE									
	+	ROXANE	4MG/ML	A078185	001	Jan 30, 2009	May	CRLD	
	RAZADYNE								
	@ JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May	DISC		
<u>GALLIUM DOTATATE GA-68</u>									
POWDER; INTRAVENOUS									
NETSPOT									
	+	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Aug	NEWA	
<u>GANCICLOVIR SODIUM</u>									
INJECTABLE; INJECTION									
GANCICLOVIR SODIUM									
>D>	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Oct	CAHN		
>A>	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Oct	CAHN		
<u>GATIFLOXACIN</u>									
SOLUTION/DROPS; OPHTHALMIC									
GATIFLOXACIN									
AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun	NEWA		
<u>GEMCITABINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
GEMCITABINE HYDROCHLORIDE									
AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar	NEWA		
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar	NEWA		
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar	NEWA		
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar	CFTG	
AP	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar	CFTG		
AP	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar	CFTG		

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun NEWA
----	-------------------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATEINJECTABLE; INJECTION
GENTAMICIN SULFATE

>D>	@ EUROHLTH INTL SARL	EQ 10MG BASE/ML	A062251	002		Oct CAHN
>D>	@	EQ 40MG BASE/ML	A062251	001		Oct CAHN
>A>	@ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A062251	002		Oct CAHN
>A>	@	EQ 40MG BASE/ML	A062251	001		Oct CAHN

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
@		2MG	A076995	002	Apr 27, 2010	Jan DISC
@		4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATETABLET; ORAL
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG; 4MG	A078709	001	Apr 01, 2016	Mar NEWA
		2MG; 4MG	A078709	002	Apr 01, 2016	Mar NEWA
		2MG; 8MG	A078709	004	Apr 01, 2016	Mar NEWA
		4MG; 4MG	A078709	003	Apr 01, 2016	Mar NEWA
		4MG; 8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLYBURIDETABLET; ORAL
GLYBURIDE

AB1	PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr NEWA
AB1		2.5MG	A203581	002	Apr 14, 2016	Apr NEWA
AB1		5MG	A203581	003	Apr 14, 2016	Apr NEWA
AB1	ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr NEWA
AB1		2.5mg	A206749	002	May 10, 2016	Apr NEWA
AB1		5MG	A206749	003	May 10, 2016	Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG; 250MG	A076731	001	Nov 19, 2004	Jan DISC
@		2.5MG; 500MG	A076731	002	Nov 19, 2004	Jan DISC
@		5MG; 500MG	A076731	003	Nov 19, 2004	Jan DISC
AB	IMPAX LABS INC	1.25MG; 250MG	A076345	001	Feb 18, 2004	Aug CAHN
AB		2.5MG; 500MG	A076345	002	Feb 18, 2004	Aug CAHN
AB		5MG; 500MG	A076345	003	Feb 18, 2004	Aug CAHN
AB	ZYDUS PHARMS USA INC	1.25MG; 250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB		2.5MG; 500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB		5MG; 500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
		ROBINUL					
>D>	@	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Oct CAHN
	@		0.2MG/ML	N017558	001		Feb DISC
>A>	@	WEST-WARD PHARMS INT	0.2MG/ML	N017558	001		Oct CAHN

TABLET; ORAL
GLYCOPYRROLATE

@	HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May CAHN	
@		2MG	A040836	002	Mar 05, 2009	May CAHN	
AA	NATCO PHARMA LTD	1MG	A091413	001	Jun 20, 2016	Jun NEWA	
AA		2MG	A091413	002	Jun 20, 2016	Jun NEWA	
AA	RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN	
AA		2MG	A040821	002	Dec 29, 2008	Jan CAHN	
	ROBINUL						
AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN

TABLET;ORAL							
ROBINUL FORTE							
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN
<u>GRANISETRON</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
SANCUSO							
	+	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008	Aug CAHN
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS							
SUSTOL							
	+	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug NEWA
<u>GRANISETRON HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
GRANISETRON HYDROCHLORIDE							
AP		AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@	CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May CAHN
AP		EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun CAHN
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE							
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
TABLET;ORAL							
GRANISETRON HYDROCHLORIDE							
	@	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
<u>GRISEOFULVIN, MICROSIZE</u>							
SUSPENSION;ORAL							
GRISEOFULVIN							
AB		CIPLA LTD	125MG/5ML	A065354	001	Sep 10, 2007	Sep CAHN
<u>GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
SOLUTION;ORAL							
HYCOFENIX							
	+	MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
<u>GUANFACINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
GUANFACINE HYDROCHLORIDE							
	@	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
	@		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
	@		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
	@		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC
<u>HALOBETASOL PROPIONATE</u>							
LOTION;TOPICAL							
ULTRAVATE							
	+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
<u>HALOPERIDOL</u>							
TABLET;ORAL							
HALOPERIDOL							
	@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
	@	FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
	@		1MG	A071157	001	Jan 02, 1987	Jul CAHN
	@		2MG	A071172	001	Jan 02, 1987	Jul CAHN
	@		5MG	A071212	001	Jan 07, 1988	Jul CAHN
	@		10MG	A071173	001	Jan 07, 1988	Jul CAHN
	@	SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
	@		1MG	A071157	001	Jan 02, 1987	Jun CAHN
	@		2MG	A071172	001	Jan 02, 1987	Mar CAHN
	@		5MG	A071212	001	Jan 07, 1988	Mar CAHN
	@		10MG	A071173	001	Jan 07, 1988	Mar CAHN
	@		20MG	A071177	001	Jan 07, 1988	Mar CAHN
	@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1

TABLET;ORAL
HALOPERIDOL

@	1MG	A071235	003	Nov 03, 1986	Jan CMS1
@	5MG	A071235	004	Nov 03, 1986	Jan CMS1
@	10MG	A071235	005	Jul 20, 1987	Jan CMS1

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

>D> AO	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Oct CAHN
AO	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Sep CAHN
>A> AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Oct CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION
HALOPERIDOL

>D> AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Oct CAHN
>A> AP	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Oct CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

>D> AP	+	EUROHLTH INTL SARL	1,000 UNITS/ML	N017037	001		Oct CAHN
>D> AP	+		5,000 UNITS/ML	N017037	002		Oct CAHN
>D>	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Oct CAHN
>D> AP	+		10,000 UNITS/ML	N017037	003		Oct CAHN
AP		FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
>A> AP	+	WEST-WARD PHARMS INT	1,000 UNITS/ML	N017037	001		Oct CAHN
>A> AP	+		5,000 UNITS/ML	N017037	002		Oct CAHN
>A>	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Oct CAHN
>A> AP	+		10,000 UNITS/ML	N017037	003		Oct CAHN

HEXACHLOROPHENE

EMULSION;TOPICAL
PHISOHEX

@	SANOFI AVENTIS US	3%	N006882	001		May DISC
---	-------------------	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
@ ACTAVIS ELIZABETH 1.5MG;5MG

A040295	001	Dec 01, 2000	Jan CMS1
---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	---------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

@	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
@		25MG	A091679	002	Mar 04, 2013	Apr DISC
@		50MG	A091679	003	Mar 04, 2013	Apr DISC
@		100MG	A091679	004	Mar 04, 2013	Apr DISC
@	FRONTIDA BIOPHARM	10MG	A089359	001	Jul 25, 1986	Jul CAHN
@		25MG	A089258	001	May 05, 1986	Jul CAHN
@		50MG	A089259	001	May 05, 1986	Jul CAHN
@		100MG	A088729	001	Apr 11, 1985	Jul CAHN
@	SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
@		25MG	A089258	001	May 05, 1986	Mar CAHN
@		50MG	A089259	001	May 05, 1986	Mar CAHN
@		100MG	A088729	001	Apr 11, 1985	Jun CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
HYDRALAZINE AND HYDROCHLOROTHIAZIDE
@ WATSON LABS 25MG;15MG

A085827	001		Feb CMS1
---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	SUN PHARM INDS	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984	Mar CAHN
---	----------------	-----------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

@ LANNETT HOLDINGS INC 12.5MG

A091662 001 Jan 27, 2012 Aug DISC

MICROZIDE

AB + ALLERGAN SALES LLC 12.5MG

N020504 001 Dec 27, 1996 Apr CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ AUROLIFE PHARMA LLC 25MG

A083899 001 Feb CAHN

@ 50MG

A085219 001 Feb CAHN

@ HIKMA INTL PHARMS 25MG

A084878 002 Jul 12, 2006 May CAHN

AB 50MG

A084878 001 May CAHN

@ LANNETT 25MG

A084325 001 Aug DISC

@ 50MG

A084324 001 Aug DISC

@ SUN PHARM INDS 25MG

A083972 001 Mar CAHN

@ 50MG

A083972 002 Mar CAHN

@ 100MG

A083972 003 Mar CAHN

ORETIC

@ ABBVIE 50MG

N011971 002 Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB ALEMBIC PHARMS LTD 12.5MG; 150MG

A091370 001 Oct 15, 2012 Sep CAHN

AB 12.5MG; 300MG

A091370 002 Oct 15, 2012 Sep CAHN

AB 25MG; 300MG

A091370 003 Oct 12, 2016 Sep NEWA

AB 25MG; 300MG

A091370 003 Oct 12, 2016 Sep CAHN

AB AUROBINDO PHARMA LTD 25MG; 300MG

A203630 003 Mar 31, 2016 Mar NEWA

>A> AB HISUN PHARM HANGZHOU 12.5MG; 150MG

A207896 001 Oct 14, 2016 Oct NEWA

>A> AB 12.5MG; 300MG

A207896 002 Oct 14, 2016 Oct NEWA

AB INTL SPECLT CHEMS 12.5MG; 150MG

A203036 001 Jan 15, 2016 Jan NEWA

AB 12.5MG; 300MG

A203036 002 Jan 15, 2016 Jan NEWA

AB 25MG; 300MG

A203036 003 Jan 15, 2016 Mar CTEC

AB 25MG; 300MG

A203036 003 Jan 15, 2016 Jan NEWA

AB MYLAN PHARMS INC 25MG; 300MG

A077969 003 Jul 20, 2016 Jul NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC

AB ALVOGEN MALTA 12.5MG; 10MG

N019888 003 Nov 18, 1993 Jan CAHN

AB + 12.5MG; 20MG

N019888 001 Sep 20, 1990 Jan CAHN

AB + 25MG; 20MG

N019888 002 Jul 20, 1989 Jan CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB + TEVA 25MG; 15MG

A076980 002 Mar 07, 2007 Aug CRLD

UNIRETIC

@ UCB INC 12.5MG; 7.5MG

N020729 001 Jun 27, 1997 Aug DISC

@ 12.5MG; 15MG

N020729 003 Feb 14, 2002 Aug DISC

@ 25MG; 15MG

N020729 002 Jun 27, 1997 Aug DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

>D> DAIICHI SANKYO 12.5MG; 20MG

N021532 002 Jun 05, 2003 Oct CFTG

>A> AB 12.5MG; 20MG

N021532 002 Jun 05, 2003 Oct CFTG

>D> 12.5MG; 40MG

N021532 003 Jun 05, 2003 Oct CFTG

>A> AB 12.5MG; 40MG

N021532 003 Jun 05, 2003 Oct CFTG

>D> + 25MG; 40MG

N021532 005 Jun 05, 2003 Oct CFTG

>A> AB + 25MG; 40MG

N021532 005 Jun 05, 2003 Oct CFTG

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A> AB MYLAN PHARMS INC 12.5MG; 20MG

A078827 001 Oct 26, 2016 Oct NEWA

>A> AB 12.5MG; 40MG

A078827 002 Oct 26, 2016 Oct NEWA

>A> AB 25MG; 40MG

A078827 003 Oct 26, 2016 Oct NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS	25MG; 25MG	A089534	001	Jul 02, 1987	Mar	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG; 80MG	A206083	001	Feb 08, 2016	Jan	NEWA
AB		12.5MG; 160MG	A206083	002	Feb 08, 2016	Jan	NEWA
AB		12.5MG; 320MG	A206083	003	Feb 08, 2016	Jan	NEWA
AB		25MG; 160MG	A206083	004	Feb 08, 2016	Jan	NEWA
AB		25MG; 320MG	A206083	005	Feb 08, 2016	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	@ ACTAVIS LABS FL INC	5MG; 200MG	A077454	001	Jun 23, 2010	Jan	DISC
AB	AUROLIFE PHARMA LLC	7.5MG; 200MG	A204575	001	Jun 02, 2016	May	NEWA

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

AB	PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr	NEWA
AB		10MG	A207029	002	Apr 26, 2016	Apr	NEWA
AB		20MG	A207029	003	Apr 26, 2016	Apr	NEWA

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

	@ RANBAXY LABS LTD	0.2%	N017950	001		Jul	CAHN
	@ SUN PHARM INDS LTD	0.2%	N017950	001		Jun	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

PEDIOTIC

	@ MONARCH PHARMS	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062822	001	Sep 29, 1987	Jan	DISC
--	------------------	---------------------------------------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May	NEWA
AB		4MG	A205814	002	May 13, 2016	May	NEWA
AB		8MG	A205814	003	May 13, 2016	May	NEWA
AB	MALLINCKRODT	2MG	A076855	002	Sep 19, 2007	Aug	NEWA
AB		4MG	A076855	003	Sep 19, 2007	Aug	NEWA

TABLET, EXTENDED RELEASE; ORAL

EXALGO

AB	+ MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Jun	CFTG
	HYDROMORPHONE HYDROCHLORIDE						
AB	ACTAVIS LABS FL INC	32MG	A202144	004	Jun 30, 2016	Jun	NEWA
AB	OSMOTICA	8MG	A205629	001	Jul 07, 2016	Jun	NEWA
AB		12MG	A205629	002	Jul 07, 2016	Jun	NEWA
AB		16MG	A205629	003	Jul 07, 2016	Jun	NEWA
AB		32MG	A205629	004	Jul 07, 2016	Jun	NEWA

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

	@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Jan	CAHN
+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Jan	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

@ ALLERGAN SALES LLC 125MG/ML

N017439 001

Jul CAHN

@ 250MG/ML

N017439 002

Jul CAHN

+ ASPEN GLOBAL INC 250MG/ML

A200271 001 Aug 24, 2015

Jan CAHN

SOLUTION; INTRAMUSCULAR

MAKENA

>D>

 >D> + AMAG PHARMA USA 250MG/ML (250MG/ML)
 + 250MG/ML (250MG/ML)
 + 1250MG/5ML (250MG/ML)
 + LUMARA HEALTH INC 250MG/ML (250MG/ML)

N021945 002 Feb 19, 2016

Oct CTNA

N021945 002 Feb 19, 2016

Jun CAHN

N021945 001 Feb 03, 2011

Jun CAHN

N021945 002 Feb 19, 2016

Feb NEWA

>A> MAKENA PRESERVATIVE FREE

>A> + AMAG PHARMA USA 250MG/ML (250MG/ML)

N021945 002 Feb 19, 2016

Oct CTNA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 10MG

A087869 001 Dec 20, 1982

Feb CAHN

@ 25MG

A087870 001 Dec 20, 1982

Feb CAHN

@ 50MG

A087871 001 Dec 20, 1982

Feb CAHN

AB ECI PHARMS LLC 10MG

A040804 001 Jun 30, 2008

May CAHN

AB 25MG

A040804 002 Jun 30, 2008

May CAHN

AB 50MG

A040804 003 Jun 30, 2008

May CAHN

AB ELITE LABS INC 10MG

A040604 002 Dec 28, 2004

Jun NEWA

AB 25MG

A040604 003 Dec 28, 2004

Jun NEWA

@ SUN PHARM INDS 10MG

A089381 001 May 19, 1986

Mar CAHN

@ 25MG

A089382 001 May 19, 1986

Mar CAHN

@ 50MG

A089383 001 May 19, 1986

Mar CAHN

@ 100MG

A087862 001 Apr 18, 1983

Mar CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB IMPAX LABS INC EQ 25MG HCL

A040156 001 Jul 15, 1996

Aug CAHN

AB EQ 50MG HCL

A040156 002 Jul 15, 1996

Aug CAHN

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

AP ACCORD HLTHCARE EQ 3MG BASE/3ML

A206058 001 Feb 05, 2016

Jan NEWA

TABLET; ORAL

IBANDRONATE SODIUM

AB AUROBINDO PHARMA LTD EQ 150MG BASE

A204502 001 Mar 11, 2016

Feb NEWA

AB SUN PHARM INDS EQ 150MG BASE

A078996 001 Aug 15, 2012

Mar CAHN

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

>A> AB HI-TECH PHARMACAL 100MG/5ML

A205647 001 Nov 03, 2016

Oct NEWA

TABLET; ORAL

IBUPROFEN

@ AUROLIFE PHARMA LLC 300MG

A070734 001 Jun 12, 1986

Feb CAHN

@ 400MG

A070735 001 Jun 12, 1986

Feb CAHN

@ 600MG

A070736 001 Jun 12, 1986

Feb CAHN

@ 800MG

A071938 001 Jan 14, 1988

Mar CAHN

AB CONTRACT PHARMACAL 400MG

A071268 002 Oct 15, 1986

Sep NEWA

AB 800MG

A071268 003 Jul 01, 1988

Sep NEWA

@ J AND J CONSUMER INC 400MG

A070081 001 Jun 16, 1986

Jul CAHN

AB STRIDES PHARMA 400MG

A078329 001 Feb 05, 2009

May CAHN

AB 600MG

A078329 002 Feb 05, 2009

May CAHN

AB 800MG

A078329 003 Feb 05, 2009

May CAHN

@ SUN PHARM INDS 400MG

A070079 001 Jul 24, 1985

Mar CAHN

@ 600MG

A070080 001 Jul 24, 1985

Mar CAHN

@ 800MG

A071448 001 Feb 18, 1987

Mar CAHN

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS
IBUPROFEN LYSINE

AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar NEWA
AP	+ RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar CFTG

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
IDARUBICIN HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	1MG/ML	A065275	001	Dec 14, 2006	Sep CAHN
AP		1MG/ML	A065288	001	May 15, 2007	Sep CAHN

IDOXURIDINE

SOLUTION/DROPS;OPHTHALMIC
DENDRID

+	ALCON	0.1%	N014169	001		Aug CTEC
	HERPLEX					
@	ALLERGAN	0.1%	N013935	002		Aug DISC

IFOSFAMIDE

INJECTABLE;INJECTION
IFOSFAMIDE

>D>	AP	EUROHLTH INTL SARL	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Oct CAHN
>D>	AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Oct CAHN
>A>	AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Oct CAHN

IMATINIB MESYLATE

TABLET;ORAL
IMATINIB MESYLATE

AB	APOTEX INC	EQ 100MG BASE	A079179	001	Aug 05, 2016	Jul NEWA
AB		EQ 400MG BASE	A079179	002	Aug 05, 2016	Jul NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A204285	001	Aug 04, 2016	Jul NEWA
AB		EQ 400MG BASE	A204285	002	Aug 04, 2016	Jul NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

>A>	AB	LUPIN LTD	10MG	A090441	002	Mar 11, 2010	Oct CMS1
>A>	AB		25MG	A090441	003	Mar 11, 2010	Oct CMS1
	AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar CAHN
	AB		25MG	A081049	001	Jun 05, 1990	Mar CAHN
	AB		50MG	A081050	001	Jun 05, 1990	Mar CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL
IMIPRAMINE PAMOATE

AB	+ ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb CRLD
----	----------	-------------	---------	-----	--------------	----------

INAMRINONE LACTATE

INJECTABLE;INJECTION
AMRINONE LACTATE

>D>	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Oct CAHN
>A>	+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Oct CAHN

INDAPAMIDE

TABLET;ORAL
INDAPAMIDE

AB	AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Sep CMFD
AB		2.5MG	A075201	002	Dec 04, 1998	Sep CMFD

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION
INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN
---	---------------------	------------	---------	-----	--------------	----------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

+ GE HEALTHCARE 1mCi/ML N019044 001 Dec 24, 1985 Mar CMS1

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION
OCTREOSCAN

+ MALLINKRODT NUCLEAR 3mCi/ML N020314 001 Jun 02, 1994 Jan CAHN

INDOCYANINE GREEN

INJECTABLE;INJECTION
INDOCYANINE GREEN

AP DIAGNOSTIC GREEN 25MG/VIAL A040811 001 Nov 21, 2007 Jan CAHN

INDOMETHACIN

CAPSULE;ORAL
INDOMETHACIN

@ SUN PHARM INDS 25MG A070900 002 Feb 09, 1987 Sep CMS1

@ 50MG A070900 001 Feb 09, 1987 Sep CAHN

INDOMETHACIN SODIUM

INJECTABLE;INJECTION
INDOMETHACIN SODIUM

>D> AP EUROHLTH INTL SARL EQ 1MG BASE/VIAL A078713 001 Jul 16, 2008 Oct CAHN

AP HOSPIRA INC EQ 1MG BASE/VIAL A204118 001 Apr 19, 2016 Apr NEWA

>A> AP WEST-WARD PHARMS INT EQ 1MG BASE/VIAL A078713 001 Jul 16, 2008 Oct CAHN

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

@ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 002 Jun 16, 2005 Feb DISC

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS
HUMULIN R

+ LILLY 10000 UNITS/20ML (500 UNITS/ML) N018780 004 Mar 31, 1994 Jan CAIN

+ HUMULIN R KWIKPEN

+ LILLY 1500 UNITS/3ML (500 UNITS/ML) N018780 002 Dec 29, 2015 Jan NEWA

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION
AFREZZA

+ MANNKIND 4 UNITS/INH N022472 001 Jun 27, 2014 Mar CAHN

+ 8 UNITS/INH N022472 002 Jun 27, 2014 Mar CAHN

+ 12 UNITS/INH N022472 003 Apr 17, 2015 Mar CAHN

IOXILAN

INJECTABLE;INJECTION
OXILAN-300

@ GUERBET 62% N020316 001 Dec 21, 1995 Jun DISC

OXILAN-350

@ GUERBET 73% N020316 002 Dec 21, 1995 Jun DISC

IPRATROPIUM BROMIDE

SOLUTION;INHALATION
IPRATROPIUM BROMIDE

>A> AN AUROBINDO PHARMA LTD 0.02% A206543 001 Oct 27, 2016 Oct NEWA

@ MYLAN SPECLT 0.02% A074755 001 Jan 10, 1997 Jul DISC

AN + RITEDOSE CORP 0.02% A075693 001 Jan 26, 2001 Jul CRLD

IRBESARTAN

TABLET;ORAL
IRBESARTAN

AB HISUN PHARM HANGZHOU 75MG A206194 001 Jun 14, 2016 May NEWA

AB 150MG A206194 002 Jun 14, 2016 May NEWA

AB 300MG A206194 003 Jun 14, 2016 May NEWA

IRINOTECAN HYDROCHLORIDEINJECTABLE;INJECTION
CAMPOTOSAR

AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
		IRINOTECAN HYDROCHLORIDE					
AP		EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun CAHN
AP			100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun CAHN
AP		QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
AP			100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
AP			300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
AP		SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
AP			100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN

IRON DEXTRANINJECTABLE;INJECTION
INFED

BP	+	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr CAHN
----	---	--------------------	-----------------	---------	-----	--	----------

ISONIAZIDTABLET;ORAL
ISONIAZID

AA		MIKART	100MG	A040090	001	Jun 26, 1997	Jun CMFD
AA			300MG	A040090	002	Jun 26, 1997	Jun CMFD
	@	SUN PHARM INDS	100MG	A080136	001		Mar CAHN
	@		300MG	A083633	001		Mar CAHN

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE;ORAL
DILATRATE-SR

+	AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar CAHN
+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul CAHN

TABLET;ORAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar CAHN
@		10MG	A086169	001	Sep 19, 1986	Jun CAHN
@		20MG	A086167	001	Sep 19, 1986	Jun CAHN
@		30MG	A087564	001	Sep 18, 1986	Jun CAHN

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun CAHN
@		5MG	A086168	001	Sep 18, 1986	Jun CAHN
@		10MG	A087545	001	Sep 18, 1986	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

@	COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar DISC
+	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar CTEC

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE

AB		DEXCEL LTD	30MG	A075522	002	Sep 20, 2016	Sep NEWA
----	--	------------	------	---------	-----	--------------	----------

ISOSULFAN BLUEINJECTABLE;INJECTION
ISOSULFAN BLUE

AP		AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan NEWA
AP	+	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan CTEC

ISOTRETINOINCAPSULE;ORAL
ABSORICA

BX		RANBAXY	10MG	N021951	001	May 25, 2012	Aug CAHN
BX			20MG	N021951	002	May 25, 2012	Aug CAHN
			25MG	N021951	005	Aug 15, 2014	Aug CAHN
BX			30MG	N021951	003	May 25, 2012	Aug CAHN
			35MG	N021951	006	Aug 15, 2014	Aug CAHN
BX	+		40MG	N021951	004	May 25, 2012	Aug CAHN
BX		RANBAXY LABS LTD	10MG	N021951	001	May 25, 2012	Jul CAHN
BX			20MG	N021951	002	May 25, 2012	Jul CAHN
			25MG	N021951	005	Aug 15, 2014	Aug CAHN
			25MG	N021951	005	Aug 15, 2014	Jul CAHN

CAPSULE; ORAL									
ABSORICA									
BX		30MG		N021951	003	May 25, 2012	Jul	CAHN	
		35MG		N021951	006	Aug 15, 2014	Aug	CAHN	
		35MG		N021951	006	Aug 15, 2014	Jul	CAHN	
BX	+	40MG		N021951	004	May 25, 2012	Jul	CAHN	
SOTRET									
	@ SUN PHARM INDS LTD	10MG		A076041	001	Dec 24, 2002	Sep	DISC	
	@	20MG		A076041	002	Dec 24, 2002	Sep	DISC	
	@	30MG		A076503	001	Jun 20, 2003	Sep	DISC	
	@	40MG		A076041	003	Dec 24, 2002	Sep	DISC	
<u>ITRACONAZOLE</u>									
CAPSULE; ORAL									
ITRACONAZOLE									
AB	ACCORD HLTHCARE	100MG		A205991	001	May 26, 2016	May	NEWA	
AB	AMNEAL PHARMS	100MG		A205080	001	Sep 26, 2016	Sep	NEWA	
SOLUTION; ORAL									
ITRACONAZOLE									
	@ AMNEAL PHARMS	10MG/ML		A205573	001	Oct 30, 2015	Apr	DISC	
SPORANOX									
+	JANSSEN PHARMS	10MG/ML		N020657	001	Feb 21, 1997	Apr	CTEC	
<u>IVACAFTOR; LUMACAFTOR</u>									
TABLET; ORAL									
ORKAMBI									
	VERTEX PHARMS INC	125MG;100MG		N206038	002	Sep 28, 2016	Sep	NEWA	
<u>IVERMECTIN</u>									
LOTION; TOPICAL									
SKLICE									
+	ARBOR PHARMS LLC	0.5%		N202736	001	Feb 07, 2012	May	CAHN	
<u>KETAMINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
KETAMINE HYDROCHLORIDE									
AP	WEST-WARD PHARMS INT	EQ 50MG BASE/ML		A074524	001	Mar 22, 1996	Sep	CAHN	
AP		EQ 100MG BASE/ML		A074524	002	Mar 22, 1996	Sep	CAHN	
<u>KETOCONAZOLE</u>									
TABLET; ORAL									
KETOCONAZOLE									
	@ SUN PHARM INDS	200MG		A075314	001	Jun 15, 1999	Jan	CAHN	
<u>KETOPROFEN</u>									
CAPSULE; ORAL									
KETOPROFEN									
	@ AUROLIFE PHARMA LLC	50MG		A074024	001	Dec 29, 1995	Feb	CAHN	
	@	75MG		A074024	002	Dec 29, 1995	Feb	CAHN	
<u>KETOROLAC TROMETHAMINE</u>									
INJECTABLE; INJECTION									
KETOROLAC TROMETHAMINE									
	@ EUROHLTH INTL SARL	15MG/ML		A075222	001	Apr 26, 1999	Apr	CAHN	
	@	30MG/ML		A075222	002	Apr 26, 1999	Apr	CAHN	
	@	30MG/ML		A075228	001	Apr 26, 1999	May	CAHN	
>A> AP	GLAND PHARMA LTD	15MG/ML		A204216	001	Nov 01, 2016	Oct	NEWA	
>A> AP		30MG/ML		A204216	002	Nov 01, 2016	Oct	NEWA	
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE</u>									
SOLUTION; IRRIGATION									
OMIDRIA									
+	OMEROS	EQ 0.3% BASE; EQ 1% BASE		N205388	001	May 30, 2014	Aug	CPOT	
<u>LABETALOL HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
LABETALOL HYDROCHLORIDE									
>D> AP	EUROHLTH INTL SARL	5MG/ML		A075303	001	May 28, 1999	Oct	CAHN	
AP	SAGENT STRIDES	5MG/ML		A079134	001	Feb 03, 2010	Jan	CTNA	
>A> AP	WEST-WARD PHARMS INT	5MG/ML		A075303	001	May 28, 1999	Oct	CAHN	

INJECTABLE; INJECTION							
TRANDATE							
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan	CAHN
TABLET; ORAL							
LABETALOL HYDROCHLORIDE							
AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan	CAHN
AB		200MG	A075215	002	Jul 29, 1999	Jan	CAHN
AB		300MG	A075215	003	Jul 29, 1999	Jan	CAHN
<u>LACOSAMIDE</u>							
SOLUTION; ORAL							
LACOSAMIDE							
AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr	NEWA
VIMPAT							
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr	CFTG
TABLET; ORAL							
LACOSAMIDE							
AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204855	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204855	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204855	004	Apr 28, 2016	Apr	NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204974	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204974	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204974	004	Apr 28, 2016	Apr	NEWA
AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	Aug	NEWA
AB		100MG	A204857	002	Sep 09, 2016	Aug	NEWA
AB		150MG	A204857	003	Sep 09, 2016	Aug	NEWA
AB		200MG	A204857	004	Sep 09, 2016	Aug	NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204994	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204994	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204994	004	Apr 28, 2016	Apr	NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204921	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204921	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr	NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A205026	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr	NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr	NEWA
VIMPAT							
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr	CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr	CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr	CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr	CFTG
<u>LACTULOSE</u>							
SOLUTION; ORAL							
CONSTULOSE							
	@ ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988	Aug	DISC
LACTULOSE							
AA	+ HI TECH PHARMA	10GM/15ML	A074076	001	Jul 03, 1995	Aug	CRLD
<u>LAMIVUDINE</u>							
TABLET; ORAL							
LAMIVUDINE							
AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb	NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb	NEWA
<u>LAMOTRIGINE</u>							
TABLET; ORAL							
LAMOTRIGINE							
AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009	Jun	CAHN
AB		100MG	A079132	002	Jan 27, 2009	Jun	CAHN
AB		150MG	A079132	003	Jan 27, 2009	Jun	CAHN
AB		200MG	A079132	004	Jan 27, 2009	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
LAMICTAL XR

AB + GLAXOSMITHKLINE LLC 200MG N022115 004 May 29, 2009 Jan CRLD

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB SCIEGEN PHARMS INC 25MG A206382 001 Jun 17, 2016 Jun NEWA
AB 50MG A206382 002 Jun 17, 2016 Jun NEWA
AB 100MG A206382 003 Jun 17, 2016 Jun NEWA
AB 200MG A206382 004 Jun 17, 2016 Jun NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

>A> AB AJANTA PHARMA LTD 15MG A203957 001 Oct 14, 2016 Oct NEWA
>A> AB 30MG A203957 002 Oct 14, 2016 Oct NEWA
AB ANCHEN PHARMS 15MG A203203 001 Jul 25, 2016 Jul NEWA
AB 30MG A203203 002 Jul 25, 2016 Jul NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT FDC LTD 0.005% A202442 001 Apr 22, 2016 Apr NEWA

LESINURAD

TABLET;ORAL
ZURAMPIC

+ IRONWOOD PHARMS INC 200MG N207988 001 Dec 22, 2015 Aug CAHN

LETROZOLE

TABLET;ORAL
LETROZOLE

AB HIKMA PHARMS 2.5MG A203796 001 Jun 03, 2016 May NEWA
AB KREMERS URBAN PHARMS 2.5MG A091098 001 Jun 03, 2011 Jan CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

>D> AP + EUROHLTH INTL SARL EQ 50MG BASE/VIAL A089384 001 Sep 14, 1987 Oct CAHN
>D> AP + EQ 100MG BASE/VIAL A089717 001 Mar 28, 1988 Oct CAHN
>A> AP + WEST-WARD PHARMS INT EQ 50MG BASE/VIAL A089384 001 Sep 14, 1987 Oct CAHN
>A> AP + EQ 100MG BASE/VIAL A089717 001 Mar 28, 1988 Oct CAHN

LEUCOVORIN CALCIUM PRESERVATIVE FREE

+ WEST-WARD PHARMS INT EQ 10MG BASE/ML A040347 001 Apr 25, 2000 Sep CAHN
AP + EQ 200MG BASE/VIAL A040056 001 May 23, 1995 Sep CAHN
AP + EQ 350MG BASE/VIAL A040335 001 Apr 20, 2000 Sep CAHN

TABLET;ORAL

LEUCOVORIN CALCIUM

@ IDT AUSTRALIA LTD EQ 15MG BASE A075327 001 Mar 24, 1999 May CAHN
ROXANE EQ 15MG BASE A072735 001 Feb 22, 1993 Jun CTEC

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN IMPAX LABS INC EQ 0.0103% BASE A077756 003 Apr 09, 2008 Aug CAHN
AN EQ 0.021% BASE A077756 001 Apr 09, 2008 Aug CAHN
AN EQ 0.042% BASE A077756 002 Apr 09, 2008 Aug CAHN
AN RITEDOSE CORP EQ 0.0103% BASE A203653 001 Mar 22, 2016 Mar NEWA
AN EQ 0.021% BASE A203653 002 Mar 22, 2016 Mar NEWA
AN EQ 0.042% BASE A203653 003 Mar 22, 2016 Mar NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A204312 001 Feb 01, 2016 Jan NEWA
AP JUBILANT LIFE 500MG/5ML (100MG/ML) A206838 001 Jun 02, 2016 May NEWA
AP MYLAN LABS LTD 500MG/5ML (100MG/ML) A203308 001 Sep 16, 2016 Sep NEWA

TABLET;ORAL

LEVETIRACETAM

>A> AB SECAN PHARMS 500MG A205102 004 Dec 16, 2015 Oct NEWA

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May NEWA
AB		750MG	A202095	001	Jun 06, 2016	May NEWA
AB	NOSTRUM LABS INC	500MG	A204754	001	Aug 26, 2016	Aug NEWA
AB		750MG	A204754	002	Aug 26, 2016	Aug NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar CAHN

TABLET, FOR SUSPENSION;ORAL
SPRITAM

	APRECIA PHARMS CO	250MG
		500MG
		750MG
+		1GM
		1GM

N207958	001	Jul 31, 2015	Feb CDFR
N207958	002	Jul 31, 2015	Feb CDFR
N207958	003	Jul 31, 2015	Feb CDFR
N207958	004	Jul 31, 2015	Mar CRLD
N207958	004	Jul 31, 2015	Feb CDFR

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

AT	ALCON LABS INC	0.25%
----	----------------	-------

A074851	001	Oct 28, 1996	Jul CAHN
---------	-----	--------------	----------

LEVOCARNITINE

INJECTABLE;INJECTION
LEVOCARNITINE

>D> AP	EUROHLTH INTL SARL	200MG/ML
>A> AP	WEST-WARD PHARMS INT	200MG/ML

A075567	001	Mar 29, 2001	Oct CAHN
A075567	001	Mar 29, 2001	Oct CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)
@		EQ 500MG/100ML (EQ 5MG/ML)
@		EQ 750MG/150ML (EQ 5MG/ML)

N020635	002	Dec 20, 1996	Jun DISC
N020635	003	Dec 20, 1996	Jun DISC
N020635	005	Dec 20, 1996	Jun DISC

LEVOFLOXACIN

>D> AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)
>A>	@	EQ 500MG/20ML (EQ 25MG/ML)
>D> AP		EQ 750MG/30ML (EQ 25MG/ML)
>A>	@	EQ 750MG/30ML (EQ 25MG/ML)

A078577	001	Aug 12, 2015	Oct DISC
A078577	001	Aug 12, 2015	Oct DISC
A078577	002	Aug 12, 2015	Oct DISC
A078577	002	Aug 12, 2015	Oct DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)
AP		EQ 500MG/100ML (EQ 5MG/ML)
AP		EQ 750MG/150ML (EQ 5MG/ML)

A206919	001	Feb 10, 2016	Jan NEWA
A206919	002	Feb 10, 2016	Jan NEWA
A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+	RISING PHARMS INC	0.5%
----	---	-------------------	------

A077700	001	Dec 20, 2010	Jan CAHN
---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

FUSILEV

AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL
		LEVOLEUCOVORIN CALCIUM	
		ACTAVIS LLC	EQ 175MG BASE/VIAL
>D> AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL
AP			EQ 50MG BASE/VIAL
>A> AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL

N020140	001	Mar 07, 2008	Jun CFTG
N208723	001	Sep 29, 2016	Sep NEWA
A206263	001	Jun 16, 2016	Oct CAHN
A206263	001	Jun 16, 2016	Jun NEWA
A206263	001	Jun 16, 2016	Oct CAHN

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE
KYLEENA

+	BAYER HLTHCARE	19.5MG
---	----------------	--------

N208224	001	Sep 16, 2016	Sep NEWA
---------	-----	--------------	----------

TABLET;ORAL

LEVONORGESTREL

AB	JAI PHARMA LTD	0.75MG	
AB	LOTUS PHARM CO LTD	0.75MG	
AB	+	PERRIGO R AND D	0.75MG
	+		0.75MG

A202740	001	Sep 02, 2016	Aug NEWA
A202684	001	Sep 02, 2016	Aug NEWA
A090740	001	Dec 30, 2010	Aug CTEC
A090740	001	Dec 30, 2010	Apr CRLD

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun NEWA
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jun NEWA
AP	+ FRESSENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
AP	+	500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

@ LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
@	0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
@	0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
@	0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
@	0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
@	0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
@	0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
@	0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
@	0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
@	0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
@	0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
@	0.3MG	N021137	012	Jun 06, 2003	Jul CAHN

LEVOTHROID

@ LLOYD	0.025MG	N021116	001	Oct 24, 2002	May DISC
@	0.05MG	N021116	002	Oct 24, 2002	May DISC
@	0.075MG	N021116	003	Oct 24, 2002	May DISC
@	0.088MG	N021116	010	Oct 24, 2002	May DISC
@	0.1MG	N021116	004	Oct 24, 2002	May DISC
@	0.112MG	N021116	011	Oct 24, 2002	May DISC
@	0.125MG	N021116	005	Oct 24, 2002	May DISC
@	0.137MG	N021116	012	Dec 07, 2004	May DISC
@	0.15MG	N021116	006	Oct 24, 2002	May DISC
@	0.175MG	N021116	007	Oct 24, 2002	May DISC
@	0.2MG	N021116	008	Oct 24, 2002	May DISC
@	0.3MG	N021116	009	Oct 24, 2002	May DISC

LEVOTHYROXINE SODIUM

AB1, MYLAN	0.3MG	A076187	011	Jun 05, 2002	May CRLD
AB2,					
AB3,					
AB4, +					

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT GLENMARK PHARMS LTD	5%	A206498	001	Sep 09, 2016	Aug NEWA
AT SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun CAHN
AT TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	400MG/100ML	N018388	002		Feb DISC
-----------	-------------	---------	-----	--	----------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982	Feb DISC
-----------	-------------	---------	-----	--------------	----------

JELLY;TOPICAL

ANESTACON

@ BIONPHARMA INC	2%	A080429	001		Jan CAHN
------------------	----	---------	-----	--	----------

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT + VINTAGE	2%	A040708	001	Feb 27, 2007	Aug CRLD
--------------	----	---------	-----	--------------	----------

XYLOCAINE VISCOUS

@ FRESSENIUS KABI USA	2%	N009470	001		Aug DISC
-----------------------	----	---------	-----	--	----------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT TELIGENT PHARMA INC	4%	A204494	001	Mar 12, 2014	May CAHN
------------------------	----	---------	-----	--------------	----------

LIFITEGRASTSOLUTION/DROPS;OPHTHALMIC
XIIDRA

+	SHIRE DEV LLC	5%	N208073	001	Jul 11, 2016	Jul NEWA
---	---------------	----	---------	-----	--------------	----------

LINAGLIPTIN; METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR

	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026	001	May 27, 2016	May NEWA
+		5MG;1GM	N208026	002	May 27, 2016	May NEWA

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	Jul NEWA
AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	Feb NEWA

TABLET;ORAL

LINEZOLID

AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Jan NEWA
AB	GLENMARK PHARMS	600MG	A078987	001	Dec 21, 2015	Mar CAHN
AB	NOVEL LABS INC	600MG	A207526	001	Aug 22, 2016	Aug NEWA

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB	MAYNE PHARMA INC	EQ 0.005MG BASE	A090097	001	Mar 20, 2009	Mar CAHN
AB		EQ 0.025MG BASE	A090097	002	Mar 20, 2009	Mar CAHN
AB		EQ 0.05MG BASE	A090097	003	Mar 20, 2009	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Apr NEWA
AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Apr NEWA
AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Apr NEWA

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016	Jul NEWA
---	-------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ZESTRIL

AB	ALVOGEN MALTA	2.5MG	N019777	005	Apr 29, 1993	Jan CAHN
AB		5MG	N019777	001	May 19, 1988	Jan CAHN
AB		10MG	N019777	002	May 19, 1988	Jan CAHN
AB		20MG	N019777	003	May 19, 1988	Jan CAHN
AB		30MG	N019777	006	Jan 20, 1999	Jan CAHN
AB	+	40MG	N019777	004	May 19, 1988	Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb CAHN
AB		300MG	A076243	001	Jun 27, 2002	Feb CAHN
AB		600MG	A078763	001	Apr 15, 2008	Feb CAHN
AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan CMFD

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB	HERITAGE PHARMA	300MG	A205532	001	Sep 29, 2016	Sep NEWA
----	-----------------	-------	---------	-----	--------------	----------

LIXISENATIDE

SOLUTION;SUBCUTANEOUS

ADLYXIN

+	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016	Aug CPOT
+		0.05MG/ML	N208471	001	Jul 27, 2016	Jul NEWA
+		0.1MG/ML	N208471	002	Jul 27, 2016	Jul NEWA
+		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016	Aug CPOT

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

	AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CRLD
+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CRLD

LOPERAMIDE HYDROCHLORIDECAPSULE; ORAL
IMODIUM

		@ J AND J CONSUMER INC	2MG	N017694	001		Feb DISC
		LOPERAMIDE HYDROCHLORIDE					
AB	+	MYLAN	2MG	A072741	001	Sep 18, 1991	Feb CRLD

LORAZEPAMINJECTABLE; INJECTION
ATIVAN

>D>	AP	+	EUROHLTH INTL SARL	2MG/ML	N018140	001		Oct CAHN
>D>	AP	+		4MG/ML	N018140	002		Oct CAHN
>A>	AP	+	WEST-WARD PHARMS INT	2MG/ML	N018140	001		Oct CAHN
>A>	AP	+		4MG/ML	N018140	002		Oct CAHN

TABLET; ORAL

LORAZEPAM

@ FRONTIDA BIOPHARM

@

@

0.5MG

1MG

2MG

A072553	001	Mar 29, 1991	Sep CAHN
A072554	001	Mar 29, 1991	Sep CAHN
A072555	001	Mar 29, 1991	Jul CAHN

LORCASERIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BELVIQ XR

	+	EISAI INC	20MG	N208524	001	Jul 15, 2016	Jul NEWA
--	---	-----------	------	---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

BX		HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr CTEC
BX			50MG	A203835	002	Aug 12, 2015	Apr CTEC
BX			100MG	A203835	003	Aug 12, 2015	Apr CTEC
>D>	BX	LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Oct CTEC
>A>	AB		25MG	A078232	001	Oct 06, 2010	Oct CTEC
	BX		25MG	A078232	001	Oct 06, 2010	Apr CTEC
>D>	BX		50MG	A078232	002	Oct 06, 2010	Oct CTEC
>A>	AB		50MG	A078232	002	Oct 06, 2010	Oct CTEC
	BX		50MG	A078232	002	Oct 06, 2010	Apr CTEC
>D>	BX		100MG	A078232	003	Oct 06, 2010	Oct CTEC
>A>	AB		100MG	A078232	003	Oct 06, 2010	Oct CTEC
	BX		100MG	A078232	003	Oct 06, 2010	Apr CTEC

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB		SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar CAHN
AB			20MG	A077520	002	Apr 14, 2006	Mar CAHN
AB			40MG	A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINEPOWDER; INHALATION
ADASUVE

	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb CAHN
--	---	---------------	------	---------	-----	--------------	----------

LUCINACTANTSUSPENSION; INTRATRACHEAL
SURFAXIN

@ WINDTREE THERAP

8.5ML

N021746	001	Mar 06, 2012	Aug CAHN
---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA
AP	+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
AP		HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA
		MAGNESIUM SULFATE IN PLASTIC CONTAINER					
AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA
AP			4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
AP			2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar NEWA
AP			20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP			40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP		HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Aug CTNA
---	-------------------	-------	---------	-----	--------------	----------

VERMOX

>A>	+	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Oct NEWA
-----	---	----------------	-------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@	RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan CAHN
@		25MG	A040179	002	Jan 30, 1997	Jan CAHN

TABLET, CHEWABLE; ORAL

ANTIVERT

@	CASPER PHARMA LLC	25MG	N010721	005		Jun DISC
---	-------------------	------	---------	-----	--	----------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May CAHN
---	-------------------	-------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN
----	---	-----------------	----------	---------	-----	--------------	----------

MELOXICAM

TABLET; ORAL

MELOXICAM

@	FRONTIDA BIOPHARM	7.5MG	A077935	001	Jul 19, 2006	Jul CAHN
@		15MG	A077935	002	Jul 19, 2006	Jul CAHN
@	SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
@		15MG	A077935	002	Jul 19, 2006	Jan CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

+	APOTEX INC	2MG	N014691	002		Jan CAHN
---	------------	-----	---------	-----	--	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan CAHN
----	---	------------	-------------------	---------	-----	--------------	----------

MELPHALAN HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Oct CAHN
-----	----	--------------------	-------------------	---------	-----	--------------	----------

AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Aug NEWA
----	--	----------------------	-------------------	---------	-----	--------------	----------

>A>	AP	WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Oct CAHN
-----	----	----------------------	-------------------	---------	-----	--------------	----------

POWDER; IV (INFUSION)

EVOMELA

		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar NEWA
--	--	-----------------	-------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

>A>	AB	AMNEAL PHARMS	7MG	A205825	001	Oct 12, 2016	Oct NEWA
>A>	AB		14MG	A205825	002	Oct 12, 2016	Oct NEWA
>A>	AB		21MG	A205825	003	Oct 12, 2016	Oct NEWA
>A>	AB		28MG	A205825	004	Oct 12, 2016	Oct NEWA
	AB	LUPIN LTD	7MG	A206028	001	Sep 28, 2016	Sep NEWA
	AB		14MG	A206028	002	Sep 28, 2016	Sep NEWA

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

AB		21MG	A206028	003	Sep 28, 2016	Sep NEWA
AB		28MG	A206028	004	Sep 28, 2016	Sep NEWA
AB	MYLAN PHARMS INC	7MG	A206032	001	Sep 28, 2016	Sep NEWA
AB		14MG	A206032	002	Sep 28, 2016	Sep NEWA
AB		21MG	A206032	003	Sep 28, 2016	Sep NEWA
AB		28MG	A206032	004	Sep 28, 2016	Sep NEWA
AB	SUN PHARMA GLOBAL	7MG	A205905	001	Sep 28, 2016	Sep NEWA
AB		14MG	A205905	002	Sep 28, 2016	Sep NEWA
AB		21MG	A205905	003	Sep 28, 2016	Sep NEWA
AB		28MG	A205905	004	Sep 28, 2016	Sep NEWA
	NAMENDA XR					
AB	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Sep CFTG
AB		14MG	N022525	002	Jun 21, 2010	Sep CFTG
AB		21MG	N022525	003	Jun 21, 2010	Sep CFTG
AB	+	28MG	N022525	004	Jun 21, 2010	Sep CFTG
	TABLET;ORAL					
	MEMANTINE HYDROCHLORIDE					
>A> AB	SILARX PHARMS INC	5MG	A207236	001	Nov 10, 2016	Oct NEWA
>A> AB		10MG	A207236	002	Nov 10, 2016	Oct NEWA

MEPERIDINE HYDROCHLORIDEINJECTABLE;INJECTION
DEMEROL

	@ US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
	@	50MG/ML	N005010	002		Jan CAHN
	@	75MG/ML	N005010	009		Jan CAHN
	@	100MG/ML	N005010	003		Jan CAHN
	SYRUP;ORAL					
	DEMEROL					
	@ US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan CAHN
	TABLET;ORAL					
	DEMEROL					
AA	+ US PHARM HOLDINGS	50MG	N005010	001		Jan CAHN
AA	+	100MG	N005010	004		Jan CAHN
	MEPERIDINE HYDROCHLORIDE					
	@ SUN PHARM INDS	50MG	A080448	001		Mar CAHN
	@	100MG	A080448	002		Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDEINJECTABLE;INJECTION
MEPERGAN

>D>	@ EUROHLTH INTL SARL	25MG/ML;25MG/ML	N011730	001		Oct CAHN
>A>	@ WEST-WARD PHARMS INT	25MG/ML;25MG/ML	N011730	001		Oct CAHN

MEPROBAMATETABLET;ORAL
MEPROBAMATE

	@ AUROLIFE PHARMA LLC	400MG	A080655	001		Feb CAHN
	@ SUN PHARM INDS	200MG	A080699	001		Mar CAHN
	@	400MG	A080699	002		Mar CAHN

MERCAPTOPURINETABLET;ORAL
MERCAPTOPURINE

AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr CAHN
	PURINETHOL					
AB	STASON PHARMS	50MG	N009053	002		Aug CMFD
	@	50MG	N009053	002		Jan CAHN

MEROPENEMINJECTABLE;INJECTION
MEROPENEM

AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar NEWA
AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May NEWA
AP		1GM/VIAL	A206141	002	Jun 08, 2016	May NEWA
AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016	May NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr NEWA

MESALAMINECAPSULE, DELAYED RELEASE;ORAL
DELZICOL

+ APIL 400MG

N204412 001 Feb 01, 2013 Jan CAHN

TABLET, DELAYED RELEASE;ORAL
ASACOL

@ APIL 400MG

N019651 001 Jan 31, 1992 Jan CAHN

ASACOL HD

+ APIL 800MG

N021830 001 May 29, 2008 Jan CAHN

MESNAINJECTABLE;INTRAVENOUS
MESNA

>D> AP EUROHLTH INTL SARL 100MG/ML

A075739 001 Jan 09, 2004 Oct CAHN

>A> AP WEST-WARD PHARMS INT 100MG/ML

A075739 001 Jan 09, 2004 Oct CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB CSPC OUYI PHARM CO 500MG

A205096 001 Jul 11, 2016 Jun NEWA

AB 850MG

A205096 002 Jul 11, 2016 Jun NEWA

AB 1GM

A205096 003 Jul 11, 2016 Jun NEWA

AB SUN PHARM INDS 500MG

A076038 001 Feb 21, 2002 Mar CAHN

AB 850MG

A076038 002 Feb 21, 2002 Mar CAHN

AB 1GM

A076038 003 Feb 21, 2002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
GLUMETZA

AB3 SANTARUS INC 500MG

N021748 001 Jun 03, 2005 Jan CTEC

AB3 + 1GM

N021748 002 Jun 03, 2005 Jan CTEC

METFORMIN HYDROCHLORIDE

AB3 ACTAVIS LABS FL INC 500MG

A203755 001 Aug 01, 2016 Jul NEWA

AB3 1GM

A203755 002 Aug 01, 2016 Jul NEWA

@ IMPAX LABS 500MG

A076249 001 Jul 30, 2004 Mar DISC

@ 750MG

A076985 001 Sep 13, 2005 Mar DISC

AB1 MARKSANS PHARMA 500MG

A090295 001 Apr 29, 2016 Apr NEWA

AB 750MG

A090295 002 Apr 29, 2016 Apr NEWA

@ SUN PHARM INDS 500MG

A077124 001 Dec 21, 2005 Mar CAHN

AB3 SUN PHARMA GLOBAL 500MG

A202917 001 Aug 01, 2016 Jul NEWA

AB3 1GM

A202917 002 Aug 01, 2016 Jul NEWA

METHACHOLINE CHLORIDEFOR SOLUTION;INHALATION
PROVOCHOLINE

>A> METHAPHARM 1600MG/VIAL

N019193 002 Aug 29, 2016 Oct NEWA

METHADONE HYDROCHLORIDETABLET, FOR SUSPENSION;ORAL
METHADOSE

AA MALLINCKRODT INC 40MG

A074184 001 Apr 29, 1993 Aug CAHN

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

METHAMPHETAMINE HYDROCHLORIDE

AA MAYNE PHARMA INC 5MG

A091189 001 Apr 21, 2010 Aug CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB + US PHARM HOLDINGS 1GM

N017681 001 Jan CAHN

METHENAMINE HIPPURATE

AB AUROBINDO PHARMA LTD 1GM

A205661 001 Jul 05, 2016 Jun NEWA

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB ECI PHARMS LLC 5MG

A040547 001 Feb 18, 2005 Jul CAHN

AB 10MG

A040547 002 Feb 18, 2005 Jul CAHN

@ 20MG

A040547 004 Feb 18, 2005 Jul CAHN

AB RISING PHARMS INC 5MG

A202068 001 Mar 07, 2012 Jan CAHN

AB 10MG

A202068 002 Mar 07, 2012 Jan CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP	AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
>A>	MONTEREY PHARMS LLC	1GM/10ML (100MG/ML)	A205354	001	Oct 27, 2016	Oct NEWA

ROBAXIN

>D>	AP	+	EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001		Oct CAHN
>A>	AP	+	WEST-WARD PHARMS INT	1GM/10ML (100MG/ML)	N011790	001		Oct CAHN

TABLET;ORAL

METHOCARBAMOL

	@	LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Aug DISC
	@		750MG	A084756	001		Aug DISC
	@	SANDOZ	500MG	A084616	001		Feb DISC
	@		750MG	A084615	001		Feb DISC
	@	SUN PHARM INDS	500MG	A084488	001		Mar CAHN
	@		750MG	A084486	001		Mar CAHN

ROBAXIN

AA	+	AUXILIUM PHARMS INC	500MG	N011011	004		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004		Jul CAHN

ROBAXIN-750

AA	+	AUXILIUM PHARMS INC	750MG	N011011	006		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Jul CAHN

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

	@	PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC
--	---	----------------------	------------	---------	-----	--------------	----------

METHOTREXATE

SOLUTION;SUBCUTANEOUS

OTREXUP

	@	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Sep DISC
			12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May NEWA
			17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May NEWA
			22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May NEWA

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM

>D>	AP	+	EUROHLTH INTL SARL	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Oct CAHN
>D>		+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Oct CAHN
>A>	AP	+	WEST-WARD PHARMS INT	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Oct CAHN
>A>		+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Oct CAHN

METHOTREXATE SODIUM PRESERVATIVE FREE

>D>	AP	+	EUROHLTH INTL SARL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Oct CAHN
>D>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Oct CAHN
	AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
	AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
	AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN
>A>	AP	+	WEST-WARD PHARMS INT	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Oct CAHN
>A>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Oct CAHN
		+		EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Sep CAHN

METHOXSALLEN

CAPSULE;ORAL

METHOXSALLEN

	@	IDT AUSTRALIA LTD	10MG	A087781	001	Jun 08, 1982	Aug CAHN
--	---	-------------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

UVADEX

+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr CAHN
---	-------------------	-----------	---------	-----	--------------	----------

METHYLDOPATABLET; ORAL
METHYLDOPA

@ SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar CAHN
@	250MG	A070060	001	Oct 09, 1986	Mar CAHN
@	500MG	A070074	001	Oct 09, 1986	Mar CAHN

METHYLENE BLUESOLUTION; INTRAVENOUS
PROVAYBLUE

+ PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr NEWA
------------------	--------------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATETABLET; ORAL
METHERGINE

@ EDISON THERAPS LLC	0.2MG	N006035	003		Jan DISC
METHYLERGONOVINE MALEATE					
+ NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan CRLD

METHYLNALTREXONE BROMIDESOLUTION; SUBCUTANEOUS
RELISTOR

+ SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Jul CRLD
----------------	-----------------------	---------	-----	--------------	----------

TABLET; ORAL
RELISTOR

+ SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016	Jul NEWA
--------------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB2	COREPHARMA	10MG	A205105	001	Jul 28, 2016	Jul NEWA
AB2		20MG	A205105	002	Jul 28, 2016	Jul NEWA
AB2		30MG	A205105	003	Jul 28, 2016	Jul NEWA
AB2		40MG	A205105	004	Jul 28, 2016	Jul NEWA
AB2		50MG	A205105	005	Jul 28, 2016	Jul NEWA
AB2		60MG	A205105	006	Jul 28, 2016	Jul NEWA
AB1	MAYNE PHARMA	20MG	A078458	001	Dec 01, 2011	Aug CAHN
AB1		30MG	A078458	002	Dec 01, 2011	Aug CAHN
AB1		40MG	A078458	003	Dec 01, 2011	Aug CAHN
AB1		60MG	A078458	004	Jun 23, 2016	Aug CAHN
AB1	WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun NEWA

AB1	+ NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun CFTG
-----	------------	------	---------	-----	--------------	----------

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016	Sep NEWA
AB		10MG	A206840	002	Sep 15, 2016	Sep NEWA
AB		20MG	A206840	003	Sep 15, 2016	Sep NEWA

TABLET, CHEWABLE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Oct CTEC
>A> AB		2.5MG	A204115	001	Feb 25, 2015	Oct CTEC
>D>		5MG	A204115	002	Feb 25, 2015	Oct CTEC
>A> AB		5MG	A204115	002	Feb 25, 2015	Oct CTEC
>D>	+	10MG	A204115	003	Feb 25, 2015	Oct CTEC
>A> AB	+	10MG	A204115	003	Feb 25, 2015	Oct CTEC
>A> AB	TEDOR PHARMA INC	2.5MG	A205756	001	Nov 07, 2016	Oct NEWA
>A> AB		5MG	A205756	002	Nov 07, 2016	Oct NEWA
>A> AB		10MG	A205756	003	Nov 07, 2016	Oct NEWA

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

>D>	JANSSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Oct CTEC
>A> AB		18MG	N021121	001	Aug 01, 2000	Oct CTEC
>D>		27MG	N021121	004	Apr 01, 2002	Oct CTEC
>A> AB		27MG	N021121	004	Apr 01, 2002	Oct CTEC
>D>		36MG	N021121	002	Aug 01, 2000	Oct CTEC
>A> AB		36MG	N021121	002	Aug 01, 2000	Oct CTEC

TABLET, EXTENDED RELEASE;ORAL
CONCERTA

>D>	+	54MG	N021121	003	Dec 08, 2000	Oct CTEC
>A>	AB	+	N021121	003	Dec 08, 2000	Oct CTEC
		METHYLPHENIDATE HYDROCHLORIDE				
	AB	CNTY LINE PHARMS	A204772	001	Feb 29, 2016	Aug CAHN
	AB		A204772	002	Feb 29, 2016	Aug CAHN
>A>	AB	MYLAN PHARMS INC	A206726	001	Oct 21, 2016	Oct NEWA
>A>	AB		A206726	002	Oct 21, 2016	Oct NEWA
>A>	AB		A206726	003	Oct 21, 2016	Oct NEWA
>A>	AB		A206726	004	Oct 21, 2016	Oct NEWA
	AB	TEDOR PHARMA INC	A204772	001	Feb 29, 2016	Feb NEWA
	AB		A204772	002	Feb 29, 2016	Feb NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>A>	AP	AMNEAL PHARMS CO	EQ 40MG BASE/VIAL	A207549	001	Nov 09, 2016	Oct NEWA
>A>	AP		EQ 125MG BASE/VIAL	A207549	002	Nov 09, 2016	Oct NEWA
	AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
	AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
	AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
	AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
	AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
	AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
	AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 10

@ VALEANT PHARM INTL

10MG

A086450 001

Apr DISC

METHYLTESTOSTERONE

@ IMPAX LABS

25MG

A084310 001

Mar DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

REGLAN

>D>	@	EUROHLTH INTL SARL	EQ 5MG BASE/ML	N017862	001		Oct CAHN
>D>	@		EQ 10MG BASE/ML	N017862	004	May 28, 1987	Oct CAHN
>A>	@	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001		Oct CAHN
>A>	@		EQ 10MG BASE/ML	N017862	004	May 28, 1987	Oct CAHN

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ SILARX

EQ 5MG BASE/5ML

A073680 001 Oct 27, 1992 Aug DISC

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		IMPAX LABS INC	EQ 5MG BASE	A072750	001	Dec 28, 1995	Aug CAHN
AB			EQ 10MG BASE	A071250	001	Feb 03, 1988	Aug CAHN
AB		SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar CAHN
	@		EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		EUROHLTH INTL SARL	1MG/ML	A076495	001	Jul 07, 2003	Apr CAHN
----	--	--------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

METOPROLOL TARTRATE

	@	SANDOZ	50MG	A073288	001	Mar 25, 1994	May DISC
	@		100MG	A073289	001	Mar 25, 1994	May DISC
AB		SUN PHARM INDS	25MG	A073654	002	Jul 15, 2009	Mar CAHN
AB			100MG	A073654	001	Dec 21, 1993	Mar CAHN

METRONIDAZOLE

GEL;VAGINAL

NUVESSA

+ ALLERGAN SALES LLC

1.3%

N205223 001 Mar 24, 2014 Apr CAHN

TABLET;ORAL

METRONIDAZOLE

AB		FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	May NEWA
AB			500MG	A207309	002	May 16, 2016	May NEWA
AB		NOSTRUM LABS INC	250MG	A070772	001	Jul 16, 1986	Jan CAHN
AB			500MG	A070773	001	Jul 16, 1986	Jan CAHN

TABLET; ORAL

METRONIDAZOLE

AB	STRIDES PHARMA	250MG	A208162	001	May 25, 2016	May NEWA
AB		500MG	A208162	002	May 25, 2016	May NEWA
AB	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	May CMFD
AB		500MG	A070039	001	Jan 29, 1985	May CMFD
>A> AB	ZYDUS PHARMS USA INC	250MG	A206560	001	Nov 16, 2016	Oct NEWA
>A> AB		500MG	A206560	002	Nov 16, 2016	Oct NEWA

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	Sep CPOT
+		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	Sep CPOT

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan CAHN
---	--------------------	------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	May CAHN
AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr CAHN
AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	May CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb CRLD
AB			100MG	N020682	003	Dec 18, 1996	Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AB	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr NEWA
AB		25MG	A205081	002	Apr 22, 2016	Apr NEWA
AB		50MG	A205081	003	Apr 22, 2016	Apr NEWA
AB		100MG	A205081	004	Apr 22, 2016	Apr NEWA
	@ LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan DISC
		12.5MG	A205071	001	Jan 27, 2016	Jan NEWA
	@	25MG	A205071	002	Jan 27, 2016	Jan DISC
		25MG	A205071	002	Jan 27, 2016	Jan NEWA
	@	50MG	A205071	003	Jan 27, 2016	Jan DISC
		50MG	A205071	003	Jan 27, 2016	Jan NEWA
	@	100MG	A205071	004	Jan 27, 2016	Jan DISC
		100MG	A205071	004	Jan 27, 2016	Jan NEWA
	SAVELLA					
AB	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr CFTG
AB		25MG	N022256	002	Jan 14, 2009	Apr CFTG
AB	+	50MG	N022256	003	Jan 14, 2009	Apr CFTG
AB		100MG	N022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr CAHN
	MILRINONE LACTATE IN DEXTROSE 5%					
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004	Sep DISC
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar CAHN
AP	EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

DYNACIN

>A>	@ CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Oct CMS1
-----	--------------------	--------------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

AB	ZYDUS WORLDWIDE	EQ 50MG BASE	A063011	001	Mar 02, 1992	Aug CAHN
AB		EQ 75MG BASE	A063009	002	Aug 12, 2003	Aug CAHN
AB	+	EQ 100MG BASE	A063009	001	Mar 02, 1992	Aug CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 45MG BASE	A204453	001	Sep 28, 2016	Sep NEWA
AB		EQ 80MG BASE	A204453	002	Sep 28, 2016	Sep NEWA
AB		EQ 90MG BASE	A204453	003	Sep 28, 2016	Sep NEWA
AB		EQ 105MG BASE	A204453	004	Sep 28, 2016	Sep NEWA
AB		EQ 135MG BASE	A204453	005	Sep 28, 2016	Sep NEWA
AB	AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May NEWA
AB		EQ 105MG BASE	A202261	007	Jun 13, 2016	May NEWA
	@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar DISC
	@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar DISC
	@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar DISC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB	SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	----------------	------	---------	-----	--------------	----------

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN
---	--------------------	---------------------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

	@ ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
	@	30MG	A076336	002	Jun 20, 2003	Jan DISC
	@	45MG	A076336	003	Jun 20, 2003	Jan DISC
>D>	@ SANDOZ	15MG	A076189	001	Jun 19, 2003	Oct CAHN
>D> AB		15MG	A076219	001	Jun 19, 2003	Oct CAHN
>D>	@	30MG	A076189	002	Jun 19, 2003	Oct CAHN
>D> AB		30MG	A076219	002	Jun 19, 2003	Oct CAHN
>D>	@	45MG	A076189	003	Jun 19, 2003	Oct CAHN
>D> AB		45MG	A076219	003	Jun 19, 2003	Oct CAHN
>A>	@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Oct CAHN
>A> AB		15MG	A076219	001	Jun 19, 2003	Oct CAHN
>A>	@	30MG	A076189	002	Jun 19, 2003	Oct CAHN
>A> AB		30MG	A076219	002	Jun 19, 2003	Oct CAHN
>A>	@	45MG	A076189	003	Jun 19, 2003	Oct CAHN
>A> AB		45MG	A076219	003	Jun 19, 2003	Oct CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB	IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005	Aug CAHN
AB		30MG	A076901	002	Jun 28, 2005	Aug CAHN
AB		45MG	A076901	003	Jun 28, 2005	Aug CAHN

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Oct CAHN
>D>	AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Oct CAHN
>D>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Oct CAHN
>A>	AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Oct CAHN
>A>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Oct CAHN

MODAFINIL

TABLET; ORAL

MODAFINIL

AB		WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB			200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

AB	+	TEVA	15MG	A076204	002	May 08, 2003	Aug CRLD
		UNIVASC					
		@ UCB INC	7.5MG	N020312	001	Apr 19, 1995	Aug DISC
		@	15MG	N020312	002	Apr 19, 1995	Aug DISC

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	+	@ MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987	Aug DISC
			0.1%	N019625	002	Apr 19, 2013	Aug CRLD

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB		APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
		NASONEX					
AB	+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

>A>	AB	CIPLA LTD	EQ 10MG BASE	A207463	001	Oct 28, 2016	Oct NEWA
-----	----	-----------	--------------	---------	-----	--------------	----------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB			20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB			30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB			40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB			50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB			60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB			70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB			80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+		100MG	N020616	003	Jul 03, 1996	Feb CTEC
	+		200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+	ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB			20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB			30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB			40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB			50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB			60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB			70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB			80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+		100MG	N020616	003	Jul 03, 1996	Apr CAHN
			130MG	N020616	011	Jul 09, 2012	Apr CAHN
			150MG	N020616	012	Jul 09, 2012	Apr CAHN
	+		200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB		IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB			30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB			50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB			60MG	A200411	004	Apr 12, 2016	Mar NEWA

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB		80MG	A200411	005	Apr 12, 2016	Mar	NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar	NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb	CTEC
AB		30MG	A200812	002	Nov 10, 2011	Feb	CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb	CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb	CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb	CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb	CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb	CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb	CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb	CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb	CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb	CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb	CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb	CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb	CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb	CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb	CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb	CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb	CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb	CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb	CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb	CTEC

INJECTABLE;INJECTION
DURAMORPH PF

>D>	AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Oct	CAHN
>D>	AP	+		1MG/ML	N018565	002	Sep 18, 1984	Oct	CAHN
>A>	AP	+	WEST-WARD PHARMS INT	0.5MG/ML	N018565	001	Sep 18, 1984	Oct	CAHN
>A>	AP	+		1MG/ML	N018565	002	Sep 18, 1984	Oct	CAHN
			INFUMORPH						
>D>		+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Oct	CAHN
>D>		+		25MG/ML	N018565	004	Jul 19, 1991	Oct	CAHN
>A>		+	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991	Oct	CAHN
>A>		+		25MG/ML	N018565	004	Jul 19, 1991	Oct	CAHN

SOLUTION;ORAL
MORPHINE SULFATE

AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar	CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar	CAHN
AA		100MG/5ML	A204053	001	Oct 06, 2016	Sep	NEWA
>A>	AA	PHARM ASSOC	A206573	001	Nov 14, 2016	Oct	NEWA
AA	RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun	NEWA
AA	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May	NEWA

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB	COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun	NEWA
AB		30MG	A091357	002	Jun 23, 2016	Jun	NEWA
AB		60MG	A091357	003	Jun 23, 2016	Jun	NEWA
AB		100MG	A091357	004	Jun 23, 2016	Jun	NEWA
AB		200MG	A091357	005	Jun 23, 2016	Jun	NEWA
>A>	AB	MAYNE PHARMA INC	A205386	001	Oct 28, 2016	Oct	NEWA
>A>	AB		A205386	002	Oct 28, 2016	Oct	NEWA
>A>	AB		A205386	003	Oct 28, 2016	Oct	NEWA
>A>	AB		A205386	004	Oct 28, 2016	Oct	NEWA
AB	SUN PHARM INDS LTD	15MG	A205634	001	Aug 25, 2016	Aug	NEWA
AB		30MG	A205634	002	Aug 25, 2016	Aug	NEWA
AB		60MG	A205634	003	Aug 25, 2016	Aug	NEWA
AB		100MG	A205634	004	Aug 25, 2016	Aug	NEWA
AB		200MG	A205634	005	Aug 25, 2016	Aug	NEWA

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

MYCOPHENOLATE MOFETIL

AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun CAHN
----	------------------	-------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

CELLCEPT

>D>	+	ROCHE PALO	500MG/VIAL	N050758	001	Aug 12, 1998	Oct CFTG
>A>	AP	+	500MG/VIAL	N050758	001	Aug 12, 1998	Oct CFTG
>A>		MYCOPHENOLATE MOFETIL HYDROCHLORIDE					
>A>	AP	PAR STERILE PRODUCTS	500MG/VIAL	A203575	001	Oct 28, 2016	Oct NEWA

NABUMETONE

TABLET;ORAL

NABUMETONE

AB		IMPAX LABS INC	500MG	A075189	001	May 26, 2000	Aug CAHN
AB	+		750MG	A075189	002	Sep 24, 2001	Aug CAHN

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		TARO	1%	A205975	001	Sep 08, 2016	Aug NEWA
AB	+	NAFTIN					
AB	+	MERZ PHARMS	1%	N019599	001	Feb 29, 1988	Aug CFTG

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NUBAIN

@	PAR PHARM INC	10MG/ML	N018024	001			Aug CAHN
@		20MG/ML	N018024	002	May 27, 1982		Aug CAHN

NALIDIXIC ACID

TABLET;ORAL

NALIDIXIC ACID

@	SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar CAHN
@		500MG	A070271	001	Jun 29, 1988	Jun CAHN
@		1GM	A070272	001	Jun 29, 1988	Mar CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

>D>	AP	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	0.4MG/ML	A070299	001	Sep 24, 1986	Oct CAHN
		NALOXONE HYDROCHLORIDE					
	AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun NEWA
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
		EVZIO					
>D>	+	KALEO INC	0.4MG/0.4ML	N205787	001	Apr 03, 2014	Oct CPOT
>A>	+		0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014	Oct CPOT
>A>	+		2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Oct NEWA

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

>D>	AB	MALLINCKRODT	50MG	A076264	002	Mar 22, 2002	Oct CRLD
>A>	AB	+	50MG	A076264	002	Mar 22, 2002	Oct CRLD
>D>		REVIA					
>D>	AB	+	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984
>A>		@	50MG	N018932	001	Nov 20, 1984	Oct DISC

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROXYCA ER

	PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016	Aug NEWA
		2.4MG;20MG	N207621	002	Aug 19, 2016	Aug NEWA
		3.6MG;30MG	N207621	003	Aug 19, 2016	Aug NEWA
		4.8MG;40MG	N207621	004	Aug 19, 2016	Aug NEWA
		7.2MG;60MG	N207621	005	Aug 19, 2016	Aug NEWA
		9.6MG;80MG	N207621	006	Aug 19, 2016	Aug NEWA

NAPROXEN

SUSPENSION;ORAL									
NAPROSYN									
AB	+	ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CAHN	
TABLET;ORAL									
NAPROSYN									
AB		ATNAHS PHARMA US	250MG	N017581	002		Feb	CAHN	
AB			375MG	N017581	003		Feb	CAHN	
AB	+		500MG	N017581	004	Apr 15, 1982	Feb	CAHN	
NAPROXEN									
	@	SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb	DISC	
	@		375MG	A074140	002	Dec 21, 1993	Feb	DISC	
	@		500MG	A074140	003	Dec 21, 1993	Feb	DISC	
TABLET, DELAYED RELEASE;ORAL									
EC-NAPROSYN									
AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb	CAHN	
AB	+		500MG	N020067	003	Oct 14, 1994	Feb	CAHN	
NAPROXEN									
	@	SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb	DISC	
	@		500MG	A075061	002	Feb 18, 1998	Feb	DISC	

NAPROXEN SODIUM

TABLET;ORAL									
ANAPROX									
AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb	CAHN	
ANAPROX DS									
AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
NAPRELAN									
AB	+	ALVOGEN MALTA	EQ 750MG BASE	N020353	003	Jan 05, 1996	Aug	CFTG	
NAPROXEN SODIUM									
AB		ACTAVIS LABS FL INC	EQ 750MG BASE	A075416	003	Aug 11, 2016	Aug	NEWA	

NATEGLINIDE

TABLET;ORAL									
NATEGLINIDE									
AB		ZYDUS PHARMS USA INC	60MG	A205248	001	Jul 06, 2016	Jun	NEWA	
AB			120MG	A205248	002	Jul 06, 2016	Jun	NEWA	

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL									
BYVALSON									
		FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jun	NEWA	

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL									
NEFAZODONE HYDROCHLORIDE									
	@	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Feb	DISC	
	@		100MG	A076409	002	Sep 16, 2003	Feb	DISC	
	@		150MG	A076409	003	Sep 16, 2003	Feb	DISC	
	@		200MG	A076409	004	Sep 16, 2003	Feb	DISC	
	@		250MG	A076409	005	Sep 16, 2003	Feb	DISC	

NEOMYCIN SULFATE

TABLET;ORAL									
NEOMYCIN SULFATE									
AA		LANNETT HOLDINGS INC	500MG	A204435	001	Jun 10, 2016	May	NEWA	

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL									
CARDENE									
	@	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	May	DISC	
	@		30MG	N019488	002	Dec 21, 1988	May	DISC	
NICARDIPINE HYDROCHLORIDE									
AB	+	MYLAN	30MG	A074642	002	Jul 18, 1996	May	CRLD	
INJECTABLE;INJECTION									
NICARDIPINE HYDROCHLORIDE									
AP		EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jun	CAHN	

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB	VALIDUS PHARMS	10MG	A073250	001	Oct 08, 1991	Jul CMFD
	@	10MG	A073250	001	Oct 08, 1991	Mar CAHN
AB		20MG	A074045	001	Apr 30, 1992	Jul CMFD
	@	20MG	A074045	001	Apr 30, 1992	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

AB1	ALVOGEN	30MG	N020198	001	Apr 21, 1993	Feb CAHN
AB1	+	60MG	N020198	002	Apr 21, 1993	Feb CAHN
AB1	+	90MG	N020198	003	Apr 21, 1993	Feb CAHN

NIFEDIPINE

AB1	NOVAST LABS LTD	30MG	A202987	001	Aug 25, 2016	Aug NEWA
AB1		60MG	A202987	002	Aug 25, 2016	Aug NEWA
AB1		90MG	A202987	003	Aug 25, 2016	Aug NEWA
AB2	OSMOTICA PHARM US	30MG	A077127	001	Nov 21, 2005	Jun CAHN
AB2		60MG	A077127	002	Nov 21, 2005	Jun CAHN
AB1	VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan CAHN
AB1		60MG	A075269	002	Dec 04, 2000	Jan CAHN
AB1		90MG	A076070	001	Aug 16, 2002	Jan CAHN

NILUTAMIDE

TABLET;ORAL

NILANDRON

AB	+ CONCORDIA PHARMS INC	150MG	N020169	002	Apr 30, 1999	Jul CFTG
AB	ANI PHARMS INC	150MG	A207631	001	Jul 15, 2016	Jul NEWA

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	+ BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan CAHN
AB	HERITAGE PHARMS INC	30MG	A077811	001	May 02, 2007	Aug CAHN

NITISINONE

CAPSULE;ORAL

ORFADIN

+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun NEWA
---	----------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL

ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr NEWA
---	----------------	--------	---------	-----	--------------	----------

NITRIC OXIDE

GAS;INHALATION

INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan CAHN
---	-------------------	--------	---------	-----	--------------	----------

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN

AB	+ CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun CAHN
AB	ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr NEWA
AB	NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	IMPAX LABS INC	50MG	A073671	001	Jan 28, 1993	Aug CAHN
AB		100MG	A073652	001	Jan 28, 1993	Aug CAHN
AB	SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb NEWA
AB		50MG	A201722	002	Feb 16, 2016	Feb NEWA
AB		100MG	A201722	003	Feb 16, 2016	Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACROBID

AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan CAHN
----	---	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May CAHN
-----	--	----------------------	----------	---------	-----	--------------	----------

POWDER;SUBLINGUAL
GONITRO

+ POHL BOSKAMP 0.4MG/PACKET

N208424	001	Jun 08, 2016	Jun NEWA
---------	-----	--------------	----------

TABLET;SUBLINGUAL
NITROGLYCERIN

AB		DR REDDYS LABS INC	0.3MG	A208191	001	Aug 26, 2016	Aug NEWA
----	--	--------------------	-------	---------	-----	--------------	----------

AB			0.4MG	A208191	002	Aug 26, 2016	Aug NEWA
----	--	--	-------	---------	-----	--------------	----------

AB			0.6MG	A208191	003	Aug 26, 2016	Aug NEWA
----	--	--	-------	---------	-----	--------------	----------

NITROSTAT

AB		PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000	Aug CFTG
----	--	---------------	-------	---------	-----	--------------	----------

AB			0.4MG	N021134	002	May 01, 2000	Aug CFTG
----	--	--	-------	---------	-----	--------------	----------

AB	+		0.6MG	N021134	003	May 01, 2000	Aug CFTG
----	---	--	-------	---------	-----	--------------	----------

NIZATIDINESOLUTION;ORAL
NIZATIDINE

+ AMNEAL PHARMS 15MG/ML

A090576	001	Nov 18, 2009	Feb CRLD
---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP		CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan CAHN
----	--	--------	----------------	---------	-----	--------------	----------

AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Apr CAHN
----	--	--------------------	----------------	---------	-----	--------------	----------

NORETHINDRONETABLET;ORAL-28
CAMILA

AB1		MAYNE PHARMA	0.35MG	A076177	001	Oct 21, 2002	Aug CAHN
-----	--	--------------	--------	---------	-----	--------------	----------

AB2		MAYNE PHARMA	0.35MG	A076225	001	Oct 21, 2002	Aug CAHN
-----	--	--------------	--------	---------	-----	--------------	----------

AB1		INCASSIA					
-----	--	----------	--	--	--	--	--

AB1		AUROBINDO PHARMA LTD	0.35MG	A207304	001	Sep 23, 2016	Sep NEWA
-----	--	----------------------	--------	---------	-----	--------------	----------

AB1	+	NOR-QD					
-----	---	--------	--	--	--	--	--

AB1		APIL	0.35MG	N017060	001		Jan CAHN
-----	--	------	--------	---------	-----	--	----------

AB1		NORETHINDRONE					
-----	--	---------------	--	--	--	--	--

AB1		AMNEAL PHARMS	0.35MG	A202260	001	Aug 01, 2013	Aug CAHN
-----	--	---------------	--------	---------	-----	--------------	----------

>D>	AB2	GLENMARK GENERICS	0.35MG	A091209	001	Jul 21, 2010	Oct CMS1
-----	-----	-------------------	--------	---------	-----	--------------	----------

>A>	AB2		0.35MG	A091209	001	Jul 22, 2010	Oct CMS1
-----	-----	--	--------	---------	-----	--------------	----------

NORETHINDRONE ACETATETABLET;ORAL
NORETHINDRONE ACETATE

>A>	AB	JAI PHARMA LTD	5MG	A205278	001	Nov 10, 2016	Oct NEWA
-----	----	----------------	-----	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC EQ 10MG BASE

A074835	001	Jun 30, 1997	Feb CAHN
---------	-----	--------------	----------

@ EQ 25MG BASE

A074835	002	Jun 30, 1997	Feb CAHN
---------	-----	--------------	----------

@ EQ 50MG BASE

A074835	003	Jun 30, 1997	Feb CAHN
---------	-----	--------------	----------

@ EQ 75MG BASE

A074835	004	Jun 30, 1997	Feb CAHN
---------	-----	--------------	----------

@ IDT AUSTRALIA LTD EQ 10MG BASE

A074054	001	Dec 31, 1992	May CAHN
---------	-----	--------------	----------

@ EQ 25MG BASE

A074054	002	Dec 31, 1992	May CAHN
---------	-----	--------------	----------

@ EQ 50MG BASE

A074054	003	Dec 31, 1992	May CAHN
---------	-----	--------------	----------

@ EQ 75MG BASE

A074054	004	Dec 31, 1992	May CAHN
---------	-----	--------------	----------

AB		MAYNE PHARMA	EQ 10MG BASE	A073553	001	Mar 30, 1992	Aug CAHN
----	--	--------------	--------------	---------	-----	--------------	----------

AB			EQ 25MG BASE	A073554	001	Mar 30, 1992	Aug CAHN
----	--	--	--------------	---------	-----	--------------	----------

AB			EQ 50MG BASE	A073555	001	Mar 30, 1992	Aug CAHN
----	--	--	--------------	---------	-----	--------------	----------

AB			EQ 75MG BASE	A073556	001	Mar 30, 1992	Aug CAHN
----	--	--	--------------	---------	-----	--------------	----------

NYSTATIN

POWDER; TOPICAL					
NYSTATIN					
AT	+ MAYNE PHARMA INC	100,000 UNITS/GM	A065203	001	Jul 15, 2004 Aug CAHN
TABLET; ORAL					
NYSTATIN					
AA	SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988 Mar CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL					
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
>A> AT	DR REDDYS LABS LTD	100,000 UNITS/GM; 0.1%	A208326	001	Oct 26, 2016 Oct NEWA
>A> AT	GLENMARK PHARMS LTD	100,000 UNITS/GM; 0.1%	A208136	001	Oct 24, 2016 Oct NEWA
NYSTATIN TRIAMCINOLONE ACETONIDE					
	@ PHARMADERM	100,000 UNITS/GM; 0.1%	A062596	001	Oct 08, 1985 Mar CMS1
OINTMENT; TOPICAL					
MYKACET					
AT	G AND W LABS INC	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987 May CMS1
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	GLENMARK PHARMS LTD	100,000 UNITS/GM; 0.1%	A208300	001	Jun 23, 2016 Jun NEWA

OBETICHOLIC ACID

TABLET; ORAL					
OCALIVA					
	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016 May NEWA
	+	10MG	N207999	002	May 27, 2016 May NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION					
OCTREOTIDE ACETATE					
>D> AP	+ EUROHLTH INTL SARL	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005 Oct CAHN
>D> AP	+	EQ 1MG BASE/ML	A076330	002	Apr 08, 2005 Oct CAHN
>A> AP	+ WEST-WARD PHARMS INT	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005 Oct CAHN
>A> AP	+	EQ 1MG BASE/ML	A076330	002	Apr 08, 2005 Oct CAHN
	@ WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011 Jan DISC
	@	EQ 1MG BASE/ML	A090986	002	May 11, 2011 Jan DISC
OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
>D> AP	+ EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005 Oct CAHN
>D> AP	+	EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005 Oct CAHN
>D> AP	+	EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005 Oct CAHN
>A> AP	+ WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005 Oct CAHN
>A> AP	+	EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005 Oct CAHN
>A> AP	+	EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005 Oct CAHN
	@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011 Jan DISC
	@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011 Jan DISC
	@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011 Jan DISC
OCTREOTIDE ACETATE PRESERVATIVE FREE					
	@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011 Feb CMS1
	@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011 Feb CMS1
	@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011 Feb CMS1

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC					
OFLOXACIN					
AT	ALVOGEN	0.3%	A076830	001	Aug 31, 2004 Mar CAHN
SOLUTION/DROPS; OTIC					
OFLOXACIN					
AT	ALVOGEN	0.3%	A090395	001	Aug 11, 2009 Mar CAHN
AT	+ BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008 Feb CRLD

OLANZAPINE

TABLET; ORAL					
OLANZAPINE					
AB	AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016 Aug NEWA
AB		5MG	A206711	002	Aug 30, 2016 Aug NEWA
AB		7.5MG	A206711	003	Aug 30, 2016 Aug NEWA
AB		10MG	A206711	004	Aug 30, 2016 Aug NEWA
AB		15MG	A206711	005	Aug 30, 2016 Aug NEWA
AB		20MG	A206711	006	Aug 30, 2016 Aug NEWA
AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016 Feb NEWA
AB		5MG	A203333	002	Mar 15, 2016 Feb NEWA

TABLET;ORAL
OLANZAPINE

AB		7.5MG	A203333	003	Mar 15, 2016	Feb NEWA
AB		10MG	A203333	004	Mar 15, 2016	Feb NEWA
AB		15MG	A203333	005	Mar 15, 2016	Feb NEWA
AB		20MG	A203333	006	Mar 15, 2016	Feb NEWA
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan NEWA
AB		5MG	A204319	002	Jan 27, 2016	Jan NEWA
AB		7.5MG	A204319	003	Jan 27, 2016	Jan NEWA
AB		10MG	A204319	004	Jan 27, 2016	Jan NEWA
AB		15MG	A204319	005	Jan 27, 2016	Jan NEWA
AB		20MG	A204319	006	Jan 27, 2016	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb NEWA
AB		10MG	A203456	002	Mar 16, 2016	Feb NEWA
AB		15MG	A203456	003	Mar 16, 2016	Feb NEWA
AB		20MG	A203456	004	Mar 16, 2016	Feb NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL
BENICAR

>D>	DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002	Oct CFTG
>A> AB		5MG	N021286	001	Apr 25, 2002	Oct CFTG
>D>		20MG	N021286	003	Apr 25, 2002	Oct CFTG
>A> AB		20MG	N021286	003	Apr 25, 2002	Oct CFTG
>D>	+	40MG	N021286	004	Apr 25, 2002	Oct CFTG
>A> AB	+	40MG	N021286	004	Apr 25, 2002	Oct CFTG
>A>	OLMESARTAN MEDOXOMIL					
>A> AB	MYLAN PHARMS INC	5MG	A078276	001	Oct 26, 2016	Oct NEWA
>A> AB		20MG	A078276	002	Oct 26, 2016	Oct NEWA
>A> AB		40MG	A078276	003	Oct 26, 2016	Oct NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN
----	----------------------	--------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	---------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL
OMTRYG

+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Mar CAIN
---	-------	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG;1.1GM	A204228	001	Jul 15, 2016	Jul NEWA
AB		40MG;1.1GM	A204228	002	Jul 15, 2016	Jul NEWA
AB	AUROLIFE PHARMA LLC	20MG;1.1GM	A204922	001	Aug 19, 2016	Aug NEWA
AB		40MG;1.1GM	A204922	002	Aug 19, 2016	Aug NEWA
AB	DR REDDYS LABS LTD	20MG;1.1GM	A204068	001	Jul 15, 2016	Jul NEWA
AB		40MG;1.1GM	A204068	002	Jul 15, 2016	Jul NEWA

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AA	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul NEWA
AA		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul NEWA

FOR SUSPENSION;ORAL
ZEGERID

AA		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul CTEC
AA	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul CTEC

ONDANSETRONFILM;ORAL
ZUPLENZ

		MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun CAHN
	+		8MG	N022524	002	Jul 02, 2010	Jun CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	+	CLARIS	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CRLD
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
		@ LANNETT	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010	Aug DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
AP	+	CLARIS	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CRLD
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN
		ZOFRAN					
		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
		ZOFRAN PRESERVATIVE FREE					
		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Aug DISC
		TABLET;ORAL					
		ONDANSETRON HYDROCHLORIDE					
		@ HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
		@	EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
		@	EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

AP		WEST-WARD PHARMS INT	30MG/ML	A040463	001	Mar 04, 2003	Sep CAHN
----	--	----------------------	---------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul NEWA
AB			EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul NEWA
AB			EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul NEWA
		TAMIFLU					
AB		ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul CFTG
AB			EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul CFTG
AB	+		EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul CFTG

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

		@ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun DISC
AP	+		200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May CFTG
		OXALIPLATIN					
AP		QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
AP			50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
AP			100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
	+		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
AP			200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
		@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Aug DISC
		@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Aug DISC

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

>A>		@ FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Oct CAHN
>A>		@	15MG	A071026	003	Aug 10, 1987	Oct CAHN
>A>		@	30MG	A071026	001	Aug 10, 1987	Oct CAHN
>D>		@ SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Oct CAHN
		@	10MG	A071026	002	Aug 10, 1987	Mar CAHN
>D>		@	15MG	A071026	003	Aug 10, 1987	Oct CAHN
		@	15MG	A071026	003	Aug 10, 1987	Mar CAHN

	CAPSULE;ORAL								
>D>	OXAZEPAM	@	30MG	A071026	001	Aug 10,	1987	Oct CAHN	
		@	30MG	A071026	001	Aug 10,	1987	Mar CAHN	
	TABLET;ORAL								
	OXAZEPAM								
	@ FRONTIDA BIOPHARM		15MG	A070683	001	Jan 16,	1987	Jul CAHN	
	@ SUN PHARM INDS		15MG	A070683	001	Jan 16,	1987	Jun CAHN	
	<u>OXCARBAZEPINE</u>								
	TABLET;ORAL								
	OXCARBAZEPINE								
AB	ANI PHARMS INC		150MG	A078005	001	Dec 11,	2007	Jun CMFD	
AB			300MG	A078005	002	Dec 11,	2007	Jun CMFD	
AB			600MG	A078005	003	Dec 11,	2007	Jun CMFD	
	<u>OXICONAZOLE NITRATE</u>								
	CREAM;TOPICAL								
	OXICONAZOLE NITRATE								
AB	TARO		EQ 1% BASE	A205076	001	Mar 07,	2016	Feb NEWA	
	OXISTAT								
AB	+ FOUGERA PHARMS		EQ 1% BASE	N019828	001	Dec 30,	1988	Feb CFTG	
	<u>OXYBUTYNIN</u>								
	FILM, EXTENDED RELEASE;TRANSDERMAL								
	OXYTROL								
AB	+ ALLERGAN SALES LLC		3.9MG/24HR	N021351	002	Feb 26,	2003	Apr CAHN	
	GEL, METERED;TRANSDERMAL								
	GELNIQUE 3%								
	+ ALLERGAN SALES LLC		3%	N202513	001	Dec 07,	2011	Apr CAHN	
	<u>OXYBUTYNIN CHLORIDE</u>								
	GEL;TRANSDERMAL								
	GELNIQUE								
	+ ALLERGAN SALES LLC		10%(100MG/PACKET)	N022204	001	Jan 27,	2009	Apr CAHN	
	TABLET, EXTENDED RELEASE;ORAL								
	OXYBUTYNIN CHLORIDE								
AB	ACCORD HLTHCARE		5MG	A207138	001	Feb 29,	2016	Feb NEWA	
AB			10MG	A207138	002	Feb 29,	2016	Feb NEWA	
AB			15MG	A207138	003	Feb 29,	2016	Feb NEWA	
AB	OSMOTICA PHARM US		5MG	A078503	001	Feb 04,	2009	Jun CAHN	
AB			10MG	A078503	002	Feb 04,	2009	Jun CAHN	
AB			15MG	A078503	003	Feb 04,	2009	Jun CAHN	
AB	UNIQUE PHARM LABS		5MG	A206121	001	May 27,	2016	May NEWA	
AB			10MG	A206121	002	May 27,	2016	May NEWA	
AB			15MG	A206121	003	May 27,	2016	May NEWA	
	<u>OXYCODONE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	XAMPZA ER								
	COLLEGIUM PHARM INC		9MG	N208090	001	Apr 26,	2016	May CAIN	
			13.5MG	N208090	002	Apr 26,	2016	May CAIN	
			18MG	N208090	003	Apr 26,	2016	May CAIN	
			27MG	N208090	004	Apr 26,	2016	May CAIN	
	+		36MG	N208090	005	Apr 26,	2016	May CAIN	
	<u>OXYCODONE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	OXYCODONE HYDROCHLORIDE								
AB	ANI PHARMS INC		5MG	A205177	001	Mar 31,	2016	Mar NEWA	
AB	MAYNE PHARMA INC		5MG	A203107	001	Jul 26,	2012	Aug CAHN	
	CAPSULE, EXTENDED RELEASE;ORAL								
	XAMPZA ER								
	COLLEGIUM PHARM INC		EQ 9MG BASE	N208090	001	Apr 26,	2016	Apr NEWA	
			EQ 13.5MG BASE	N208090	002	Apr 26,	2016	Apr NEWA	
			EQ 18MG BASE	N208090	003	Apr 26,	2016	Apr NEWA	
			EQ 27MG BASE	N208090	004	Apr 26,	2016	Apr NEWA	
	+		EQ 36MG BASE	N208090	005	Apr 26,	2016		

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE						
AA	MAYNE PHARMA INC	100MG/5ML	A204092	001	Jun 05, 2014	Aug CAHN
TABLET; ORAL						
OXYCODONE HYDROCHLORIDE						
AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN
AB		15MG	A202116	002	Dec 30, 2011	Jan CAHN
AB		30MG	A202116	003	Dec 30, 2011	Jan CAHN
AB	COASTAL PHARMS	10MG	A091313	004	Apr 29, 2016	Apr NEWA
AB		20MG	A091313	005	Apr 29, 2016	Apr NEWA
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar NEWA
AB		10MG	A207119	002	Apr 12, 2016	Mar NEWA
AB		15MG	A207119	003	Apr 12, 2016	Mar NEWA
AB		20MG	A207119	004	Apr 12, 2016	Mar NEWA
AB		30MG	A207119	005	Apr 12, 2016	Mar NEWA
AB	MAYNE PHARMA INC	5MG	A091313	001	Feb 18, 2011	Aug CAHN
AB		10MG	A091313	004	Apr 29, 2016	Aug CAHN
AB		15MG	A091313	002	Feb 18, 2011	Aug CAHN
AB		20MG	A091313	005	Apr 29, 2016	Aug CAHN
AB		30MG	A091313	003	Feb 18, 2011	Aug CAHN

OXYMETAZOLINE HYDROCHLORIDE; TETRACAIN HYDROCHLORIDE

SPRAY, METERED; NASAL

KOVANAZE

+	ST RENATUS	0.1MG/SPRAY; 6MG/SPRAY	N208032	001	Jun 29, 2016	Jun NEWA
---	------------	------------------------	---------	-----	--------------	----------

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

>D>	AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Oct CAHN
>D>	AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Oct CAHN
>A>	AP	+	WEST-WARD PHARMS INT	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Oct CAHN
>A>	AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Oct CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Aug NEWA	
	PACLITAXEL						
>D>	AP	EUROHLTH INTL SARL	6MG/ML	A075190	001	Jan 28, 2002	Oct CAHN
	AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan CAHN
>A>	AP	WEST-WARD PHARMS INT	6MG/ML	A075190	001	Jan 28, 2002	Oct CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

	JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar CRLD
+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr NEWA

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar NEWA
		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar NEWA
	EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Aug NEWA

PAMIDRONATE DISODIUMINJECTABLE;INJECTION
PAMIDRONATE DISODIUM

>D>	AP	EUROHLTH INTL SARL	30MG/VIAL	A075290	001	Apr 30, 2001	Oct CAHN
>D>	AP		90MG/VIAL	A075290	003	Apr 30, 2001	Oct CAHN
	AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan CAHN
	AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan CAHN
>A>	AP	WEST-WARD PHARMS INT	30MG/VIAL	A075290	001	Apr 30, 2001	Oct CAHN
	AP	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Sep CAHN
>A>	AP		90MG/VIAL	A075290	003	Apr 30, 2001	Oct CAHN
	AP	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Sep CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)CAPSULE, DELAYED RELEASE;ORAL
PERTZYE

>A>		DIGESTIVE CARE INC	15,125USP UNITS;4,000USP UNITS;14,375USP UNITS	N022175	003	Oct 06, 2016	Oct NEWA
-----	--	--------------------	--	---------	-----	--------------	----------

PANTOPRAZOLE SODIUMINJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar NEWA
		TABLET, DELAYED RELEASE;ORAL					
		PANTOPRAZOLE SODIUM					
AB		AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan NEWA
AB			EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan NEWA

PARICALCITOLCAPSULE;ORAL
PARICALCITOL

AB		BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB			2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB			4MCG	A202539	003	Mar 27, 2014	Jan CAHN
>A>	AB	ECI PHARMS LLC	1MCG	A206710	001	Feb 24, 2016	Oct CAHN
>A>	AB		2MCG	A206710	002	Feb 24, 2016	Oct CAHN
>A>	AB		4MCG	A206710	003	Feb 24, 2016	Oct CAHN
>D>	AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Oct CAHN
	AB		1MCG	A206710	001	Feb 24, 2016	Feb NEWA
>D>	AB		2MCG	A206710	002	Feb 24, 2016	Oct CAHN
	AB		2MCG	A206710	002	Feb 24, 2016	Feb NEWA
>D>	AB		4MCG	A206710	003	Feb 24, 2016	Oct CAHN
	AB		4MCG	A206710	003	Feb 24, 2016	Feb NEWA
	AB	MARKSANS PHARMA	1MCG	A204948	001	Oct 07, 2016	Sep NEWA
	AB		2MCG	A204948	002	Oct 07, 2016	Sep NEWA
	AB		4MCG	A204948	003	Oct 07, 2016	Sep NEWA
AB	+	TEVA PHARMS USA	4MCG	A090829	003	Sep 27, 2013	Aug CRLD
		ZEMPLAR					
		@ ABBVIE	4MCG	N021606	003	May 26, 2005	Aug DISC
		SOLUTION;INTRAVENOUS					
		PARICALCITOL					
AP		ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb NEWA
AP			0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb NEWA
AP			0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb NEWA
AP		DR REDDYS LABS LTD	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Aug NEWA
AP			0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Aug NEWA
AP			0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Aug NEWA

PAROXETINE HYDROCHLORIDETABLET;ORAL
PAROXETINE HYDROCHLORIDE

>D>		@ SANDOZ	EQ 10MG BASE	A075566	001	Mar 08, 2004	Oct CAHN
>D>		@	EQ 20MG BASE	A075566	002	Mar 08, 2004	Oct CAHN
>D>		@	EQ 30MG BASE	A075566	003	Mar 08, 2004	Oct CAHN
>D>		@	EQ 40MG BASE	A075566	004	Mar 08, 2004	Oct CAHN
>A>		@ UPSHER-SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004	Oct CAHN
>A>		@	EQ 20MG BASE	A075566	002	Mar 08, 2004	Oct CAHN
>A>		@	EQ 30MG BASE	A075566	003	Mar 08, 2004	Oct CAHN
>A>		@	EQ 40MG BASE	A075566	004	Mar 08, 2004	Oct CAHN

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB		KREMERS URBAN PHARMS	EQ 12.5MG BASE	A204744	001	Jun 10, 2016	May NEWA
AB			EQ 25MG BASE	A204744	002	Jun 10, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB EQ 37.5MG BASE A204744 003 Jun 10, 2016 May NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL
BRISDELLE

+ SEBELA IRELAND LTD EQ 7.5MG BASE N204516 001 Jun 28, 2013 Aug CAHN

TABLET;ORAL
PEXEVA

SEBELA IRELAND LTD EQ 10MG BASE N021299 001 Jul 03, 2003 Aug CAHN
EQ 20MG BASE N021299 002 Jul 03, 2003 Aug CAHN
EQ 30MG BASE N021299 003 Jul 03, 2003 Aug CAHN
+ EQ 40MG BASE N021299 004 Jul 03, 2003 Aug CAHN

PENBUTOLOL SULFATE

TABLET;ORAL
LEVATOL

@ AUXILIUM PHARMS INC 10MG N018976 001 Dec 30, 1987 Mar CAHN
@ 20MG N018976 004 Jan 05, 1989 Mar CAHN
@ AUXILIUM PHARMS LLC 10MG N018976 001 Dec 30, 1987 Aug CAHN
@ 20MG N018976 004 Jan 05, 1989 Aug CAHN

PENCICLOVIR

CREAM;TOPICAL
DENA VIR

+ DENCO ASSET 1% N020629 001 Sep 24, 1996 Apr CAIN

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

+ HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021749 001 Aug 11, 2004 Apr CMFD
@ EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021749 001 Aug 11, 2004 Feb CAHN

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

+ HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021751 001 Aug 11, 2004 Apr CMFD
@ EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021751 001 Aug 11, 2004 Feb CAHN

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION
NEMBUTAL SODIUM

AP + OAK PHARMS 50MG/ML A083246 001 May CTEC

AP MYLAN INSTITUTIONAL 50MG/ML A206404 001 May 23, 2016 May NEWA

PENTOSTATIN

INJECTABLE;INJECTION
PENTOSTATIN

>D> AP EUROHLTH INTL SARL 10MG/VIAL A077841 001 Aug 07, 2007 Oct CAHN
>A> AP WEST-WARD PHARMS INT 10MG/VIAL A077841 001 Aug 07, 2007 Oct CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB + APOTEX 400MG A075191 001 Jun 09, 1999 Mar CRLD
@ IMPAX LABS 400MG A075093 001 Aug 10, 1999 Mar DISC
@ PLIVA 400MG A074874 001 May 25, 1999 Mar DISC
TRENTAL
@ US PHARM HOLDINGS 400MG N018631 001 Aug 30, 1984 Jan CAHN

PERAMPANEL

SUSPENSION;ORAL
FYCOMPA

+ EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016 Apr NEWA

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

@ LUPIN LTD	2MG	A078263	001	Jan 27, 2010	Sep DISC
@	4MG	A078263	002	Jan 27, 2010	Sep DISC
@	8MG	A078263	003	Jan 27, 2010	Sep DISC

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	SANDOZ	2MG	A089685	002	Dec 08, 1988	Sep NEWA	
AB		4MG	A089685	003	Dec 08, 1988	Sep NEWA	
AB	+	16MG	A089685	004	Dec 08, 1988	Sep NEWA	
>A>	AB	WATSON LABS INC	2MG	A207582	001	Oct 17, 2016	Oct NEWA
>A>	AB		4MG	A207582	002	Oct 17, 2016	Oct NEWA
>A>	AB		8MG	A207582	003	Oct 17, 2016	Oct NEWA
>A>	AB		16MG	A207582	004	Oct 17, 2016	Oct NEWA
AB	WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan CAHN	
AB		4MG	A205973	002	Dec 17, 2015	Jan CAHN	
AB		8MG	A205973	003	Dec 17, 2015	Jan CAHN	
AB		16MG	A205973	004	Dec 17, 2015	Jan CAHN	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@ ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG	N021105	001	Jun 26, 2001	Jan CMS1
--------	------------------------------------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA	AUROLIFE PHARMA LLC	15MG	A204318	001	Nov 09, 2016	Oct NEWA
>A>	AA		30MG	A204318	002	Nov 09, 2016	Oct NEWA
	AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar CAHN
		@	37.5MG	A040527	001	Oct 23, 2003	Mar CAHN

TABLET; ORAL

LOMAIRA

	+	AVANTHI INC	8MG	A203495	001	Sep 12, 2016	Aug NEWA
		PHENTERMINE HYDROCHLORIDE					
AA		INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan CAHN
AA		SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

@ CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun DISC
@	30MG	N202088	002	Jun 13, 2011	Jun DISC
@	37.5MG	N202088	003	Mar 27, 2012	Jun DISC

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

@ LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Aug DISC
@	EQ 30MG BASE	A040872	002	Jul 28, 2011	Aug DISC

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP		WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Sep CAHN
----	--	----------------------	----------	---------	-----	--------------	----------

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

@ SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar CAHN
------------------	-------	---------	-----	--------------	----------

TABLET; ORAL

PHENYLBUTAZONE

@ SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar CAHN
------------------	-------	---------	-----	--------------	----------

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Apr	NEWA
---	-------------------	--------------	---------	-----	--------------	-----	------

PINDOLOL

TABLET;ORAL

PINDOLOL

	@ IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May	CAHN
	@	10MG	A073609	001	Mar 29, 1993	May	CAHN
AB	SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar	CAHN
AB		10MG	A074063	002	Jan 27, 1994	Mar	CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Aug	NEWA
AB		20MG	A207938	002	Sep 09, 2016	Aug	NEWA
AB	MYLAN IRELAND LTD	10MG	A074116	001	Jun 15, 1993	Aug	CAHN
AB		20MG	A074118	001	Jun 15, 1993	Aug	CAHN
AB	MYLAN PHARMS INC	20MG	A074118	001	Jun 15, 1993	Jan	CAHN
	@ SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar	CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

+	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CONDYLOX

AT	+	ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar	CAHN
----	---	--------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

	@ MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	May	DISC
AA	COLYTE WITH FLAVOR PACKS MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr	NEWA
AP	+	WEST-WARD PHARMS INT	EQ 500,000 UNITS BASE/VIAL	A060716	001		Sep CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan	NEWA
AB	KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar	NEWA
AB		10MEQ	A204210	002	Mar 28, 2016	Mar	NEWA
AB	NOVEL LABS INC	8MEQ	A204828	001	Aug 16, 2016	Aug	NEWA
AB		10MEQ	A204828	002	Aug 16, 2016	Aug	NEWA
AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb	NEWA
AB		10MEQ	A201944	002	Mar 04, 2016	Feb	NEWA

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

+	PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Jul	CRLD
---	---------------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1	GLENMARK PHARMS LTD	10MEQ	A203562	001	Jul 26, 2016	Jul	NEWA
AB1		20MEQ	A203562	002	Jul 26, 2016	Jul	NEWA
AB2	NOVEL LABS INC	8MEQ	A206759	001	Aug 09, 2016	Jul	NEWA
AB1		10MEQ	A206347	001	Jan 21, 2016	Jan	NEWA
AB2		10MEQ	A206759	002	Aug 09, 2016	Jul	NEWA
AB1		20MEQ	A206347	002	Jan 21, 2016	Jan	NEWA
AB2	SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016	Aug	NEWA
AB2		10MEQ	A207528	002	Aug 19, 2016	Aug	NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr NEWA
AB		0.75MG	A201963	002	Apr 21, 2016	Apr NEWA
AB		1.5MG	A201963	003	Apr 21, 2016	Apr NEWA
>A> AB		2.25MG	A203615	001	Oct 14, 2016	Oct NEWA
AB		3MG	A201963	004	Apr 21, 2016	Apr NEWA
AB		4.5MG	A201963	005	Apr 21, 2016	Apr NEWA
AB	MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun NEWA
AB		0.75MG	A206156	002	Jun 24, 2016	Jun NEWA
AB		1.5MG	A206156	003	Jun 24, 2016	Jun NEWA
AB		2.25MG	A206156	004	Jun 24, 2016	Jun NEWA
AB		3MG	A206156	005	Jun 24, 2016	Jun NEWA
AB		4.5MG	A206156	007	Jun 24, 2016	Jun NEWA
AB	SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul CDFR
AB		0.75MG	A202353	002	Dec 04, 2014	Jul CDFR
AB		1.5MG	A202353	003	Dec 04, 2014	Jul CDFR
AB		3MG	A202353	004	Dec 04, 2014	Jul CDFR
AB		4.5MG	A202353	005	Dec 04, 2014	Jul CDFR

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
@	MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
@		20MG	A077013	002	Oct 23, 2006	Mar DISC
@		40MG	A077013	003	Oct 23, 2006	Mar DISC
@		80MG	A077013	004	Dec 28, 2007	Mar DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
@		EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
@		EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN
AB	TEVA PHARMS	EQ 1MG BASE	A071745	002	Sep 12, 1988	Sep NEWA
AB		EQ 2MG BASE	A071745	003	Sep 12, 1988	Sep NEWA

PREDNISOLONE

TABLET;ORAL
PREDNISOLONE
@ AUROLIFE PHARMA LLC 5MG

A084773 001 Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL
PREDNISOLONE SODIUM PHOSPHATE

AA	+ WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD
----	-------------	------------------	---------	-----	--------------	----------

PREDNISONE

TABLET;ORAL
PREDNISONE
@ AUROLIFE PHARMA LLC 5MG
@ 10MG
@ 20MG
@ 50MG
AB DELCOR ASSET CORP 5MG
AB 10MG
AB 20MG
AB SUN PHARM INDS 20MG
@ 50MG

A084774 001 Mar CAHN
A089983 001 Jan 12, 1989 Mar CAHN
A085813 001 Mar CAHN
A089984 001 Jan 12, 1989 Mar CAHN
A080292 001 Mar CAHN
A088832 001 Dec 04, 1985 Mar CAHN
A083677 001 Mar CAHN
A089247 001 Dec 04, 1985 Mar CAHN
A086596 001 Jun CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016	Jun NEWA
----	-------------------	--------------	---------	-----	--------------	----------

PRIMIDONE

TABLET; ORAL

PRIMIDONE

AB	FRONTIDA BIOPHARM	50MG	A040626	001	Sep 29, 2005	Jul	CAHN
AB		250MG	A040626	002	Sep 29, 2005	Jul	CAHN
	@ HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006	Jul	CAHN
AB		250MG	A040667	002	Jul 27, 2006	Jul	CAHN
	@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar	DISC
	@	250MG	A040717	002	Feb 12, 2008	Mar	DISC
AB	SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Mar	CAHN
AB		250MG	A040626	002	Sep 29, 2005	Mar	CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May	CAHN
--	---------------------	-------	---------	-----	--------------	-----	------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

	@	AMPHASTAR PHARMS INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Aug	DISC
AP			EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jun	CAHN
>D>	+	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Oct	CTEC
>A>	AP	+	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Oct	CTEC
		+	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Sep	CTEC
AP	+		EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Aug	CRLD
AP		EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr	CAHN
>D>		@	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Oct	CMFD
>A>	AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Oct	CMFD
		@	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Aug	DISC

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan	CAHN
	PROMETRIUM						
AB	VIRTUS PHARMS	100MG	N019781	001	May 14, 1998	Jun	CAHN
AB	+	200MG	N019781	002	Oct 15, 1999	Jun	CAHN
	@	300MG	N019781	003	Oct 15, 1999	Jun	CAHN

GEL; VAGINAL

CRINONE

	+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr	CAHN
	+		8%	N020701	002	Jul 31, 1997	Apr	CAHN

INJECTABLE; INJECTION

PROGESTERONE

AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002		Apr	CAHN
----	---	--------------------	---------	---------	-----	--	-----	------

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Feb	CAHN
----	------------------	------------	---------	-----	--------------	-----	------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

	@ IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008	Mar	DISC
	@	25MG	A040724	002	Feb 12, 2008	Mar	DISC
	@	50MG	A040791	001	May 20, 2008	Mar	DISC
	@ SUN PHARM INDS	12.5MG	A084555	001		Mar	CAHN
	@	25MG	A084554	001		Mar	CAHN
	@	50MG	A084557	001		Jan	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

AB	MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016	Apr	NEWA
AB		325MG	A203803	002	Apr 29, 2016	Apr	NEWA
AB		425MG	A203803	003	Apr 29, 2016	Apr	NEWA

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr	NEWA
AB		225MG	A202445	002	May 11, 2016	Apr	NEWA

TABLET;ORAL

PROPAPENONE HYDROCHLORIDE

AB		300MG	A202445	003	May 11, 2016	Apr NEWA
AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar CAHN
AB		225MG	A075998	002	Nov 29, 2001	Mar CAHN
AB		300MG	A075998	003	Nov 29, 2001	Mar CAHN

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

AB	SAGENT PHARMS	10MG/ML	A075102	001	Jan 04, 1999	Aug CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A074848	001	Apr 19, 2005	Sep CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr CAHN
AB		80MG	N018553	002	Apr 19, 1983	Apr CAHN
AB		120MG	N018553	003	Apr 19, 1983	Apr CAHN
AB	+	160MG	N018553	001	Apr 19, 1983	Apr CAHN

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Jun CMFD
	@	60MG	A078311	001	Mar 06, 2009	May DISC
BX		60MG	A078311	001	Mar 06, 2009	Mar CTEC
BX		80MG	A078311	002	Mar 06, 2009	Jun CMFD
	@	80MG	A078311	002	Mar 06, 2009	May DISC
BX		80MG	A078311	002	Mar 06, 2009	Mar CTEC
BX		120MG	A078311	003	Mar 06, 2009	Jun CMFD
	@	120MG	A078311	003	Mar 06, 2009	May DISC
BX		120MG	A078311	003	Mar 06, 2009	Mar CTEC
BX		160MG	A078311	004	Mar 06, 2009	Jun CMFD
	@	160MG	A078311	004	Mar 06, 2009	May DISC
BX		160MG	A078311	004	Mar 06, 2009	Mar CTEC

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr CAHN
	@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	@ FRONTIDA BIOPHARM	10MG	A070319	001	Oct 22, 1985	Jul CAHN
	@	20MG	A070320	001	Oct 22, 1985	Jul CAHN
	@	40MG	A070103	001	Oct 22, 1985	Jul CAHN
	@	60MG	A070321	001	Sep 24, 1986	Jul CAHN
	@	80MG	A070322	001	Aug 04, 1986	Jul CAHN
AB	IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988	Aug CAHN
AB		20MG	A071973	001	Apr 06, 1988	Aug CAHN
AB		40MG	A071974	001	Apr 06, 1988	Aug CAHN
AB		60MG	A071975	001	Apr 06, 1988	Aug CAHN
AB	+	80MG	A071976	001	Apr 06, 1988	Aug CAHN
	@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar CAHN
	@	20MG	A070320	001	Oct 22, 1985	Mar CAHN
	@	40MG	A070103	001	Oct 22, 1985	Mar CAHN
	@	60MG	A070321	001	Sep 24, 1986	Jun CAHN
	@	80MG	A070322	001	Aug 04, 1986	Mar CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

	@ HIKMA INTL PHARMS	50MG	A080154	001		Jul CAHN
	@ SUN PHARM INDS	50MG	A083982	001		Mar CAHN

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB	VERSAPHARM INC	500MG	A081319	001	Jun 30, 1992	Sep CAHN
----	----------------	-------	---------	-----	--------------	----------

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION
PYRIDOXINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	100MG/ML	A080618	001		Jul CTEC
AP		MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016	Jul NEWA

QUAZEPAM

TABLET;ORAL
DORAL

@ CUTIS HEALTH LLC 7.5MG
+ 15MG
@ 15MG

N018708	003	Feb 26, 1987	Mar CAHN
N018708	001	Dec 27, 1985	Apr CMFD
N018708	001	Dec 27, 1985	Mar CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

	@	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr DISC
	@		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr DISC
	@		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr DISC
	@		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr DISC
	@		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr DISC
	@		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr DISC
	@		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr DISC
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May NEWA
AB			EQ 50MG BASE	A203359	002	May 17, 2016	May NEWA
AB			EQ 100MG BASE	A203359	003	May 17, 2016	May NEWA
AB			EQ 200MG BASE	A203359	004	May 17, 2016	May NEWA
AB			EQ 300MG BASE	A203359	005	May 17, 2016	May NEWA
AB			EQ 400MG BASE	A203359	006	May 17, 2016	May NEWA
AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb NEWA
AB			EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb NEWA
AB			EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb NEWA
AB			EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb NEWA
AB			EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb NEWA
AB			EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

>A>							
>A>	AB	ACCORD HLTHCARE INC	EQ 400MG BASE	A090681	004	Nov 01, 2016	Oct NEWA
		SEROQUEL XR					
>D>		ASTRAZENECA	EQ 400MG BASE	N022047	004	May 17, 2007	Oct CFTG
>A>	AB		EQ 400MG BASE	N022047	004	May 17, 2007	Oct CFTG

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan DISC
	@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan DISC
	@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan DISC
	@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan DISC
AB		PRINSTON INC	EQ 5MG BASE	A205823	001	Sep 15, 2016	Sep NEWA
AB			EQ 10MG BASE	A205823	002	Sep 15, 2016	Sep NEWA
AB			EQ 20MG BASE	A205823	003	Sep 15, 2016	Sep NEWA
AB			EQ 40MG BASE	A205823	004	Sep 15, 2016	Sep NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

	@	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar CAHN
BX	+	SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

	@	SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun CAHN
AB			200MG	A081030	001	Apr 14, 1989	Mar CAHN
AB			300MG	A081031	001	Apr 14, 1989	Mar CAHN

QUININE SULFATECAPSULE;ORAL
QUALAQUIN

AB	+	SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun CAHN
----	---	----------------	-------	---------	-----	--------------	----------

RABEPRAZOLE SODIUMCAPSULE, DELAYED RELEASE;ORAL
ACIPHEX SPRINKLE

		FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun CAHN
	+		10MG	N204736	002	Mar 26, 2013	Jun CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar NEWA
AB		GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar NEWA
>A> AB		SCIEGEN PHARMS INC	60MG	A206384	001	Oct 12, 2016	Oct NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		DR REDDYS LABS INTL	8MG	A091693	001	Jul 26, 2013	Aug CAHN
----	--	---------------------	-----	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@	SANDOZ	1.25MG	A077514	001	Jun 18, 2008	Aug DISC
@		2.5MG	A077514	002	Jun 18, 2008	Aug DISC
@		5MG	A077514	003	Jun 18, 2008	Aug DISC
@		10MG	A077514	004	Jun 18, 2008	Aug DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

>D> AP		EUROHLTH INTL SARL	EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	Oct CAHN
AP		MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May NEWA
AP		WEST-WARD PHARMS INT	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Sep CAHN
>A> AP			EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	Oct CAHN
AP		ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May CPOT
AP	+	IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
		ZANTAC IN PLASTIC CONTAINER					
	@	IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
	@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar CAHN
	@	WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
	@		EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB		STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Aug NEWA
AB			EQ 300MG BASE	A205512	002	Aug 22, 2016	Aug NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB		ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
AB			EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA

RESERPINE

TABLET;ORAL

RESERPINE

@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
@		0.25MG	A080975	002		Feb CAHN
@		1MG	A080975	003		Feb CAHN

RETAPAMULINOINTMENT; TOPICAL
ALTABAX

+ AQUA PHARMS LLC 1%

N022055 001 Apr 12, 2007 Jan CAHN

RIBAVIRINFOR SOLUTION; INHALATION
RIBAVIRINAN NAVINTA LLC 6GM/VIAL
VIRAZOLE

A207366 001 Oct 06, 2016 Sep NEWA

AN + VALEANT PHARM INTL 6GM/VIAL

N018859 001 Dec 31, 1985 Sep CFTG

RIBOFLAVIN 5'-PHOSPHATE SODIUMSOLUTION/DROPS; OPHTHALMIC
PHOTREXA+ AVEDRO INC 0.146%
PHOTREXA VISCOUS IN DEXTRAN 20%

N203324 001 Apr 15, 2016 Apr NEWA

+ AVEDRO INC 0.146%
PHOTREXA VISCOUS IN DEXTROSE 20%

N203324 002 Apr 15, 2016 Jun CMS1

+ AVEDRO INC 0.146%

N203324 002 Apr 15, 2016 Apr NEWA

RIFAMPININJECTABLE; INJECTION
RIFAMPIN

AP EUROHLTH INTL SARL 600MG/VIAL

A064217 001 Oct 29, 1999 Apr CAHN

AP HIKMA PHARMS 600MG/VIAL

A205039 001 Mar 03, 2016 Feb NEWA

AP WATSON PHARMS INC 600MG/VIAL

A206736 001 Jan 19, 2016 Jan NEWA

RILUZOLETABLET; ORAL
RILUZOLE

AB ALKEM LABS LTD 50MG

A204048 001 Mar 30, 2016 Mar NEWA

RIMEXOLONESUSPENSION/DROPS; OPHTHALMIC
VEXOL

@ ALCON 1%

N020474 001 Dec 30, 1994 Jun DISC

RISEDRONATE SODIUMTABLET; ORAL
ACTONEL

AB APIL 5MG

N020835 002 Apr 14, 2000 Jan CAHN

AB 30MG

N020835 001 Mar 27, 1998 Jan CAHN

AB + 35MG

N020835 003 May 25, 2002 Jan CAHN

@ 75MG

N020835 004 Apr 16, 2007 Jan CAHN

AB + 150MG

N020835 005 Apr 22, 2008 Jan CAHN

RISEDRONATE SODIUM

>A> AB AUROBINDO PHARMA LTD 150MG

A206768 001 Oct 21, 2016 Oct NEWA

TABLET, DELAYED RELEASE; ORAL
ATELVIA

AB + APIL 35MG

N022560 001 Oct 08, 2010 Jan CAHN

RISPERIDONESOLUTION; ORAL
RISPERIDONE

@ SILARX PHARMS INC 1MG/ML

A202386 001 Jan 12, 2015 Aug DISC

@ WOCKHARDT 1MG/ML

A078744 001 Oct 08, 2009 Apr DISC

RIVASTIGMINEFILM, EXTENDED RELEASE; TRANSDERMAL
RIVASTIGMINE

AB ALVOGEN MALTA 4.6MG/24HR

A204403 001 Sep 03, 2015 Jan CAHN

AB 9.5MG/24HR

A204403 002 Sep 03, 2015 Jan CAHN

AB 13.3MG/24HR

A204403 003 Aug 31, 2015 Jan CAHN

RIVASTIGMINE TARTRATECAPSULE; ORAL
EXELON

AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
		RIVASTIGMINE TARTRATE					
AB		AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB			EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB			EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB			EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

AB		ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB			EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB		NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

ROPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
		SOLUTION; INJECTION					
		NAROPIN					
		@ FRESenius KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May DISC
			50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May NEWA
AP			20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May CMS1
AP			20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
AP			40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
		@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
			75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
AP			100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun CFTG
			100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May CMS1
			100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
AP			100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
AP			150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
AP			150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
AP			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun CFTG
			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
AP	+		200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
			400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA
			500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
			500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
			1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
			1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA
		ROPIVACAINE HYDROCHLORIDE					
AP		AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun NEWA
AP			100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun NEWA
AP			100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun NEWA
AP			150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun NEWA
AP			150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun NEWA
AP			200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun NEWA
AP			200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun NEWA
AP		HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP			40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP			100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR
AP			150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar CDFR
AP			150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar CDFR
AP			200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar NEWA
AP		NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar CDFR
AP			200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar CDFR
AP		SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar CDFR
AP			150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar CDFR
AP			150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar CDFR
AP			200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar CDFR

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

AB		IPR	5MG	N021366	002	Aug 12, 2003	Apr CFTG
AB			10MG	N021366	003	Aug 12, 2003	Apr CFTG
AB			20MG	N021366	004	Aug 12, 2003	Apr CFTG

TABLET;ORAL							
CRESTOR							
AB	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG
ROSUVASTATIN CALCIUM							
>A>	AB	ACCORD HLTHCARE INC	5MG	A206434	001	Oct 31, 2016	Oct NEWA
>A>	AB		10MG	A206434	002	Oct 31, 2016	Oct NEWA
>A>	AB		20MG	A206434	003	Oct 31, 2016	Oct NEWA
>A>	AB		40MG	A206434	004	Oct 31, 2016	Oct NEWA
	AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079145	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079145	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079145	004	Jul 19, 2016	Jul NEWA
	AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079170	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079170	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079170	004	Jul 19, 2016	Jul NEWA
>A>	AB	BIOCON LTD	5MG	A207752	001	Oct 31, 2016	Oct NEWA
>A>	AB		10MG	A207752	002	Oct 31, 2016	Oct NEWA
>A>	AB		20MG	A207752	003	Oct 31, 2016	Oct NEWA
>A>	AB		40MG	A207752	004	Oct 31, 2016	Oct NEWA
>A>	AB	CHANGZHOU PHARM	5MG	A207408	001	Oct 31, 2016	Oct NEWA
>A>	AB		10MG	A207408	002	Oct 31, 2016	Oct NEWA
>A>	AB		20MG	A207408	003	Oct 31, 2016	Oct NEWA
>A>	AB		40MG	A207408	004	Oct 31, 2016	Oct NEWA
	AB	GLENMARK PHARMS	5MG	A079172	001	Jul 19, 2016	Sep CAHN
	AB		10MG	A079172	002	Jul 19, 2016	Sep CAHN
	AB		20MG	A079172	003	Jul 19, 2016	Sep CAHN
	AB		40MG	A079172	004	Jul 19, 2016	Sep CAHN
	AB	GLENMARK PHARMS LTD	5MG	A079172	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079172	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079172	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079172	004	Jul 19, 2016	Jul NEWA
>A>	AB	HETERO LABS LTD V	5MG	A207616	001	Oct 31, 2016	Oct NEWA
>A>	AB		10MG	A207616	002	Oct 31, 2016	Oct NEWA
>A>	AB		20MG	A207616	003	Oct 31, 2016	Oct NEWA
>A>	AB		40MG	A207616	004	Oct 31, 2016	Oct NEWA
>A>	AB	JUBILANT GENERICS	5MG	A207062	001	Oct 31, 2016	Oct NEWA
>A>	AB		10MG	A207062	002	Oct 31, 2016	Oct NEWA
>A>	AB		20MG	A207062	003	Oct 31, 2016	Oct NEWA
>A>	AB		40MG	A207062	004	Oct 31, 2016	Oct NEWA
	AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079161	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079161	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079161	004	Jul 19, 2016	Jul NEWA
	AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079168	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079168	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079168	004	Jul 19, 2016	Jul NEWA
	AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079171	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079171	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079171	004	Jul 19, 2016	Jul NEWA
	AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079169	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079169	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079169	004	Jul 19, 2016	Jul NEWA
	AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul NEWA
	AB		10MG	A079166	002	Jul 19, 2016	Jul NEWA
	AB		20MG	A079166	003	Jul 19, 2016	Jul NEWA
	AB		40MG	A079166	004	Jul 19, 2016	Jul NEWA
>A>	AB	TORRENT PHARMS LLC	5MG	A201619	001	Oct 31, 2016	Oct NEWA
>A>	AB		10MG	A201619	002	Oct 31, 2016	Oct NEWA
>A>	AB		20MG	A201619	003	Oct 31, 2016	Oct NEWA
>A>	AB		40MG	A201619	004	Oct 31, 2016	Oct NEWA
	AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr NEWA
	AB		10MG	A079167	002	Apr 29, 2016	Apr NEWA
	AB		20MG	A079167	003	Apr 29, 2016	Apr NEWA
	AB		40MG	A079167	004	Apr 29, 2016	Apr NEWA

RUBIDIUM CHLORIDE RB-82SOLUTION;INTRAVENOUS
RUBY-FILL

JUBILANT DRAXIMAGE

N/A

N202153 001 Sep 30, 2016 Sep NEWA

RUFINAMIDE

TABLET;ORAL

BANZEL

AB EISAI INC

200MG

N021911 002 Nov 14, 2008 May CFTG

AB +

400MG

N021911 003 Nov 14, 2008 May CFTG

RUFINAMIDE

AB GLENMARK PHARMS LTD

200MG

A205075 001 May 16, 2016 May NEWA

AB 400MG

A205075 002 May 16, 2016 May NEWA

AB MYLAN PHARMS INC 200MG

A205095 001 May 16, 2016 May NEWA

AB 400MG

A205095 002 May 16, 2016 May NEWA

AB ROXANE 200MG

A204988 001 May 16, 2016 May NEWA

AB 400MG

A204988 002 May 16, 2016 May NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

TRANSDERM SCOP

AB + GLAXOSMITHKLINE CON 1MG/72HR

N017874 001 May CAHN

SECOBARBITAL SODIUM

CAPSULE;ORAL

SECONAL SODIUM

+ VALEANT PHARMS NORTH 50MG

A086101 001 Oct 03, 1983 Aug CAHN

+ 100MG

A086101 002 Oct 03, 1983 Aug CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ FRONTIDA BIOPHARM EQ 25MG BASE

A077818 001 Feb 06, 2007 Jul CAHN

@ EQ 50MG BASE

A077818 002 Feb 06, 2007 Jul CAHN

@ EQ 100MG BASE

A077818 003 Feb 06, 2007 Jul CAHN

@ SUN PHARM INDS EQ 25MG BASE

A077818 001 Feb 06, 2007 Mar CAHN

@ EQ 50MG BASE

A077818 002 Feb 06, 2007 Mar CAHN

@ EQ 100MG BASE

A077818 003 Feb 06, 2007 Mar CAHN

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB @ ACTAVIS GRP PTC EQ 20MG BASE

A200149 001 Feb 25, 2013 Apr DISC

RUBICON RES PVT LTD EQ 20MG BASE

A204883 001 Jun 20, 2016 Jun NEWA

@ TEVA EQ 25MG BASE

A077342 001 Mar 09, 2016 Feb DISC

EQ 25MG BASE

A077342 001 Mar 09, 2016 Feb NEWA

@ EQ 50MG BASE

A077342 002 Mar 09, 2016 Feb DISC

EQ 50MG BASE

A077342 002 Mar 09, 2016 Feb NEWA

@ EQ 100MG BASE

A077342 003 Mar 09, 2016 Feb DISC

EQ 100MG BASE

A077342 003 Mar 09, 2016 Feb NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

+ ALLERGAN SALES LLC 4MG

N022206 001 Oct 08, 2008 Apr CAHN

8MG

N022206 002 Oct 08, 2008 Apr CAHN

SIMVASTATIN

SUSPENSION;ORAL

SIMVASTATIN

ROSEMONT PHARMS LTD 20MG/5ML

N206679 001 Apr 21, 2016 Apr NEWA

+ 40MG/5ML

N206679 002 Apr 21, 2016 Apr NEWA

TABLET;ORAL

SIMVASTATIN

@ SUN PHARM INDS LTD 5MG

A076285 001 Dec 20, 2006 Feb DISC

@ 10MG

A076285 002 Dec 20, 2006 Feb DISC

@ 20MG

A076285 003 Dec 20, 2006 Feb DISC

@ 40MG

A076285 004 Dec 20, 2006 Feb DISC

@ 80MG

A076285 005 Jun 23, 2006 Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)
AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
AP		SODIUM PHENYLACETATE AND SODIUM BENZOATE		A207096	001	Feb 24, 2016	Feb NEWA
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	Jul NEWA
AP		NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)				

SODIUM BICARBONATEINJECTABLE; INJECTION
SODIUM BICARBONATE

		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb NEWA
--	--	-------------	-----------	---------	-----	--------------	----------

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	HOSPIRA	450MG/100ML	N018090	001		Aug CRLD
		SODIUM CHLORIDE 0.9%					
		B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016	Aug NEWA
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May NEWA
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Aug CRLD

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May NEWA
AP		ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

		JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005	Mar CMS1
	@		2-200mCi	N021305	004	Nov 18, 2004	Mar CMS1

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB	+	HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CAHN
		SODIUM PHENYLBUTYRATE					
AB		PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun NEWA
		TABLET; ORAL					
		BUPHENYL					
AB	+	HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar CAHN
		SODIUM PHENYLBUTYRATE					
AB		PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb NEWA
AA		INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb NEWA

SOFOSBUVIR; VELPATASVIR

TABLET; ORAL

EPCLUSA

	+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016	Jun NEWA
--	---	---------------------	-------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

>A>	AB1	BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	Oct NEWA
>A>	AB1		120MG	A207428	002	Oct 21, 2016	Oct NEWA
>A>	AB1		160MG	A207428	003	Oct 21, 2016	Oct NEWA
	@	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar DISC
	@		120MG	A075663	002	Nov 07, 2000	Mar DISC
	@		160MG	A075663	003	Nov 07, 2000	Mar DISC
	@		240MG	A075663	004	Nov 07, 2000	Mar DISC
>D>	AB1	SANDOZ	80MG	A075366	001	May 01, 2000	Oct CAHN

TABLET; ORAL

SOTALOL HYDROCHLORIDE

>D>	AB1		120MG	A075366	002	May 01, 2000	Oct CAHN
>D>	AB1		160MG	A075366	003	May 01, 2000	Oct CAHN
>D>	AB1		240MG	A075366	004	May 01, 2000	Oct CAHN
	@	SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar CAHN
	@		80MG	A076576	001	Apr 08, 2004	Mar CAHN
	@		120MG	A075515	004	Oct 15, 2001	Mar CAHN
	@		120MG	A076576	002	Apr 08, 2004	Mar CAHN
	@		160MG	A075515	002	Oct 15, 2001	Mar CAHN
	@		160MG	A076576	003	Apr 08, 2004	Mar CAHN
	@		240MG	A075515	003	Oct 15, 2001	Mar CAHN
>A>	AB1	UPSHER-SMITH LABS	80MG	A075366	001	May 01, 2000	Oct CAHN
>A>	AB1		120MG	A075366	002	May 01, 2000	Oct CAHN
>A>	AB1		160MG	A075366	003	May 01, 2000	Oct CAHN
>A>	AB1		240MG	A075366	004	May 01, 2000	Oct CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB		ACCORD HLTHCARE INC	25MG	A203512	001	Sep 19, 2016	Sep NEWA
AB			50MG	A203512	002	Sep 19, 2016	Sep NEWA
AB			100MG	A203512	003	Sep 19, 2016	Sep NEWA
AB		SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar CAHN
AB			50MG	A089424	002	Aug 11, 1999	Mar CAHN
AB			100MG	A089424	003	Aug 11, 1999	Mar CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB		MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan CAHN
----	--	-------------------	-----	---------	-----	--------------	----------

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

>D>	AP	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Oct CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Oct CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

		ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan CPOT
	+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan CPOT

SULCONAZOLE NITRATE

SOLUTION; TOPICAL

EXELDERM

>D>	+	RANBAXY	1%	N018738	001	Aug 30, 1985	Oct CAHN
>A>	+	SUN PHARM INDS LTD	1%	N018738	001	Aug 30, 1985	Oct CAHN

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@	AUROLIFE PHARMA LLC	500MG	A085844	001			Feb CAHN
---	---------------------	-------	---------	-----	--	--	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	@	EUROHLTH INTL SARL	80MG/ML; 16MG/ML	A070627	001	Dec 29, 1987	Oct CAHN
>D>	@		80MG/ML; 16MG/ML	A070628	001	Dec 29, 1987	Oct CAHN
>A>	@	WEST-WARD PHARMS INT	80MG/ML; 16MG/ML	A070627	001	Dec 29, 1987	Oct CAHN
>A>	@		80MG/ML; 16MG/ML	A070628	001	Dec 29, 1987	Oct CAHN

SUSPENSION; ORAL

BACTRIM

@	SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	001			Jun CAHN
	BACTRIM PEDIATRIC						
@	SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	002			Jun CAHN

TABLET; ORAL

BACTRIM

AB		SUN PHARM INDS	400MG; 80MG	N017377	001		Mar CAHN
----	--	----------------	-------------	---------	-----	--	----------

TABLET;ORAL							
BACTRIM DS							
AB	+	SUN PHARM INDS	800MG;160MG	N017377	002		Mar CAHN
		SULFAMETHOXAZOLE AND TRIMETHOPRIM					
AB		SUN PHARM INDS	800MG;160MG	A071017	001	Aug 25, 1986	Mar CAHN
<u>SULFASALAZINE</u>							
TABLET;ORAL							
SULFASALAZINE							
	@	SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987	Mar CAHN
<u>SULFISOXAZOLE</u>							
TABLET;ORAL							
SULFISOXAZOLE							
	@	AUROLIFE PHARMA LLC	500MG	A085628	001		Feb CAHN
<u>SULINDAC</u>							
TABLET;ORAL							
SULINDAC							
AB		SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991	Mar CAHN
AB			200MG	A072051	001	Apr 17, 1991	Mar CAHN
<u>SUMATRIPTAN</u>							
SPRAY;NASAL							
IMITREX							
AB	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb CFTG
AB	+		20MG/SPRAY	N020626	003	Aug 26, 1997	Feb CFTG
		SUMATRIPTAN					
AB		LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb NEWA
AB			20MG/SPRAY	A204841	002	Feb 19, 2016	Feb NEWA
<u>SUMATRIPTAN SUCCINATE</u>							
INJECTABLE;SUBCUTANEOUS							
ALSUMA							
	@	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Sep DISC
		SUMATRIPTAN SUCCINATE					
AP		EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun CAHN
POWDER;INHALATION							
ONZETRA XSAIL							
+		AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan NEWA
SOLUTION;SUBCUTANEOUS							
ZEMBRACE SYMTOUCH							
	DR	REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan NEWA
<u>TACROLIMUS</u>							
OINTMENT;TOPICAL							
PROTOPIC							
AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN
<u>TAMOXIFEN CITRATE</u>							
SOLUTION;ORAL							
SOLTAMOX							
		MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005	Jan CAHN
TABLET;ORAL							
TAMOXIFEN CITRATE							
	@	ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003	Jan DISC
	@		EQ 20MG BASE	A076179	002	Feb 20, 2003	Jan DISC
AB		MAYNE PHARMA	EQ 10MG BASE	A075797	001	Feb 20, 2003	Aug CAHN
AB	+		EQ 20MG BASE	A074858	001	Feb 20, 2003	Aug CAHN
<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>							
SOLUTION;INTRAVENOUS							
ULTRA-TECHNEKOW FM							
+		MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
	@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE;INJECTION
MPI DMSA KIDNEY REAGENT
@ GE HEALTHCARE N/A

N017944 001 May 18, 1982 Aug DISC

TEGASEROD MALEATE

TABLET;ORAL
ZELNORM
@ US WORLDMEDS LLC EQ 2MG BASE
@ EQ 6MG BASE

N021200 001 Jul 24, 2002 Jan CAHN
N021200 002 Jul 24, 2002 Jan CAHN

TELITHROMYCIN

TABLET;ORAL
KETEK
@ SANOFI AVENTIS US 300MG
@ 400MG

N021144 002 Feb 09, 2005 Mar DISC
N021144 001 Apr 01, 2004 Mar DISC

TELMISARTAN

TABLET;ORAL
TELMISARTAN

AB HETERO LABS LTD V 20MG
AB 40MG
AB 80MG
AB JUBILANT GENERICS 20MG
AB 40MG
AB 80MG

A205901 001 Apr 22, 2016 Apr NEWA
A205901 002 Apr 22, 2016 Apr NEWA
A205901 003 Apr 22, 2016 Apr NEWA
A204164 001 Aug 22, 2016 Aug NEWA
A204164 002 Aug 22, 2016 Aug NEWA
A204164 003 Aug 22, 2016 Aug NEWA

TEMAZEPAM

CAPSULE;ORAL
TEMAZEPAM

AB AMNEAL PHARMS 7.5MG
AB 15MG
AB 22.5MG
AB 30MG
AB SUN PHARM INDS 7.5MG
@ 15MG
AB 22.5MG
@ 30MG

A203482 001 May 23, 2016 May NEWA
A203482 002 May 23, 2016 May NEWA
A203482 003 May 23, 2016 May NEWA
A203482 004 May 23, 2016 May NEWA
A078581 001 Sep 08, 2009 Mar CAHN
A071174 001 Jul 10, 1986 Mar CAHN
A071175 002 Sep 14, 2009 Mar CAHN
A071175 001 Jul 10, 1986 Mar CAHN

TEMOZOLOMIDE

CAPSULE;ORAL
TEMOZOLOMIDE

AB AMERIGEN PHARMS LTD 5MG
AB 20MG
AB 100MG
AB 140MG
AB 180MG
AB 250MG
AB IDT AUSTRALIA LTD 5MG
AB 20MG
AB 100MG
AB 140MG
AB 180MG
AB 250MG
AB KREMERS URBAN PHARMS 5MG
AB 20MG
AB 100MG
AB 140MG
AB 180MG
AB 250MG
AB LOTUS PHARM CO LTD 5MG
AB 20MG
AB 100MG
AB 140MG
AB 180MG
AB 250MG
AB MYLAN PHARMS INC 5MG
AB 20MG
AB 100MG
AB 140MG
AB 180MG
AB 250MG

A203490 001 Jul 13, 2016 Jul NEWA
A203490 002 Jul 13, 2016 Jul NEWA
A203490 003 Jul 13, 2016 Jul NEWA
A203490 004 Jul 13, 2016 Jul NEWA
A203490 005 Jul 13, 2016 Jul NEWA
A203490 006 Jul 13, 2016 Jul NEWA
A206413 001 Apr 12, 2016 Mar NEWA
A206413 002 Apr 12, 2016 Mar NEWA
A206413 003 Apr 12, 2016 Mar NEWA
A206413 004 Apr 12, 2016 Mar NEWA
A206413 005 Apr 12, 2016 Mar NEWA
A206413 006 Apr 12, 2016 Mar NEWA
A203898 001 Feb 10, 2016 Jan NEWA
A203898 002 Feb 10, 2016 Jan NEWA
A203898 003 Feb 10, 2016 Jan NEWA
A203898 004 Feb 10, 2016 Jan NEWA
A203898 005 Feb 10, 2016 Jan NEWA
A203898 006 Feb 10, 2016 Jan NEWA
A206309 001 Apr 27, 2016 Apr NEWA
A206309 002 Apr 27, 2016 Apr NEWA
A206309 003 Apr 27, 2016 Apr NEWA
A206309 004 Apr 27, 2016 Apr NEWA
A206309 005 Apr 27, 2016 Apr NEWA
A206309 006 Apr 27, 2016 Apr NEWA
A205227 001 Jun 29, 2016 Jun NEWA
A205227 002 Jun 29, 2016 Jun NEWA
A205227 003 Jun 29, 2016 Jun NEWA
A205227 004 Jun 29, 2016 Jun NEWA
A205227 005 Jun 29, 2016 Jun NEWA
A205227 006 Jun 29, 2016 Jun NEWA

TERBUTALINE SULFATE

INJECTABLE;INJECTION						
BRETHINE						
	@ PHARMACARE	1MG/ML	N018571	001		Sep CAHN
TERBUTALINE SULFATE						
AP	+ AMPHASTAR PHARMS INC	1MG/ML	A076770	001	Apr 23, 2004	Jun CAHN
AP	+ EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Apr CAHN
TABLET;ORAL						
TERBUTALINE SULFATE						
	@ IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001	Mar DISC
	@	5MG	A075877	002	Jun 26, 2001	Mar DISC
	LANNETT	2.5MG	A077152	001	Mar 25, 2005	Mar CTEC
		5MG	A077152	002	Mar 25, 2005	Mar CTEC

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL						
ANDRODERM						
	+ ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar CAHN
	@	2.5MG/24HR	N020489	001	Sep 29, 1995	Mar CAHN
	+	4MG/24HR	N020489	004	Oct 20, 2011	Mar CAHN
	@	5MG/24HR	N020489	002	May 02, 1997	Mar CAHN
GEL, METERED;NASAL						
NATESTO						
	AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun CAHN
PELLET;IMPLANTATION						
TESTOPEL						
	+ AUXILIUM PHARMS INC	75MG	A080911	001		Mar CAHN
TABLET, EXTENDED RELEASE;BUCCAL						
STRIANT						
	+ AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar CAHN

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION						
TESTOSTERONE CYPIONATE						
AO	EUROHLTH INTL SARL	100MG/ML	A090387	001	Jul 15, 2010	Jun CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jun CAHN

TETRABENAZINE

TABLET;ORAL						
TETRABENAZINE						
AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC						
TETRACAINE HYDROCHLORIDE						
	+ ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Feb NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL						
TETRACYCLINE HYDROCHLORIDE						
AB	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr CMFD
	@ IDT AUSTRALIA LTD	250MG	A061471	001		Aug CAHN
	@ SUN PHARM INDS	250MG	A060736	001		Mar CAHN
	@	500MG	A060736	002		Mar CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL						
THEO-24						
	AUXILIUM PHARMS INC	200MG	A087943	001	Aug 22, 1983	Mar CAHN
		300MG	A087944	001	Aug 22, 1983	Mar CAHN
	+	400MG	A081034	001	Feb 28, 1992	Mar CAHN
	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Jul CAHN
		300MG	A087944	001	Aug 22, 1983	Jul CAHN
SOLUTION, ELIXIR;ORAL						
ELIXOPHYLLIN						
	+ NOSTRUM LABS INC	80MG/15ML	A085186	001		Jan CAHN

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan CAHN
THEOPHYLLINE						
AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	Jan CAHN
AB	RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Aug CTNA

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar CAHN

THIOTEPA

INJECTABLE;INJECTION
THIOTEPA

+	WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Sep CAHN
---	----------------------	-----------	---------	-----	--------------	----------

THIOTHIXENE

CAPSULE;ORAL

NAVANE

@ PFIZER

@

@

@

THIOTHIXENE

MYLAN

		1MG	N016584	001		Aug DISC
		2MG	N016584	002		Aug DISC
		5MG	N016584	003		Aug DISC
		10MG	N016584	004		Aug DISC
		1MG	A071093	002	Jun 23, 1987	Aug CTEC
		2MG	A071093	003	Jun 23, 1987	Aug CTEC
+		5MG	A071093	004	Jun 23, 1987	Aug CRLD
		10MG	A071093	001	Jun 23, 1987	Aug CTEC
	@ SANDOZ	1MG	A071529	002	Jun 24, 1987	Sep CMS1
	@	2MG	A071529	003	Jun 24, 1987	Sep CMS1
	@	5MG	A071529	001	Jun 24, 1987	Mar DISC
	@	10MG	A071529	004	Jun 24, 1987	Sep CMS1

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

AT	+	OAK PHARMS INC	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Sep CFTG
AT	+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Sep CFTG
TIMOLOL							
AT		AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Sep NEWA
AT			EQ 0.5% BASE	A205309	002	Sep 30, 2016	Sep NEWA

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr CTEC
BX		500MG	A202489	002	Oct 09, 2013	Apr CTEC

TIROFIBAN HYDROCHLORIDE

SOLUTION;INJECTION

AGGRASTAT

+	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016	Aug NEWA
---	----------	---	---------	-----	--------------	----------

TOBRAMYCIN

SOLUTION;INHALATION

BETHKIS

+	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Sep CRLD
---	----------------	-----------	---------	-----	--------------	----------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun	NEWA
>D>	@ EUROHLTH INTL SARL	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991	Oct	CAHN
>D>	@	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991	Oct	CAHN
>D> AP		EQ 40MG BASE/ML	A063117	001	Apr 26, 1991	Oct	CAHN
>D>	@	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991	Oct	CAHN
>D>	@	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991	Oct	CAHN
>A>	@ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991	Oct	CAHN
>A>	@	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991	Oct	CAHN
>A> AP		EQ 40MG BASE/ML	A063117	001	Apr 26, 1991	Oct	CAHN
>A>	@	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991	Oct	CAHN
>A>	@	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991	Oct	CAHN

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE; ORAL
XELJANZ XR

+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb	NEWA
---	------------	--------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

@	SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
@		250MG	A071358	001	Jul 16, 1987	Mar	CAHN
@		500MG	A071359	001	Jul 16, 1987	Mar	CAHN

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM

@	SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar	CAHN
---	----------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL
TOLMETIN SODIUM

AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar	CAHN
----	----------------	---------------	---------	-----	--------------	-----	------

TOPIRAMATE

TABLET; ORAL
TOPIRAMATE

@	ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr	DISC
AB		25MG	A078637	001	Feb 27, 2013	Jan	CAHN
@		50MG	A078637	002	Feb 27, 2013	Apr	DISC
AB		50MG	A078637	002	Feb 27, 2013	Jan	CAHN
@		100MG	A078637	003	Feb 27, 2013	Apr	DISC
AB		100MG	A078637	003	Feb 27, 2013	Jan	CAHN
@		200MG	A078637	004	Feb 27, 2013	Apr	DISC
AB		200MG	A078637	004	Feb 27, 2013	Jan	CAHN

TORSEMIDE

INJECTABLE; INJECTION
TORSEMIDE

>D>	@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Oct	CAHN
>D>	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Oct	CAHN
>A>	@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Oct	CAHN
>A>	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Oct	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar	CAHN
AB	SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL
TRAMADOL HYDROCHLORIDE

>D> AB1	LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Oct	CRLD
>A> AB1	+	100MG	A200503	001	Aug 29, 2011	Oct	CRLD
>D>	ULTRAM ER						
>D> AB1	+	100MG	N021692	001	Sep 08, 2005	Oct	DISC
>A>	@	100MG	N021692	001	Sep 08, 2005	Oct	DISC
AB1	+	100MG	N021692	001	Sep 08, 2005	Mar	CAHN
>D> AB1		200MG	N021692	002	Sep 08, 2005	Oct	DISC
>A>	@	200MG	N021692	002	Sep 08, 2005	Oct	DISC
AB1		200MG	N021692	002	Sep 08, 2005	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL									
ULTRAM ER									
>D>									
>D>	AB1	300MG		N021692	003	Sep 08, 2005	Oct	DISC	
>A>	@	300MG		N021692	003	Sep 08, 2005	Oct	DISC	
	AB1	300MG		N021692	003	Sep 08, 2005	Mar	CAHN	
<u>TRANEXAMIC ACID</u>									
INJECTABLE;INJECTION									
TRANEXAMIC ACID									
AP	AKORN	100MG/ML		A206634	001	Jun 09, 2016	May	NEWA	
AP	AUROBINDO PHARMA LTD	100MG/ML		A205035	001	Jan 14, 2016	Jan	NEWA	
AP	NORTH CREEK PHARMS	100MG/ML		A202755	001	Feb 25, 2016	Feb	NEWA	
TABLET;ORAL									
TRANEXAMIC ACID									
	@ AMERIGEN PHARMS LTD	650MG		A203256	001	Jul 25, 2016	Jul	DISC	
AB		650MG		A203256	001	Jul 25, 2016	Jul	NEWA	
<u>TRAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
TRAZODONE HYDROCHLORIDE									
	@ AUROLIFE PHARMA LLC	50MG		A072484	001	Apr 30, 1990	Feb	CAHN	
AB	SUN PHARM INDS	50MG		A073137	002	Mar 24, 1993	Mar	CAHN	
AB		100MG		A073137	001	Mar 24, 1993	Mar	CAHN	
AB		150MG		A073137	003	Dec 22, 1995	Mar	CAHN	
<u>TREPROSTINIL DIOLAMINE</u>									
TABLET, EXTENDED RELEASE;ORAL									
ORENITRAM									
>A>	UNITED THERAP	EQ 5MG BASE		N203496	005	Oct 07, 2016	Oct	NEWA	
<u>TRETINOIN</u>									
CREAM;TOPICAL									
TRETINOIN									
	+ ALLERGAN SALES LLC	0.0375%		A090098	001	Mar 22, 2010	Jul	CAHN	
		0.075%		A202209	001	Oct 11, 2012	Jul	CAHN	
AB	ELAN PHARMA INTL LTD	0.025%		A075264	001	Dec 24, 1998	Feb	CAHN	
AB1		0.05%		A075265	001	Dec 24, 1998	Feb	CAHN	
AB		0.1%		A075213	001	Dec 24, 1998	Feb	CAHN	
AB	PERRIGO PHARMA INTL	0.025%		A075264	001	Dec 24, 1998	Jul	CAHN	
AB1		0.05%		A075265	001	Dec 24, 1998	Jul	CAHN	
AB		0.1%		A075213	001	Dec 24, 1998	Jul	CAHN	
GEL;TOPICAL									
TRETINOIN									
AB	ELAN PHARMA INTL LTD	0.01%		A075589	001	Jun 11, 2002	Feb	CAHN	
AB		0.025%		A075529	001	Feb 22, 2000	Feb	CAHN	
AB	PERRIGO PHARMA INTL	0.01%		A075589	001	Jun 11, 2002	Jul	CAHN	
AB		0.025%		A075529	001	Feb 22, 2000	Jul	CAHN	
<u>TRIAMCINOLONE ACETONIDE</u>									
CREAM;TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT	GLENMARK PHARMS LTD	0.1%		A207117	001	Aug 05, 2016	Jul	NEWA	
LOTION;TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT	TELIGENT PHARMA INC	0.025%		A204608	001	Jul 07, 2016	Jun	NEWA	
AT		0.1%		A204606	001	Jul 07, 2016	Jun	NEWA	
OINTMENT;TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT	GLENMARK PHARMS LTD	0.5%		A206379	001	Jul 22, 2016	Jul	NEWA	
AT	TELIGENT PHARMA INC	0.1%		A205373	001	May 13, 2016	May	NEWA	
PASTE;DENTAL									
TRIAMCINOLONE ACETONIDE									
AT	VERSAPHARM INC	0.1%		A206312	001	Aug 11, 2016	Jul	NEWA	
SPRAY;TOPICAL									
KENALOG									
AT	+ RANBAXY LABS LTD	0.147MG/GM		N012104	001		Jul	CAHN	
>D>	SPRAY, METERED;NASAL								
>D>	TRIAMCINOLONE ACETONIDE								
>D>	TEVA PHARMS	0.055MG/SPRAY		A078104	001	Jul 30, 2009	Oct	DISC	
>A>	@	0.055MG/SPRAY		A078104	001	Jul 30, 2009	Oct	DISC	

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar CAHN
----	----------------	-------	---------	-----	--------------	----------

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB	+	MAYNE PHARMA	100MG	N018679	001	Jul 30, 1982	Aug CAHN
	@	SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun CAHN
	@		200MG	A070495	001	Sep 24, 1986	Mar CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

+	AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun CAHN
@	AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun CMS2
@		EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jan CAHN
+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIMUM CHLORIDE

AB	+	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Aug CRLD
>D>	@	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Oct CAHN
	@		60MG	A091635	001	Apr 29, 2015	Apr DISC
>A>	@	UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Oct CAHN

TABLET;ORAL

TROSPIMUM CHLORIDE

AB	+	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Aug CRLD
AB		HERITAGE PHARMS INC	20MG	A204945	001	Aug 30, 2016	Aug NEWA
AB		INVAGEN PHARMS	20MG	A091688	001	Aug 23, 2016	Aug NEWA

URSODIOL

CAPSULE;ORAL

ACTIGALL

	@	ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
AB	+		300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Jul CFTG
----	---	-------------------	---------	---------	-----	--------------	----------

VALGANCICLOVIR HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016	Jul NEWA
----	--	---------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB		HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

AP		AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
AP		EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

SYRUP;ORAL

VALPROIC ACID

AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
----	------------------	-----------	---------	-----	--------------	----------

VALSARTAN

TABLET;ORAL

VALSARTAN

AB	MACLEODS PHARMS LTD	40MG	A202696	001	Sep 16, 2016	Sep NEWA
AB		80MG	A202696	002	Sep 16, 2016	Sep NEWA
AB		160MG	A202696	003	Sep 16, 2016	Sep NEWA
AB		320MG	A202696	004	Sep 16, 2016	Sep NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOLED

>D>	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Oct CAHN
>D>	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Oct CAHN
>D>	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Oct CAHN
>D>	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Oct CAHN
>D>	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Oct CAHN
>A>	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Oct CAHN
>A>	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Oct CAHN
>A>	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Oct CAHN
>A>	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Oct CAHN
>A>	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Oct CAHN

VANCOMYCIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
AP	CFT PHARMS LLC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Jul CAHN
AP		EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Jul CAHN
AP		EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Jul CAHN
AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Jul CAHN
>D>	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988	Oct CAHN
>D>	@	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988	Oct CAHN
AP	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A062663	005	Aug 17, 2016	Aug NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA
>A>	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988	Oct CAHN
>A>	@	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988	Oct CAHN

VANDETANIB

TABLET;ORAL

CAPRELSA

GENZYME CORP

+

100MG

300MG

N022405	001	Apr 06, 2011	Jun CAHN
N022405	002	Apr 06, 2011	Jun CAHN

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP	EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr CAHN
AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr CAHN
AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
AP		20MG/VIAL	A205390	002	May 26, 2016	May NEWA
AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAX

TABLET;ORAL

VENCLEXTA

ABBVIE INC

+

10MG

50MG

100MG

N208573	001	Apr 11, 2016	Apr NEWA
N208573	002	Apr 11, 2016	Apr NEWA
N208573	003	Apr 11, 2016	Apr NEWA

VERAPAMIL HYDROCHLORIDE

	SOLUTION;INTRAVENOUS									
	VERAPAMIL HYDROCHLORIDE									
AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr	CMFD			
	TABLET;ORAL									
	CALAN									
	@ GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988	Sep	DISC			
	VERAPAMIL HYDROCHLORIDE									
	@ SUN PHARM INDS	80MG	A071489	002	Jan 13, 1988	Jun	CAHN			
	@	120MG	A071489	001	Jan 13, 1988	Jun	CAHN			
	TABLET, EXTENDED RELEASE;ORAL									
	CALAN SR									
	@ PFIZER	180MG	N019152	002	Dec 15, 1989	Feb	DISC			
	VERAPAMIL HYDROCHLORIDE									
AB	+ GLENMARK GENERICS	180MG	A090700	002	Aug 03, 2011	Aug	CRLD			

VINBLASTINE SULFATE

INJECTABLE; INJECTION		VINBLASTINE SULFATE							
>D>	+ EUROHLTH INTL SARL	10MG/VIAL	A089395	001	Apr 09, 1987	Oct	CAHN		
>A>	+ WEST-WARD PHARMS INT	10MG/VIAL	A089395	001	Apr 09, 1987	Oct	CAHN		

VINORELBINE TARTRATE

INJECTABLE; INJECTION		VINORELBINE TARTRATE							
AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr	CAHN		

VORAPAXAR SULFATE

TABLET; ORAL		ZONTIVITY							
	+ ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014	Sep	CAHN		

VORICONAZOLE

	FOR SUSPENSION;ORAL						
	VORICONAZOLE						
AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar	NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May	NEWA
	INJECTABLE;IV (INFUSION)						
	VORICONAZOLE						
AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar	NEWA
	TABLET;ORAL						
	VORICONAZOLE						
AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May	NEWA
AB		200MG	A206181	002	May 24, 2016	May	NEWA
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May	NEWA
AB		200MG	A206762	002	May 24, 2016	May	NEWA
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan	NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan	NEWA
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May	NEWA
AB		200MG	A207371	002	May 24, 2016	May	NEWA
AB	PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul	NEWA
AB		200MG	A206654	002	Aug 08, 2016	Jul	NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May	NEWA
AB		200MG	A206747	002	May 24, 2016	May	NEWA

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL		TRINTELLIX							
	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun	CTNA		
		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun	CTNA		
		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun	CTNA		
	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun	CTNA		

XENON XE-133

GAS; INHALATION		XENON XE 133							
	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC		
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD		
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD		

ZALEPLON

CAPSULE;ORAL

ZALEPLON

>D>	@ SANDOZ	5MG	A 078095	001	Jun 06, 2008	Oct CAHN
>D>	@	10MG	A 078095	002	Jun 06, 2008	Oct CAHN
>A>	@ UPSHER-SMITH LABS	5MG	A 078095	001	Jun 06, 2008	Oct CAHN
>A>	@	10MG	A 078095	002	Jun 06, 2008	Oct CAHN

ZIDOVUDINE

TABLET;ORAL

ZIDOVUDINE

@ SUNSHINE LAKE	300MG	A 202058	001	Oct 07, 2011	Aug DISC
-----------------	-------	----------	-----	--------------	----------

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A 207751	001	Sep 26, 2016	Sep NEWA
AP	GLAND PHARMA LTD	EQ 5MG BASE/100ML	A 204217	001	Aug 18, 2016	Aug NEWA

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	2.5MG	A 204041	001	May 20, 2016	May NEWA
AB		5MG	A 204041	002	May 20, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A 207021	001	May 11, 2016	Apr NEWA
AB		5MG	A 207021	002	May 11, 2016	Apr NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB	SANDOZ INC	5MG	A 077322	001	Apr 23, 2007	Aug CAHN
AB		10MG	A 077322	002	Apr 23, 2007	Aug CAHN
	@ SUN PHARM INDS	5MG	A 077288	001	Apr 23, 2007	Mar CAHN
	@	10MG	A 077288	002	Apr 23, 2007	Mar CAHN

TABLET;SUBLINGUAL

EDLUAR

AB	MEDA PHARMS	5MG	N 021997	001	Mar 13, 2009	Jul CFTG
AB	+	10MG	N 021997	002	Mar 13, 2009	Jul CFTG
	ZOLPIDEM TARTRATE					
AB	MYLAN PHARMS INC	5MG	A 202657	001	Aug 08, 2016	Jul NEWA
AB		10MG	A 202657	002	Aug 08, 2016	Jul NEWA
AB	PAR FORM	5MG	A 201509	001	Aug 01, 2016	Jul NEWA
AB		10MG	A 201509	002	Aug 01, 2016	Jul NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N 020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N 020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N 020789	001	Mar 27, 2000	Feb CAHN

ZONISAMIDE

AB	BIONPHARMA INC	25MG	A 077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A 077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A 077813	003	Aug 16, 2006	Jan CAHN
>D>	@ SANDOZ	25MG	A 077644	001	Dec 22, 2005	Oct CAHN
>D>	@	50MG	A 077644	002	Dec 22, 2005	Oct CAHN
>D>	@	100MG	A 077644	003	Dec 22, 2005	Oct CAHN
	@ SUN PHARM INDS	25MG	A 077635	001	Dec 22, 2005	Mar CAHN
	@	50MG	A 077635	002	Dec 22, 2005	Mar CAHN
	@	100MG	A 077635	003	Dec 22, 2005	Mar CAHN
>A>	@ UPSHER-SMITH LABS	25MG	A 077644	001	Dec 22, 2005	Oct CAHN
>A>	@	50MG	A 077644	002	Dec 22, 2005	Oct CAHN
>A>	@	100MG	A 077644	003	Dec 22, 2005	Oct CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

>A> AUROBINDO PHARMA LTD 650MG A207229 001 Nov 09, 2016 Oct NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG;250MG;65MG N020802 001 Jan 14, 1998 Feb CAHN

ADAPALENE

GEL;TOPICAL

DIFFERIN

+ GALDERMA LABS LP 0.1% N020380 002 Jul 08, 2016 Aug NEWA

BUDESONIDE

SPRAY, METERED;NASAL
BUDESONIDE

APOTEX INC 0.032MG/SPRAY A078949 002 Nov 20, 2015 Apr NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG A077355 001 Feb 06, 2008 Aug CTNA

800MG;10MG;165MG A204782 001 Aug 29, 2016 Aug NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX INC 10MG A207235 001 Aug 12, 2016 Aug NEWA

BIONPHARMA INC 5MG N022429 001 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG N022429 002 Jul 23, 2009 Jan CAHN

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ CYPRESS PHARM 5MG/5ML A090300 001 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CYPRESS PHARM 5MG/5ML A090300 002 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG A206793 001 Mar 08, 2016 Feb NEWA

10MG A206793 002 Mar 08, 2016 Feb NEWA

CHLORHEXIDINE GLUCONATE

SPONGE;TOPICAL

CHLORHEXIDINE GLUCONATE

+ BECTON DICKINSON 4% A072525 001 Oct 24, 1989 Jun CRLD

PHARMASEAL SCRUB CARE

@ CAREFUSION 4% N019793 001 Dec 02, 1988 Jun DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ BECTON DICKINSON CO 2%;70% (3ML) N020832 001 Jul 14, 2000 May CAHN

+ 2%;70% (10.5ML) N020832 004 Aug 20, 2003 May CAHN

+ 2%;70% (26ML) N020832 006 Nov 21, 2006 May CAHN

CHLORAPREP ONE-STEP FREPP

+ BECTON DICKINSON CO 2%;70% (1.5ML) N020832 003 Apr 26, 2002 May CAHN

CHLORAPREP WITH TINT

+ BECTON DICKINSON CO 2%;70% (26ML) N020832 002 May 03, 2005 May CAHN

+ 2%;70% (10.5ML) N020832 005 Apr 03, 2006 May CAHN

+ 2%;70% (3ML) N020832 007 Oct 10, 2006 May CAHN

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+ BECTON DICKINSON CO 2%;70% (0.67ML) N021555 001 Oct 07, 2002 May CAHN

SWAB;TOPICAL						
CHLORAPREP SINGLE SWABSTICK						
+	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005	May CAHN
CHLORAPREP TRIPLE SWABSTICK						
+	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	May CAHN
<u>CHLORPHENIRAMINE MALEATE</u>						
CAPSULE, EXTENDED RELEASE;ORAL						
CHLORPHENIRAMINE MALEATE						
@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb CAHN
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN</u>						
CAPSULE;ORAL						
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE						
	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN
<u>FAMOTIDINE</u>						
TABLET;ORAL						
FAMOTIDINE						
	AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016	Apr NEWA
		20MG	A206531	002	Apr 26, 2016	Apr NEWA
<u>FEXOFENADINE HYDROCHLORIDE</u>						
TABLET;ORAL						
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY						
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016	Aug NEWA
FEXOFENADINE HYDROCHLORIDE ALLERGY						
	HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016	Aug NEWA
		180MG	A204097	003	Aug 19, 2016	Aug NEWA
<u>FLUTICASONE FUROATE</u>						
SPRAY, METERED;NASAL						
FLONASE SENSIMIST ALLERGY RELIEF						
+	GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051	002	Aug 02, 2016	Aug NEWA
<u>FLUTICASONE PROPIONATE</u>						
SPRAY, METERED;NASAL						
FLUTICASONE PROPIONATE						
	APOTEX INC	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Jul CAHN
	APOTEX TECHNOLOGIES	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Feb NEWA
	ROXANE	0.05MG/SPRAY	A207957	001	May 26, 2016	May NEWA
<u>IBUPROFEN</u>						
CAPSULE;ORAL						
IBUPROFEN						
	BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Sep CAHN
	PURACAP PHARM LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Jun NEWA
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016	Aug NEWA
MIDOL LIQUID GELS						
+	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002	Jan CAHN
TABLET;ORAL						
IBUPROFEN						
	GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016	Sep NEWA
	STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011	May CAHN
		200MG	A091355	001	Apr 04, 2011	May CAHN
@	SUN PHARM INDS	200MG	A070493	001	Dec 24, 1985	Mar CAHN
@		200MG	A070908	001	Sep 26, 1986	Mar CAHN
@		200MG	A071462	001	Oct 02, 1986	Mar CAHN
<u>KETOTIFEN FUMARATE</u>						
SOLUTION/DROPS;OPHTHALMIC						
KETOTIFEN FUMARATE						
+	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Aug CRLD
ZADITOR						
@	ALCON PHARMA	EO 0.025% BASE	N021066	002	Oct 19, 2006	Aug DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016	May NEWA
PREVACID 24 HR					
+ GLAXOSMITHKLINE CONS	15MG	N022327	001	May 18, 2009	Aug CAHN
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
LANSOPRAZOLE					
DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016	Jun NEWA

LEVONORGESTREL

TABLET;ORAL
HER STYLE

NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb NEWA
LEVONORGESTREL					
GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016	Mar NEWA
JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug NEWA
LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan CAHN
+	2MG	N021855	002	Aug 04, 2005	Jan CAHN

LORATADINE

CAPSULE;ORAL
LORATADINE

MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016	Sep NEWA
TABLET, ORALLY DISINTEGRATING;ORAL					
LORATADINE					

>D>	IMPAX LABS	10MG	A076011	001	Sep 29, 2003	Oct CAHN
>A>	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003	Oct CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE

>D>	IMPAX LABS	5MG;120MG	A076050	001	Jan 30, 2003	Oct CAHN
>D>		10MG;240MG	A075989	001	Mar 04, 2004	Oct CAHN
>A>	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003	Oct CAHN
>A>		10MG;240MG	A075989	001	Mar 04, 2004	Oct CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
MONISTAT 3 COMBINATION PACK

+	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996	Mar CMS1
---	------------------	----------	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

+	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar CAHN
TABLET;ORAL						
NAPROXEN SODIUM						
	AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
HABITROL

DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999	Aug CRLD
	14MG/24HR	N020076	005	Nov 12, 1999	Aug CRLD
NICODERM CQ					
SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996	Aug CRLD
	14MG/24HR	N020165	005	Aug 02, 1996	Aug CRLD

NICOTINE POLACRILEXGUM, CHEWING;BUCCAL
NICOTINE POLACRILEXACTAVIS LABS NY INC EQ 2MG BASE
EQ 4MG BASEA204794 001 May 10, 2016 Apr NEWA
A204833 001 Feb 26, 2016 Feb NEWAOMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A> ACTAVIS ELIZABETH 20MG;1.1GM
AUROLIFE PHARMA LLC 20MG;1.1GM
PAR PHARM 20MG;1.1GM
PERRIGO R AND D 20MG;1.1GMA204137 001 Jul 15, 2016 Jul NEWA
A204923 001 Nov 07, 2016 Oct NEWA
A201946 001 Jul 15, 2016 Jul NEWA
A201361 001 Jul 15, 2016 Jul NEWAOXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

>A> NUVO PHARM INC 17GM/SCOOPFUL
STRIDES PHARMA 17GM/SCOOPFUL
17GM/PACKETA206105 001 Oct 28, 2016 Oct NEWA
A203928 001 Aug 24, 2016 Aug NEWA
A203928 002 Aug 24, 2016 Aug NEWAPOTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

>A> TEVA PHARMS 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Oct NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2016

NO OCTOBER 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - ABACAVIR SULFATE AND LAMIVUDINE</u>						
A 079246 001					PC	Mar 28, 2017
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP			
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031	U-1882			
	9399012*PED	Mar 11, 2032				
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	>A> 9427421	May 08, 2032	DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	>A> 9427421	May 08, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	>A> 6514980	Jul 24, 2018	DP U-1006			
	>A> 6514980	Jul 24, 2018	DP U-1484			
	>A> 7223387	Nov 13, 2022	DP U-1006			
	>A> 7223387	Nov 13, 2022	DP U-1484			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 002					RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	>A> 9463289	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	>A> 9463288	May 19, 2025	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
	9440922	Jun 09, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	>A> 6559183	Nov 12, 2019	DP U-804		NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023			U-1529	
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023			U-1529	
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9452131	Mar 19, 2035			U-543	
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9452131	Mar 19, 2035			U-543	
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9452131	Mar 19, 2035			U-543	
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					PC	Nov 28, 2016
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP		U-1893	
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP		U-1893	
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032			U-1731	
	9226892	Sep 29, 2032			U-1732	
	9226892	Sep 29, 2032			U-1733	
	9351984	Dec 19, 2021	DP			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	>A> 6926907	Feb 28, 2023	DP		U-1902	
	>A> 8206741	Feb 28, 2023	DP		U-1902	
	>A> 9364439	May 31, 2022	DP		U-1902	
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	>A> 6926907	Feb 28, 2023	DP		U-1902	
	>A> 8206741	Feb 28, 2023	DP		U-1902	
	>A> 9364439	May 31, 2022	DP		U-1902	
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP		U-155	
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP		U-155	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	>A> 8163723	Aug 29, 2023	U-77		>A> NPP	Feb 20, 2018
	>A> 8163723	Aug 29, 2023	U-81		>A> PED	Aug 20, 2018
	>A> 8163723	Aug 29, 2023	U-644			
	>A> 8163723	Aug 29, 2023	U-707			
	>A> 8163723	Aug 29, 2023	U-1667			
	>A> 8163723*PED	Feb 29, 2024				
	>A> 9259428	Jun 13, 2023	U-644			
	>A> 9259428*PED	Dec 13, 2023				
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	>A> 9463289	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	>A> 9463289	May 18, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					M-186	Sep 23, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006					M-186	Sep 23, 2019
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	>A> 9421265	Jun 17, 2030	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	>A> 9474751	Apr 19, 2022	DP U-1524			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	>A> 8454996	Sep 24, 2019	U-1421		>A> I-713	Aug 10, 2018
	>A> 8470361	May 22, 2030	DP U-1425			
	>A> 8658198	Dec 03, 2027	DP U-1494			
	>A> 8940330	Sep 18, 2032	DP			
	>A> 9259421	Sep 18, 2032	DP			
	>A> 9439900	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	>A> 6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	>A> 7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	>A> 7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	>A> 8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	>A> 7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	>A> 7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	>A> 8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	>A> 6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	>A> 7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	>A> 7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	>A> 8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	>A> 8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	>A> 7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	>A> 7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	>A> 8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8785403	Jul 30, 2024	DP			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	>A> 7635773	Mar 13, 2029	DP			
	>A> 8410077	Mar 13, 2029	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9463246	Dec 26, 2028	DP U-219			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	8129346	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	7232818	Apr 14, 2025	DS DP		>A> I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		>A> I-722	Jan 21, 2019
	7491704	Apr 14, 2025	U-1260		>A> I-723	Jan 21, 2019
	7737112	Dec 07, 2027	DP		>A> NCE	Jul 20, 2017
	8129346	Apr 14, 2025	U-1260		>A> ODE	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	>A> 9457036	Jan 13, 2024	DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9399036	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	9415007	Jul 28, 2024	U-1896			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	9421192	Aug 08, 2027	DS	U-1724	D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS	U-1725	D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	9421192	Aug 08, 2027	DS	U-1724	D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS	U-1725	D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 003	9421192	Aug 08, 2027	DS	U-1724		
	9421192	Aug 08, 2027	DS	U-1725		
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016		U-124		
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003 >A>	9138456	Nov 23, 2030	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8492386	Sep 04, 2032		U-1840	D-163	Apr 22, 2019
	8685984	Sep 04, 2032		U-1840		
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	7148359	Jul 19, 2019		DP	NCE	Dec 19, 2019
	7364752	Nov 10, 2020		DP		
	8188104	May 17, 2029	DS	DP	U-1636	
	8268349	Aug 25, 2024		DP		
	8399015	Aug 25, 2024		DP		
	8420596	Apr 10, 2031	DS	DP		
	8466159	Sep 04, 2032			U-1637	
	8492386	Sep 04, 2032			U-1840	
	8501238	Sep 17, 2028	DS	DP	U-1636	
	8642538	Sep 10, 2029	DS	DP	U-1638	
	8680106	Sep 04, 2032			U-1637	
	8685984	Sep 04, 2032			U-1840	
	8686026	Jun 09, 2031		DP		
	8691938	Apr 13, 2032	DS	DP		
	9006387	Jun 10, 2030			U-1687	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9415085	Apr 27, 2032	U-1895			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9415085	Apr 27, 2032	U-1895			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	9320712	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	9320712	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	9320712	Jan 04, 2032	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 003	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431	005				PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	007	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
		9446057	Dec 23, 2034	DP U-918		
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	008	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
		9446057	Dec 23, 2034	DP U-918		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM</u>						
A 203593	001				>A> PC	Apr 09, 2017
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	>A> 9457036	Jan 13, 2024	DP U-257		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	9302009	Oct 24, 2030	DP		
<u>ELBASVIR; GRAZOPREXIN - ZEPATIER</u>						
N 208261	001	7973040	Jul 24, 2029	DS DP U-1813	NCE	Jan 28, 2021
		8871759	May 04, 2031	DS DP U-1813		
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	001	9364489	Jul 07, 2028	U-1709		
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	002	9364489	Jul 07, 2028	U-1709		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	001	8551957	Oct 14, 2029	DP U-1651	M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	002	8551957	Oct 14, 2029	DP U-1651	M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	001	7407955	May 02, 2025	DS DP		
		8551957	Oct 14, 2029	DP U-1651		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	002	7407955	May 02, 2025	DS DP		
		8551957	Oct 14, 2029	DP U-1651		
		8673927	May 04, 2027	DP U-1652		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	001				M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	002				M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	003				M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	004				M-174	Mar 18, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	7125879	Apr 21, 2025	DS DP U-257			
	>A> 9457036	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	>A> 9457036	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-1892			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	6369085	May 25, 2018	DS DP U-1509			
	6369085	May 25, 2018	DS DP U-1875			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810	Nov 03, 2019	DP U-1874			
	6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031			U-1781	
	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029			U-1781	
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029			U-1781	
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	>A> 8486907	Jun 28, 2025			NCE	Sep 19, 2021
	>A> 9018368	Jun 28, 2025	DS DP		>A> ODE	Sep 19, 2023
	>A> 9416361	May 04, 2021	DS			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	>A> 8486907	Jun 28, 2025			NCE	Sep 19, 2021
	>A> 9018368	Jun 28, 2025	DS DP		>A> ODE	Sep 19, 2023
	>A> 9416361	May 04, 2021	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 020788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 003	9241935	Jan 25, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001 >A>	9468639	Oct 16, 2022	U-1734			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001 >A>	5808146	Nov 09, 2017	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026	U-1879			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	6858596	Aug 03, 2021	DP U-1890			
	7101866	Aug 03, 2021	DS DP U-1890			
	7541350	Aug 03, 2021	DP U-1890			
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
	9415009	May 28, 2030	U-1841			
>A>	9463161	May 28, 2030	DP U-1841			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001					NCE ODE	Jun 01, 2021 Jun 01, 2023
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP		NCE	Jul 01, 2016
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183	001				NP	Nov 06, 2018
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827	001			>A>	PC	Oct 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827	002			>A>	PC	Oct 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827	003			>A>	PC	Oct 24, 2017
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001	9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002	9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	003	9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	004	9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005	9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	006	9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOXYDRO ER</u>						
N 202880 006	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
	>A> 9486412	Aug 24, 2027	DP			
	>A> 9486413	Aug 24, 2027	DP			
	>A> 9492389	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
	>A> 9486412	Aug 24, 2027	DP			
	>A> 9486413	Aug 24, 2027	DP			
	>A> 9492389	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
	>A> 9486412	Aug 24, 2027	DP			
	>A> 9486413	Aug 24, 2027	DP			
	>A> 9492389	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
	>A> 9486412	Aug 24, 2027	DP			
	>A> 9486413	Aug 24, 2027	DP			
	>A> 9492389	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
	>A> 9486412	Aug 24, 2027	DP			
	>A> 9486413	Aug 24, 2027	DP			
	>A> 9492389	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
	>A> 9486412	Aug 24, 2027	DP			
	>A> 9486413	Aug 24, 2027	DP			
	>A> 9492389	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
	>A> 9486412	Aug 24, 2027	DP			
	>A> 9486413	Aug 24, 2027	DP			
	>A> 9492389	Aug 24, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165 I-729 I-736 I-737 ODE ODE	May 06, 2019 Mar 04, 2019 May 06, 2019 May 06, 2019 Mar 04, 2023 May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6958335	Dec 19, 2021		U-791		
	6958335	Dec 19, 2021		U-1883		
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6958335	Dec 19, 2021		U-791		
	6958335	Dec 19, 2021		U-1883		
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	7410656	Oct 10, 2020	U-1222			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005 >A>	9457154	Sep 27, 2027	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001 >A>	9457154	Sep 27, 2027	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001 >A>	9457154	Sep 27, 2027	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002 >A>	9457154	Sep 27, 2027	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001 >A>	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002 >A>	5866538	Jun 20, 2017	DP			
	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003 >A>	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004 >A>	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005 >A>	9457154	Sep 27, 2027	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP	U-1855		
	9408979	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP	U-1861		
	9393372	Jul 04, 2029	DP			
>A>	9446133	Jun 12, 2029	DP	U-1861		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
>A>	9446133	Jun 12, 2029	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
>A>	9446133	Jun 12, 2029	DP U-1861			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	>A> 8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	>A> 8324242	Aug 05, 2027	U-1906			
	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	>A> 8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	>A> 8324242	Aug 05, 2027	U-1906			
	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	>A> 8324242	Aug 05, 2027	U-1311		>A> ODE	Sep 28, 2023
	>A> 8324242	Aug 05, 2027	U-1911			
	>A> 8716338	Sep 20, 2030	DP U-1718			
	>A> 8716338	Sep 20, 2030	DP U-1910			
	>A> 8741933	Nov 08, 2026	U-1717			
	>A> 8741933	Nov 08, 2026	U-1909			
	>A> 8846718	Dec 04, 2028	U-1717			
	>A> 8846718	Dec 04, 2028	U-1908			
	>A> 9150552	Dec 04, 2028	U-1908			
	>A> 9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	>A> 7495103	May 20, 2027	DS DP		>A> NCE	Jul 02, 2020
	>A> 8324242	Aug 05, 2027	U-1911		NPP	Sep 28, 2019
	>A> 8410274	Dec 28, 2026	DP		>A> ODE	Jul 02, 2022
	>A> 8507534	Sep 20, 2030	DS DP		>A> ODE	Sep 28, 2023
	>A> 8653103	Dec 04, 2028	DP			
	>A> 8716338	Sep 20, 2030	DP U-1910			
	>A> 8741933	Nov 08, 2026	U-1909			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8846718	Dec 04, 2028	U-1908			
	>A> 8993600	Dec 11, 2030	DP			
	>A> 9150552	Dec 04, 2028	U-1908			
	>A> 9192606	Sep 29, 2029	DP U-1912			
	>A> 9216969	Nov 08, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFITOR - ORKAMBI</u>						
N 206038 002	>A> 7495103	May 20, 2027	DS DP		>A> NCE	Jul 02, 2020
	>A> 8324242	Aug 05, 2027	U-1911		NPP	Sep 28, 2019
	>A> 8410274	Dec 28, 2026	DP		>A> ODE	Jul 02, 2022
	>A> 8507534	Sep 20, 2030	DS DP		>A> ODE	Sep 28, 2023
	>A> 8653103	Dec 04, 2028	DP			
	>A> 8716338	Sep 20, 2030	DP U-1910			
	>A> 8741933	Nov 08, 2026	U-1909			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8846718	Dec 04, 2028	U-1908			
	>A> 8993600	Dec 11, 2030	DP			
	>A> 9150552	Dec 04, 2028	U-1908			
	>A> 9192606	Sep 29, 2029	DP U-1912			
	>A> 9216969	Nov 08, 2026	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
	>A> 9486406	Oct 23, 2033	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158	Feb 12, 2019
	9393256	Sep 14, 2032	U-1470		D-159	Feb 12, 2019
					D-160	Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
>A>	9216179	Aug 01, 2031	U-1806			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	>A> 9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP U-1850			
>A>	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP U-1850			
>A>	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP U-1850			
>A>	9463160	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 206263 001					PC	Feb 11, 2017
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	7252839	Nov 13, 2023	DP		NP	Sep 16, 2019
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7691411	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7691411	Mar 14, 2024	DP			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP	U-1880		
	7790743	Nov 05, 2024		U-1880		
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029		U-1880		
	8367701	Apr 15, 2029	DP	U-1880		
	8592450	May 17, 2026		U-1880		
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029		U-1900		
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	>A> 8802628	Nov 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	>A> 8802628	Nov 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017		U-802		
	6340475	Sep 19, 2016	DP	U-1852		
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019		U-803		
	7078381	Feb 02, 2019		U-803		
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019		U-803		
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-1853		
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001 >A>	9457154	Sep 27, 2027	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					>A> M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					>A> M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					>A> M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					>A> M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					>A> M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					>A> M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					>A> M-188	Oct 14, 2019
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001 >A>	9463183	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1884			
	9169213	Dec 06, 2032	U-1885			
	9169213	Dec 06, 2032	U-1886			
	9169213	Dec 06, 2032	U-1887			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
	>A> 9439907	Oct 26, 2021	DP			
	>A> 9440034	Oct 26, 2021	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEBENDAZOLE - VERMOX</u>						
N 208398 001					>A> NS	Oct 19, 2019
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	9382191	Mar 07, 2026	DP			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>MESALAMINE - CANASA</u>						
N 021252 001					M-187	Sep 02, 2019
<u>MESALAMINE - CANASA</u>						
N 021252 002					M-187	Sep 02, 2019
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	6559158	Nov 03, 2017	U-1185		NP	Jul 19, 2019
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	9314461	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386 9295642	Aug 14, 2033 Aug 14, 2033	DP DP U-1827		NP	Dec 04, 2018
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386 9295642	Aug 14, 2033 Aug 14, 2033	DP DP U-1827		NP	Dec 04, 2018
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386 9295642	Aug 14, 2033 Aug 14, 2033	DP DP U-1827		NP	Dec 04, 2018
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532 RE44872	Mar 27, 2022 Nov 04, 2023	DS DP U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532 RE44872	Mar 27, 2022 Nov 04, 2023	DS DP U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001					M-185	Sep 27, 2019
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001					M-185	Sep 27, 2019
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7786133	Dec 19, 2027	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7786133	Dec 19, 2027	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
	>A> 9474869	Feb 28, 2031	DP U-1907			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	>A> 9468747	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	>A> 7731686	Jun 01, 2026	DP			
	>A> 7731690	Jan 15, 2025	DP			
	>A> 7749194	Oct 30, 2028	DP			
	>A> 7918823	Nov 23, 2024	DP			
	>A> 7947017	Mar 12, 2028	DP			
	>A> 8016788	Mar 21, 2025	DP			
	>A> 8021344	Nov 02, 2029	DP			
	>A> 8206360	Feb 27, 2027	DP			
	>A> 8226610	Apr 10, 2029	DP			
	>A> 8231573	Nov 25, 2028	DP			
	>A> 8313466	Nov 23, 2024	DP			
	>A> 8361029	Nov 23, 2024	DP			
	>A> 8425462	Nov 23, 2024	DP			
	>A> 8608698	Nov 23, 2024	DP			
	>A> 8627816	Feb 04, 2032	DP			
	>A> 8926594	Mar 31, 2026	DP			
	>A> 8939943	Feb 28, 2031	DP			
	>A> 9022022	Feb 28, 2031	DP			
	>A> 9056170	Nov 23, 2024	DP			
	>A> 9238108	Jan 22, 2027	DP			
	>A> 9474869	Feb 28, 2031	DP U-1907			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	>A> 9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	>A> 9474750	Dec 22, 2018	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	>A> 9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	>A> 9474750	Dec 22, 2018	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	>A> 9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	>A> 9474750	Dec 22, 2018	DP U-1556			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 001	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 002	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 003	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 004	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 005	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 006	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>OBETICHOIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OBETICHOIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 001					>A> PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 002					>A> PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 003					>A> PC	Apr 24, 2017
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588	Y		
	6645988	Jul 15, 2016	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	6699885	Jul 15, 2016	U-588	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	>A> 5840684	Nov 24, 2017	DS DP U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Aug 03, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
>A>	9457020	Jan 30, 2024	DP			
>A>	9457021	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
>A>	9457020	Jan 30, 2024	DP			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 001				>A> NPP		Oct 18, 2019
				>A> NPP		Oct 18, 2019
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 002				>A> NPP		Oct 18, 2019
				>A> NPP		Oct 18, 2019
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 003				>A> NPP		Oct 18, 2019
				>A> NPP		Oct 18, 2019
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
	9393237	Aug 04, 2026	U-904			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
	9393237	Aug 04, 2026	U-904			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					PC	Jan 01, 2017
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>QUETIAPINE FUMARATE - QUETIAPINE FUMARATE</u>						
A 090681 004					>A> PC	Apr 30, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001 >A>	9458107	Apr 08, 2031	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	8207191	Aug 30, 2024	U-805			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
>A>	9421195	Mar 10, 2030	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001 >A>	9468598	Feb 19, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	9388134	Nov 08, 2026	U-1723			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	9433624	Nov 17, 2024	U-1589			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 008 >A>	9457154	Sep 27, 2027	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 009 >A>	9457154	Sep 27, 2027	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 010 >A>	9457154	Sep 27, 2027	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 011 >A>	9457154	Sep 27, 2027	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001 >A>	6174442	Dec 19, 2017	DS U-1468			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2017	DS DP		I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001 >A>	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002 >A>	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003 >A>	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004 >A>	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005 >A>	8536130	Sep 22, 2028	U-1276			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001 >A>	9439985	Sep 27, 2033	DS DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 002	5733919	Oct 23, 2016	DS			
	5965581	Oct 23, 2016	DP			
	5972967	Oct 23, 2016	DP			
	5978698	Oct 08, 2017	U-1897			
	6136794	Jan 29, 2019	U-1898			
	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001 >A>	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002 >A>	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956041	Dec 08, 2020	DP		NCE	Nov 06, 2017
	6965027	Mar 25, 2023	DS			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-183	Aug 12, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-183	Aug 12, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035	U-1857			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	>A> 9447089	Jun 06, 2032	DP		M-184	Aug 31, 2019
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm